



20 **BIOTECH IN BAVARIA**

years of growth and innovation

REPORT

2016/17

including more than 300 company
profiles and contact addresses

managed by



297 m



99 m



10 nm



2962 m



Gipfelstürmern bieten wir in Penzberg die beste Basis.

Roche in Penzberg ist aktiver Teil der Life-Science-Region Greater Munich. Als Powerhouse für Antikörper haben wir hohe Ziele. Mit Mut zu neuen Ideen, dem Willen zur Lösung drängender Gesundheitsfragen und gelebter kultureller Vielfalt arbeiten wir global vernetzt an den Gesundheitslösungen von morgen.

From Science to Patients.



Bio^M – central point of contact for pharma and biotechnology in Munich and Bavaria

consulting for founders-to-be,
start-ups & SMEs
grant & seed financing support
pre-seed incubation & m⁴ award
matchmaking, networking & partnering
events, conferences & training

representing Bavarian biotechnology
world-wide
investment opportunities
central online platform:
job exchange, company database
and much more



Imprint

Editorial staff: Dr. Almut Windhager,
Dr. Georg Kääb
Company Profiles: Dr. Christina Grimm
Dr. Andreas Berghammer

Data analysis was compiled together with
BIO-Deutschland e.V., special thanks to
Nicole Kukuk and Florian Matznick.

We thank the Bavarian companies and the regional
organizations of the Bavarian Biotechnology Cluster for
supporting this survey.

April, 2017

Contact

Prof. Dr. Horst Domdey, Managing Director
Spokesman of the Bavarian Biotechnology Cluster

**The Bavarian and the Munich Biotechnology Clusters
are managed by:**

Bio^M Biotech Cluster Development GmbH

Am Klopferspitz 19 a

D-82152 Martinsried

Phone: +49 (0)89-8996 79-0

Fax: +49 (0)89-8996 79-79

E-Mail: info@bio-m.org

Internet: www.biotech-bavaria.de # www.bio-m.org



The layout, graphics and other contents of this brochure
of the Bavarian Biotechnology Cluster are protected by
copyright law.

Layout-Design: MxM, Munich, www.mxm.de

Pictures copyright as indicated

Supported by the Bavarian Ministry of Economic
Affairs and Media, Energy and Technology
www.stmwi.bayern.de/en/



NEU:
Wachstumsfonds
Bayern



Ihr Hightech-Unternehmen sucht Eigenkapital?

Bayern Kapital bietet:

- Eigenkapital für Seedphase, F&E, Markteinführung und Wachstum
- Co-Investments mit Partnern
- Langjährige Finanzierungserfahrung
- Zugang zu einem starken Netzwerk


WWW.BAYERNKAPITAL.DE

Bayern Kapital GmbH | Ländgasse 135a | 84028 Landshut

Telefon 0871 92325-0 | info@bayernkapital.de

BREEDING GROUND FOR INNOVATIONS

Our Network of Universities and Universities of Applied Sciences



#happy20thanniversaryBio^M

BAYERISCHE PATENTALLIANZ

www.baypat.de

Content

Biotech in Bavaria - looking back and across 7

- Prof. Dr. Horst Domdey – Spokesman Bavarian Biotechnology Cluster
-

Biopharma in Bavaria at a glance 9

Facts and Figures 2016 10–13

Companies 10-11

Employment 12–13

Bavarian Biotech Cluster - Trends and Topics 14–21

Trends and Topics 14-15

Spotlight on Munich 16-17

Founding and Incubation 18

Biotech Centers in Bavaria 20-21

Timeline: 20 Years Munich Biotech Cluster - 20 Years Bio^M 22-27

Company Profiles 29–160

in alphabetical order


About this survey:

For the following report, a biotechnology company has been defined as a company, which develops and/or manufactures products on the basis of state-of-the-art molecular biological methods. Since “conventional” pharmaceutical companies are increasingly also using such methods, it is often difficult to differentiate between biotech and pharma. We conducted separate surveys for biotech companies, pharmaceutical companies, (pre)clinical contract research organizations (CROs), contract manufacturing organizations (CMOs), suppliers and others with activities in the biotechnology sector. When referring to biotech companies, a distinction was once again made between small and medium-sized companies (SMEs/native Biotech) having their headquarters in Bavaria on the one hand, and branch offices and subsidiaries of national and international biotech companies (international biotech or non-SMEs) on the other hand. The term “non-SME” therefore gives no indication about the actual size of this branch office. The data were collected in cooperation with BIO-Deutschland e.V.. It was possible to achieve a response rate of almost 70 %. Possible deviations from previously published figures are the result of additional data obtained in this survey that also may refer to previous years. The period under review for this report is the year 2016.

Company profiles:

There are about 300 companies listed in the appendix of this brochure (pp. 21). Not every company being listed is also “counted” in this survey (for example some companies with very specific services or those few from the medtech area), and there are further Bavarian biotech and pharma companies having not activated their listing.

Published in April 2017




Bei Amgen
sind biologische
Arzneimittel in
Qualität
verwurzelt
und werden von
Zuverlässigkeit
genährt.

Eine solide Qualitätskontrolle und zuverlässige Versorgung sind genau so wichtig wie wissenschaftliche Innovationen.

Seit mehr als drei Jahrzehnten wird bei Amgen jedes Medikament mit Engagement, Leidenschaft und dem Streben nach Perfektion hergestellt.

Darum finden Sie bei Amgen die Biologika, die für die Behandlung Ihrer Patienten so enorm wichtig sind. Und das auch für die zukünftigen Generationen.

Weitere Informationen über Amgens Engagement für eine gleichbleibende Qualität und zuverlässige Versorgung finden Sie unter biotechnologybyamgen.de.



**BIOTECHNOLOGY
BY AMGEN®**

Biotech in Bavaria - looking back and across

Looking back over my shoulder . . . is not only one of my favorite songs (by Mike & The Mechanics), but also one of my main activities since we started to prepare this year's Bavarian biotech report. As most of you know, the Munich Biotech Cluster originally (and at least formally) began with the creation and foundation of Bio^M 20 years ago in the spring of 1997. In the years before, the foundation of several biotech companies had formed a sound basis for Munich's application in the national BioRegio Competition, in which Munich became one of the three winners in 1996, receiving an award of 50 million Deutsche Mark to be distributed to the emerging Munich biotech companies.

Looking back, the Munich biotech industry had an almost perfect start in those times of the roaring high-tech 1990s, when (almost) every tech-dream looked easy to achieve. It was the flourishing years of the still young and not yet negatively perceived "Neuer Markt". The cluster grew on the fertile basis provided by the excellent research carried out at many scientific institutions in Munich. The number of companies increased by 50 % per year, the number of employees even doubled from year to year, and in 2000, the incredible amount of 500 million Euro was invested in the local biotech industry.

Looking back, this biotech dreamland was, however, in danger to collapse when the first financial crisis hit Germany in 2001. Since then, the entire sector has been experiencing a turbulent, still ongoing, up and down. A number of biotech companies were unfortunately forced to go out of business, and the number of venture capital companies dropped sharply. Nevertheless, Munich has succeeded to remain the center of German life sciences. Darwinian-like forces have created a strong, successful and sustainable biotech industry and a globally acknowledged center of innovation in the life sciences.

Look across at dreamland (another of my favorite songs from the same band) now in 2017, I see again a very promising future for the Munich Biotech Cluster and the entire Bavarian biotech industry. First of all, there is this very strong backbone of biotech

companies with a positive cash flow based on their marketed products, technologies and services – not only locally or on the national level, but worldwide. Second, innovative business concepts have been identified and financially supported in a straightforward way for many years. This has created new start-up companies on a strong and very professional basis.

To some extent, this is due to the efforts of Bio^M about 15 years ago, when we developed innovative funding concepts which finally became the basis for the now available EXIST, GO-Bio and m⁴ Award programs. Furthermore, Bio^M offers a comprehensive incubation program for biotech entrepreneurs-to-be. Last but not least, due to Munich's successful performance in the Leading-Edge Cluster Competition (Spitzencluster-Wettbewerb), most of the companies engaged in the development of innovative diagnostics and therapeutics, are focusing on personalized medicine. Today, personalized (or precision) medicine is acknowledged as the most promising concept of the medicine of the future.


Looking across at dreamland – I can clearly see that, besides medical and pharmaceutical biotechnology, other areas in life sciences such as industrial biotechnology and medical technology have similar success stories. I am convinced that not only the Munich Biotech Cluster, but also the other Bavarian biotech centers have a bright future – together with Bio^M, your Biotech Cluster Management and Development Organization.

Yours sincerely, Horst Domdey



PROF. DR.
HORST DOMDEY

Bio^M; Spokesman Bavarian
Biotechnology Cluster



invest
in
bavaria



Think global.
Start in Bavaria.

Right this way for R&D

Bavaria is the leading biotech and pharma location in Germany. With a high number of international pharma companies and new rising biotech stars, Bavaria offers the right environment and infrastructure for your company – especially when it comes to R&D.

In Bavaria you'll find the right ingredients: a wealth of potential partners and customers throughout the entire industry value chain and highly qualified personnel. Bavaria is the home of digital future and your perfect business location.




Discover the benefits of expanding your business to Bavaria. We do everything to get your business started: From arranging contacts with relevant players to identifying the perfect location for your company.

Our service is confidential and free of charge. Get in touch with us!

→ www.invest-in-bavaria.com

Biopharma in Bavaria at a glance*


Employees



Marketed drugs (derived from SME)



Druggipeline (2016)



*in more detail on the following pages

Facts and Figures 2016

Number of Companies

As in the past we have categorized companies into 4 distinct groups and we combine 'native' Bavarian biotech-SMEs (small and medium sized enterprises according to OECD, as non-subsiary, independent firms) and international biotech companies (with headquarters outside Bavaria) to one single category "Biotechnology".

We are counting **225** such Biotech companies with core focus in this area or at least a major portion of the business (105 of them after the strict definition of the OECD. Additionally we count "Pharma", "CROs" (contract research organizations that support clients through clinical development, as well as CROs that focus on preclinical laboratory research) and "Suppliers".


With many new additions, the number of **biotechnology companies** in Bavaria in 2016 amounts to **225**. There were 10 new start-ups in Bavaria. Additionally, some relocations to our area took place (see table) and some subsidiaries have been closed for different

reasons or by the global headquarters (4). **Pharma**, and **Supplier and CMOs** (contract manufacturing organisations) showed no significant changes in numbers.

Bavaria is lucky to domicile all different players – and thus to provide for the whole value-added chain of (bio)pharmaceuticals from innovative start-ups to established and globally active companies, from drug and target screening to preclinical and clinical services to formulation and production. Even some biosimilar companies complement the scene perfectly.

Overall, there are about **360 companies in Bavaria which work in the (bio)pharmaceutical sector!**

BIOTECH/PHARMA COMPANIES IN BAVARIA



Company Foundations

In 2016, 10 newly established companies (SMEs) and a relocated one started operations in Bavaria. Many foundations could be established by using services including business consulting and the financing network of public and private support offered by the local cluster management of Bio^M and partners in our investor network.

Most of them have been founded in Munich or Martinsried with the exception of assay.works GmbH which choose Regensburg's BioPark as location.

NEW COMPANIES (FOUNDED & RELOCATED)

COMPANY	CATEGORY	ORIGIN
2016		
Thermosome GmbH	Biotech & Therapeutics	start-up
Preonics GmbH	Reagents & Devices	start-up
Freeline Therapeutics GmbH	Biotech & Therapeutics	start-up
Rigontec GmbH	Biotech & Therapeutics	relocated
Scimab GmbH	Biotech & Therapeutics	start-up
Morphochem AG	Biotech & Therapeutics	re-start
assay.works GmbH	Biotech & Therapeutics	start-up
iOmx therapeutics GmbH	Biotech & Therapeutics	start-up
Immunic AG	Biotech & Therapeutics	start-up
UgiSense AG	Biotech & Therapeutics	start-up

Funding in Bavaria improved in 2016

Funding opportunities in the biotechnology sector have been exceptional for some years, particularly in the USA, and large investments were made in some European countries as well. Even though Germany is still struggling with managing large investment rounds, for a whole range of companies Bavarian enterprises fortunately were among those profiting more than others from this external funding. Companies in the biotechnology sector throughout Germany could raise EUR 508 million in 2016, accounting for about 8% less than the preceding year, but nevertheless almost keeping up with the high levels recorded in 2015. Moreover, the biotechnology sector has become even more attractive on the stock markets: the listed companies have raised EUR 258 million in total, which amounts to a 5% increase on the preceding year (EUR 246 million). BRAIN AG has been the first biotechnology company to go public on the Frankfurt Stock Exchange since 2007. Venture capitalists have invested a total of EUR 216 million in German enterprises, a 17% decrease compared to 2015 records (EUR 260 million). These are the results of a survey carried out by 'BIO Deutschland', an association representing the biotechnology sector, in collaboration with the magazine "Transkript", at the beginning of 2017.

Besides this, Bavarian companies were able to raise about 30% of the entire German biotechnology sector's external funding (debt financing, about EUR 253 million) shared in equal parts between private equity/VC (EUR 123 million) and capital increase via public capital markets (EUR 130 million).

It therefore remains pivotal to fight for better venture capital frameworks, even though some progress has been made after many years of stagnation. External funding opportunities are crucial to young companies in the field of biotechnology. New or changing shareholders are rather frequent due to the often laborious development and should remain affordable without additional fiscal obligations for the affected enterprises.

Indeed, three biotechnology companies from Bavaria managed to announce a successful two-digit initial financing in 2016: Rigontec GmbH, Immunic AG and iOmx Therapeutics AG – with a total volume of more than EUR 70 million.


Employment

Jobs in Biotechnology, Pharma and related suppliers

According to the annual survey of Bio^M carried out for the Bavarian Biotech Cluster, about 360 enterprises actively contribute to the biotechnology and pharmaceutical sector in Bavaria, with 225 companies especially in the biotechnology field at the turn of the year 2016/2017. Fortunately, those companies showed a solid annual growth rate in terms of sales and employment (+5,5%). At the end of 2016, small and medium-sized enterprises (SMEs) employed more than 4,500 people. Together with some large compa-

nies and international branches, the whole sector has about 13,600 employees in Bavaria today. Furthermore, 18,000 staff members working for pharmaceutical companies, clinical research institutions, producers and subcontractors have to be taken into account. Those more than 32,000 people represent a comprehensive, healthy and innovative sector along the pharmaceutical value chain including large production capacities.


NUMBER OF EMPLOYEES IN THE BAVARIAN BIOTECH CLUSTER



Altogether, the sector provides more than 32,000 jobs in industry throughout Bavaria, the greatest portion in the Munich area. In addition there are about 10,000 scientists in LifeSciences in world-renowned institutions in Bavaria (universities, non-university institutes like Max-Planck, Helmholtz and Fraunhofer, hospitals).

No other place in Germany provides you this work force and talent pool in biopharmaceutics.

EMPLOYEES IN BIOTECH IN BAVARIA



For the sake of completeness and currentness of data we do no longer include a survey of company news (financing deals, collaborations...) and the drug and product pipeline in this printed report. Please refer to our website, where all data can be found up to date: www.bio-m.org


Employees total



32,000

+ 4%

Employment in BioPharma
(compared to 2015)



13,600

+ 5,5%

Employment in Biotechnology alone
(compared to 2015)

Look for latest news, figures and trends in Bavaria's Biotech Cluster: www.biotech-bavaria.de



PRECISELY FOR ME.

Dedicated to giving cancer patients
better answers than „maybe“.

Trends and Topics in Bavaria

Trends in Science

The Bavarian biotechnology sector is particularly successful as it is based on global and competitive cutting-edge research. Leading research institutions including two excellent universities and their medical centers, the Max Planck Institutes and the Fraunhofer Institute, as well as the Helmholtz Zentrum München provide the stimulus for the strategic advancement of the whole sector.

Personalized Medicine

The Leading-Edge Cluster Competition held by the German federal government has also significantly influenced the sector. Under the leadership of Bio^M, the Munich region succeeded with the concept “m⁴ – Personalized Medicine and Targeted Therapies”. Between 2010 and 2015, one of the most comprehensive European programs on Personalized Medicine was implemented, including 60 projects and a total volume of more than EUR 80 million. Over the course of the program, drug developers realized that effective therapeutic approaches need stratification and appropriate biomarkers are essential for subgrouping all patients according to their individual characteristics. The collaborative nature of m⁴ program which included joint projects between industry, research institutes and medical centers, largely increased networking and the translation of research findings to the industry.

Digital Health

Besides working closely together, Digitalization of Medicine has to be addressed to make full use of the potential of Personalized Medicine. Research data from medical centers and research institutions have to be integrated in Big Data analysis to gain new insights into relevant findings, an issue which Bio^M is constantly promoting in Munich and Bavaria. To this end, totally new networks are implemented and partnerships established, e.g. in collaboration with the Center for Digitalization in Bavaria (Zentrum für Digitalisierung Bayern, ZD.B) as well as the integrated platform “Digital Health/Medicine” (Digitale Gesundheit/Medizin). Furthermore, systems biology significantly contributes to the analysis and understanding of the “human being as a complex system”. The Research Center for Molecular Biosystems (BioSys-M) was opened at the

Campus Martinsried-Großhadern in 2016 combining the highly interdisciplinary expertise in systems biology of the Ludwig-Maximilians University (Munich). BioSys-M is part of the Bavarian research network BioSysNet, linking the expertise of the Bavarian research sites in Munich, Regensburg, Würzburg, and Erlangen.

Immunotherapy

Bavaria also has outstanding expertise in the field of immunotherapy/immunooncology. This research and treatment approach aims at activating and using the individual immune system of respective patients suffering from diseases which require special medical treatment. It may eventually lead not only to the treatment of cancer but also its permanent cure. With that in mind, Bio^M has built up the company network **ImmPact Bavaria** to pool together the expertise and accompanying skills of participating enterprises. ImmPact Bavaria is designed to advance the development of immunotherapeutics and diagnostics in Bavaria in a more stringent and efficient way. ImmPact Bavaria will collaborate with other initiatives in the field, e.g. the Regensburg Center for Interventional Immunology or the Science Alliance in Immune Medicine.

Stemcell network

The planned Center for Advanced Regenerative Engineering (CARE / ISAR Bioscience) will provide further benefits for drug development in Bavaria. The stem cell institute will develop high-throughput assays for drug research, using induced pluripotent stem cells and individual disease models. Bavaria offers excellent synergies in the field of stem cell research including FORIPS, the Bavarian research network for induced pluripotent stem cells, as well as the Translational Center Würzburg. The latter focuses on contract research for biotechnology, pharmaceutical and medical enterprises as well as medical centers, diagnostic laboratories and research institutes.

International network


The Biotech Cluster aims to advance close collaboration not only in Bavaria but also on an international level. In 2011, Bio^M and the Biotech Cluster in Osaka/ Japan signed an official cooperation agreement. This

partnership involves the mutual exchange of information about new technologies on site, industrial development and academic opportunities as well as discussions on best practices in technology transfer and the support of small and medium-sized enterprises in the biotechnology sector. This will pave the way for fruitful B2B working relationships between companies as well as companies and academic institutes, respectively. This was the basis for the **InnoMuNiCH** project which was started in 2017. The InnoMuNiCH project is funded by the German Federal Ministry of Education and Research (BMBF) and managed by Bio^M. The idea is to link pharmaceutical companies, research groups as well as small and medium-sized biotechnology enterprises from Japan with cooperation partners in Munich, Bavaria and beyond. The ability to effectively translate the findings of academic research into pharmaceutical products is challenging for global

health progress. As many research findings are not directly applicable to major industry projects, small and medium-sized enterprises (SMEs) might function as catalysts in this context. SMEs may significantly increase the process of innovation by evolving small projects step by step. The project offers a platform for German-Japanese cooperation and aims at initiating and enhancing binational joint projects in research and development. Partners on both sides, in Germany as well as in Japan, will profit from this equal cooperation between partners.

EIT Health

Great impetus for innovation as well as entrepreneurship has been given by the European consortium **EIT Health - Healthy Living and Active Ageing**. With a funding volume of up to EURO 700 million as well as a total



Bio^M – 20 YEARS OF LIVING CLUSTER PARTNERSHIP!

- ✓ Excellence in networking plus high-class events & conferences
- ✓ Great supporters of the local biotech companies
- ✓ Best interface between science and industry

HAPPY BIRTHDAY, Bio^M!


volume of more than EURO 2 billion, it constitutes one of the largest publicly funded initiatives in the area of healthcare worldwide. The consortium consists of more than 140 partners from 16 European countries. Bio^M, the Technical University Munich (TUM) and UnternehmerTUM, the Friedrich-Alexander-University Erlangen-Nuremberg, Medical Valley e.V., the Max-Planck-Society, the Fraunhofer Society, and companies like Siemens Healthineers and others are among the Bavarian players. The EIT Health international headquarters are located in Munich. In 2016 and 2017, the first project calls were opened with a focus on entrepreneurship and innovation. Bavarian companies like Arthroscan or Preomics received Head Start funding. Tubulis Technologies was one of the winners of the EIT Health Launch Lab, which offers a program to facilitate and validate business models for future entrepreneurs. EIT Health Launch Lab will stop off at Bio^M in Munich to investigate the German market again in 2017.

Spotlight on Munich Cluster evolution over the years


Most Munich-based biotechnology companies show an enormous potential for innovation. The Biotech Cluster started as spin-off derived from academic research institutes in Munich. The cluster organization has always

aimed to increase cooperation with various well established enterprises, venture capitalists and other investors to support the foundation of new companies. Starting with 30 companies in 1995, about 200 new biotechnology enterprises have since been founded. The graph shows an enormous boom in the late 1990s. Today, more than 188 companies from the biotechnology sector are located in the Munich greater area with an additional 37 enterprises in the rest of Bavaria. 700 companies from the medical technology field are quite evenly distributed in northern and southern Bavaria, with equal shares in Munich and the 'Medical Valley' in Erlangen-Nuremberg.

Constantly increasing employment was recorded in the biotechnology sector in Munich until 2002 (see graph). In the following years, however, employment numbers slightly decreased in the context of small and medium enterprises (SMEs), which was attributed to the difficult funding environment following the financial crisis in 2000/2001, as well as the breakdown of the New Market. Fortunately, the large international companies in the fields of biotechnology and pharmaceuticals located on site were able to compensate for the decline. The whole sector was remarkably robust in view of the financial and economic crisis beginning in 2007. However, several SMEs from the biotechnolo-



SPOTLIGHT ON MUNICH Number of Biotech Companies and Employees in Greater Munich Area, 1997-2016



SPOTLIGHT ON MUNICH Number of Employees in BioPharma in Greater Munich Area, 1997-2016

gy sector, as well as contract research companies and pharmaceutical enterprises had to record a decrease in employment in 2011 and 2012.

Both crises were followed by a fast economic recovery. SMEs from the biotechnology sector experienced a strong boost following their first product launches and drug approvals. This was found to be the first success story of the Munich-based Biotech Cluster. Medigene in Munich was the first German biotechnology company to receive market approval for a drug (Eligard) in 2004, followed by more and more drugs developed in Bavaria over the coming years. Some of them were developed by SMEs in Bavaria and later acquired and brought to the market by larger companies. Eight drugs from the Munich greater area have been approved so far (see table). In addition, market approval of the first therapeutic antibody developed by Morphosys AG (in partnership with Janssen/Johnson&Johnson) is expected this year.

Read more about 20 years of Munich Biotech Cluster development on pp. 22!

Year of approval	Name	Comment	Company
2004	Eligard®	for the treatment of hormone-dependent prostate cancer	Medigene AG
2006	Veregen®	treatment of external genital warts based on green tea extract	Medigene AG
2006	Veregen®	treatment of external genital warts based on green tea extract	Medigene AG
2009	Removab® (Catumaxumab)	EpCAM and CD3 targeting monoclonal antibody to treat malignant ascites, occurring in patients with metastasizing cancer	Trion Pharma and Fresenius Biotech; now marketed by Neovii Biotech
2011	ATG-Fresenius® S	antibody-based immunosuppressant used in organ and stem cell transplantation to suppress graft-versus-host disease or prevent organ rejection	Fresenius Biotech, now marketed by Neovii Biotech
2013	IMVANEX® / IMVAMUNE	active immunization smallpox vaccine	Bavarian Nordic
2014	Blinicyto® (Blinatumomab)	BiTE® antibody for the treatment of ALL	Micromet AG
2016	Endolucin Beta ®	¹⁷⁷ Lu radiopharmaceutical precursor to be coupled with carrier molecules for targeted radionuclide therapy	itm/itg

Founding and Incubation

Entrepreneurs as innovation drivers

The biotechnology sector in Bavaria focuses on the pharmaceutical and diagnostics markets. The role of bio-engineered drugs is increasing in the context of the German health care system, with a share of almost 23% of the whole pharmaceutical market, according to a study published by the vfa bio. New ideas and innovative treatment concepts are prevailing due to excellent scientific institutions in Bavaria. The instant translation of research findings to their application in economic projects in line with patient benefit is essential for the advancement of innovation. The important foundation of innovative companies is enhanced by the initiative “Gründerland Bayern” established by the Bavarian government.

As it is important for new start-ups to receive comprehensive guidance and support through expert networking, Bio^M has developed a multistep program specifically tailored for the biotechnology sector. This program provides support for companies in any stage of business, including possibilities for exchanging experiences

during network meetings (BioEntrepreneur Lounge), as well as a mentoring program (Mentor Circle) where successful entrepreneurs share their experiences. In addition, Bio^M provides a broad range of assistance, such as business development and presentation training (Boot Camp, Pitch Doctor), funding support e.g. the pre-seed competition m⁴ Award, as well as contact to investors in life sciences (BioAngels). This strategy has significantly promoted foundations in the biotechnology sector in terms of quality and numbers, demonstrated by an increased amount of foundations in 2016 (10) compared to 2015 (3), as well as successful fundraising by various Bavarian start-ups recently.



We guide you step by step – from idea to success
www.bio-m.org



THE SUCCESSFUL INNOVATION CENTRE

MADE IN REGENSBURG

Health Industry of Regensburg

- 1.4 billion Euro turnover
- 15,500 employees

Cluster BioRegio Regensburg

- 51 companies (Life Sciences)
- 3,863 employees

BioPark Regensburg

- 18.000 qm area
- 36 tenants
- 600 employees
- flexible leasehold concept & single offices
- comprehensive range of technology & services
- personal consulting and flair
- direct motorway connection
- located on the University Campus (Infrastructure)
- excellent location factors
- own day-care facility
- over 40 start-ups since 1999
- conference rooms and theatre for external rent
- accessible routes to the most important networks
- active location marketing



Member of



A company of the City of Regensburg

BIO**PARK**
R E G E N S B U R G G M B H

Biotech Centers in Bavaria

Regional Networks and Incubators

In the past 20 years, five biotechnology clusters have developed in Bavaria. In the biotechnology regions of Wuerzburg, Regensburg and Munich, the focus lies on biotechnology and healthcare. The other two clusters, Freising-Weihenstephan and Straubing, are specialized more on “white” (industrial) applications of biotechnology. In order to support and make better use of the particularities and strengths of the different regions, individual network organizations are responsible for the management of the respective clusters. Bio^M Biotech Cluster Development GmbH manages the metropolitan region of Munich, ranging from the Alps in the South nearly up to the river Danube in the North. The BioPark Regensburg GmbH manages the region in and around Regensburg and the IGZ Center’s organization represents the region of Wuerzburg and Northern Bavaria. Their objective is the development and marketing of the respective clusters in the interest of the founders, companies and scientists in each location. Furthermore, they are building a network of companies, universities, research facilities, university hospitals, chambers and associations, investors, funding authorities, advisers, and other players in the clusters. Bio^M Biotech Cluster Development GmbH has been coordinating and networking the biotechnology activities and endeavours all over Bavaria since 2006.

Erlangen and Nuremberg

The European Metropolitan Area Erlangen-Nuremberg is an internationally leading location for medical technology.

Cluster organization:

Medical Valley

Incubator: Medical Valley Centers in Erlangen (>5,000 sqm) and Forchheim (>2,300 sqm)

www.medical-valley-emn.de



Munich

Bio^M is located in Martinsried, the heart of the Munich Biotech Cluster. The cluster has a strong focus on health, i.e. personalized medicine. The cluster organization Bio^M is the central point of contact for the biotechnology sector in Munich and Bavaria. Bio^M offers a wide range of services and events and has developed a comprehensive incubation programme for company founders in the field of biotechnology.

www.bio-m.org



IZB Martinsried and Freising

The Innovation and Start-up Center for Biotechnology (IZB) in Planegg-Martinsried (focus on medical biotechnology) and Freising-Weihenstephan (focus on bio, agricultural and nutritional sciences) has developed into one of the top biotechnology centers in the world and offers young biotech start-ups 26,000 sqm of optimal building infrastructure for biotechnology.

www.izb-online.de





Wuerzburg

The Innovation and Start-up Center close to the Julius-Maximilians-University offers lab space and has developed a comprehensive programme for promoting start-up activities in the region.
 Cluster organization: Innovation- and Start-up Center (IGZ) Wuerzburg
 Incubator: IGZ Wuerzburg (>5,000 sqm)
www.igz.wuerzburg.de




Regensburg

The start-up center on the campus of the University of Regensburg offers state-of-the-art laboratories as well as comprehensive technology services.
 Cluster organization: BioPark Regensburg
 Incubator: BioPark Regensburg (>18,000 sqm)
www.bioregio-regensburg.de



Straubing

Straubing is a hot spot for industrial biotechnology. Its core competency is creating value from renewable resources, and residues, biomass logistics and start-up management.
 Cluster organization: BioCampus Straubing
 Incubator: BioCubator (1,200 sqm)
www.biocampus-straubing.de



Industrial Biotechnology in Bavaria

Managed by Industrielle Biotechnologie Bayern Netzwerk GmbH – in brief IBB Netzwerk GmbH. Established in 2008, IBB Netzwerk GmbH catalyzes the implementation of innovative biotechnological processes and industrial procedures. The main task is to connect partners from large industry, small and medium-sized enterprises, and academia, to implement joint projects.
www.ibb-netzwerk-gmbh.com

20 Years Munich Biotech Cluster - 20 Years Bio^M

History of the Munich Biotech Cluster

Munich was one of the BioRegio Competition winners in 1996. With the foundation of the cluster management organization Bio^M in 1997, the Munich Biotech Cluster was born 20 years ago. To mark this anniversary, we have selected certain milestones achieved by Munich as it developed into a global and successful biotechnology region. The main focus here is on the development of companies in Martinsried which today is the heart of the Munich Biotech Cluster.



Initial nucleus: The Max Planck Institute of Biochemistry was founded in 1973.

Pioneers: Mikrogen was set up as the first Munich-based biotechnology company in 1989. Other companies including MorphoSys (1992), Micromet (1993) and Medigene (1994) were established in the following years.

Public-Private-Partnership: The Gene Center was founded in Martinsried in 1984. It was set up as a very first „Biotech Cluster“ with several research groups from the field of applied molecular biology.

1970er

1980er

1989

1990

1991

Groundbreaking: Boehringer Mannheim established the Penzberg Biotechnology Center (1972) and the Genetics working group in Tutzing (1977).

High-end medicine: The University Hospital of the LMU in Großhadern was opened in 1974.

Genetic Engineering Act: Legal framework conditions for genetic engineering were developed for Germany in 1990. The amendment of 1993 provided considerable relaxation.



BioRegio Competition: The BioRegio Competition was launched by the former Ministry of Research and Technology to make biotechnology more economically viable and to catch up with progress made in the USA. The former Head of the Gene Center, Prof. Dr. Ernst-Ludwig Winnacker, and his team applied for the competition with a concept to advance innovation and the dream of a Munich Biotech Cluster. In 1996, Munich was one of the competition winners, receiving funding of 50 million DM (about 25 million Euro). That could be given to companies in the biotechnological sector to fund 50% of their project costs. By 2000, more than 20 companies in the Munich area were able to profit from it.



IZB: The Innovation and Start-Up Center for Biotechnology was launched in Martinsried in 1995.

Research and Production: Roche took over Boehringer Mannheim in 1997. The Penzberg site expanded greatly over the course of the following years.

1993

1994

1995

1996

1997

New building: The Gene Center on the Campus of Martinsried-Großhadern was opened in 1994.



Anniversary: The cluster management organization Bio^M was set up in 1997 to coordinate the implementation of the BioRegio concept. Horst Domdey was appointed as chief executive of Bio^M AG.



Pharma: MSD Sharp & Dohme (the German branch of Merck & Co.) was established in Haar near Munich in 1994.



Cluster expansion: Launch of the Innovation and Start-Up Center for Biotechnology in Weihenstephan north of Munich in 2002.

Up- and Downturn: The record amount of 500 million external financing was reached in 2000. But almost simultaneously, the research-intensive, high-risk biotechnology sector had to learn its lesson after the breakdown of the so-called *New Market* at Frankfurt Stock Exchange. Investment dropped sharply with significant effects over the next few years such as decreased numbers of Biotech funds and IPOs. However, increasing numbers and more active VC companies have been reported since 2014.

IPO: MorphoSys was the first Munich biotechnology company to go public in 1999, followed by GPC and Medigene one year later.

1998 1999 2000 2001 2002

Localization: The Faculty of Chemistry and Pharmacy (LMU) was transferred to Martinsried-Großhadern in 1999.

TUM: Foundation of the TUM School of Life Sciences Weihenstephan in 2000.
(Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt)



Booming Biotech: In 2001, there were already more than 100 biotechnology enterprises located in Munich.

Network: Since 2001, Bio^M has constantly offered expert lectures, discussion forums and other events. Moreover, Bio^M has regularly invited international pharmaceutical and biotechnology companies to convince them of the location's research quality. In 2001, one of the first partnering events was held in collaboration with Genentech (now Roche), many others of Top-20 pharmaceutical companies followed until today.

Funding: Since 2001, Bio^M has developed new funding sources, has offered consulting in terms of business development and has helped companies to apply for public funding programmes.

New tasks: Bio^M separated investment activities (now Bio^M AG) from cluster development and networking (now Bio^M GmbH). The *Bavarian Biotechnology Cluster* was founded in 2006 by the Bavarian government and Bio^M GmbH was engaged in connecting all biotechnology regions in Bavaria.



2005: Novartis took over Hexal and relocates the *International Generica Division Headquarters* to Holzkirchen near Munich. The Strüngmann Brothers (former Hexal owners) started investing in German Biotechnology.

Biocenter: The Faculty of Biology (LMU) opened the Biocenter at the Campus Martinsried-Großhadern in 2004.

2003

2004

2005

2006

2007

Medical engineering: General Electric Healthcare (GEHC) opened its European R&D Center in Garching in 2004.



Ready for the market: In 2004, Martinsried-based Medigene was the first German biotechnology company to launch a drug.



Elite Universities: The two Munich Universities (LMU and TUM) succeeded in the German Universities Excellence Initiative (2006).






Major Deal: Amgen purchased Munich-based Micromet (Inc.) for 1.2 billion dollars in 2012. Munich developed into Amgen's largest research center outside the USA.

Personalized medicine: The future strategy "m⁴ – Personalized Medicine and Targeted Therapies" was among the winners of the BMBF Leading-Edge Cluster Competition in 2010. The Leading-Edge Cluster managed by Bio^M has funded 60 collaborative projects between 2010 and 2015. Personalized medicine is increasingly considered indispensable for the development of safer and more effective drugs. Moreover, mutual trust increases between the industrial and academic sectors leading to successful collaborations. Bio^M developed a comprehensive concept for supporting start-ups, which continues til today.

The applicants (from left to right): Dr. Moroney, MorphoSys AG; Prof. Dr. Domdey, Bio^M GmbH; Prof. Dr. Muntau, LMU; Prof. Dr. Wess, HMGU; Dr. Käab, Bio^M GmbH, Prof. Dr. Peschel, TUM



Innovation: Removab (Trion Pharma/ Fresenius Biotech) is the world's first multi-specific antibody, which was developed in Munich and brought to market in 2009.

Branching: Between December 2010 and March 2012, three US companies specializing in personalized medicine opened up new branches in Munich: Exosome Diagnostics, Lab-PMM and Myriad.

Partnership: Bio^M and the Life Science Cluster of Osaka/Japan signed a collaboration agreement in 2011.



Hotel: Opening of the IZB Residence at the Campus Martinsried-Großhadern (2014). After several extensions, the total area of the Innovation and Start-Up Center for Biotechnology (IZB) in Martinsried and Weihenstephan amounts to more than 26,000 m².

EIT Health: The European headquarters of EIT Health was opened in Munich in 2014. Bio^M is a partner in the largest European healthcare initiative comprising 140 partners from 16 countries.

BMC: The Biomedical Center dedicated to applied cell research was opened at the Campus Martinsried-Großhadern in 2015.



BioSys-M: Opening of the Research Center for Molecular Biosystems at the Campus Martinsried-Großhadern (2016).

2013

2014

2015

2016

2017

Award: Bio^M was awarded the *European Gold Label for Cluster Excellence* in 2013.

Investment: In 2015, Roche invested about 600 million Euro in biopharmaceutical production facilities, an education center, diagnostics production facilities as well as infrastructure in Penzberg. 5,800 people work at this location today.



Medicine of the future: Bio^M constantly initiates new projects. Digitalization of the medical sector is promoted in cooperation with the Center for *Digitalisation in Bavaria* (Zentrum Digitalisierung Bayern). The network *ImmPact Bavaria* pools Bavarian immunotherapy expertise. The project *InnoMuNiCH* aims to increase Bavarian-Japanese research collaboration and deepen existing partnerships between the Munich Biotech Cluster and Japan.

Company Profiles



Contact:
Dr. Thomas Schubert

Am BioPark 13, BioPark III
D-93053 Regensburg
Phone: +49 (0) 160 96938061
E-Mail: info@2bind.de
Internet: www.2-bind.com



Contact:
Dr. Anna Niedl

Fraunhoferstraße 22
D-82152 Martinsried
Phone: +49 (0) 89 700763-0
Fax: +49 (0) 89 700763-29
E-Mail: public@4sc.com
Internet: www.4sc.com

2bind GmbH

BIOTECH DNA & PROTEIN ANALYTICS

Keywords: Antisense/Nucleotides, Drug Development, Peptide/Protein, Molecular Diagnostics, Antibiotics, Small Molecules

The 2-bind GmbH is a service provider for molecular interaction analyses based on the patented and powerful Microscale Thermophoresis technology of Nano Temper. This new technology detects changes in the hydration shell of molecules in solution and is the ideal assay for measuring biomolecule interactions and for determination of dissociation constants. Applications range from the analysis of molecular interactions to enzymatic assays.

- Advantages of Microscale Thermophoresis
- Measurement in solution without surface immobilisation
- Free choice of reaction conditions
- Small reaction volumes (3 µl) with low material requirement
- Fast measurements in a dynamic range (nM-mM)
- Interactions between very small and very large molecules can be determined

4SC AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Autoimmune Diseases, Small Molecules, Molecular Modelling, Medicinal Chemistry, Drug Development, Oncology

The Group managed by 4SC AG discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises products in various stages of clinical development and drug discovery. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount of 66 employees at 31 December 2014.

ABF GmbH

CRO

Metabolomics, Analytical Chemistry, Biomarker Discovery & Development

ABF is an accredited (ISO 17025, GLP) bioanalytical contract research laboratory with almost three decades of experience in method development, validation and application in the field of biomarkers and biomonitoring. The lab has particular experience in the analysis of compounds within clinical and toxicological studies by application of LC-MS/MS and GC-MS(/MS). Clients are from the occupational, environmental, food, tobacco and pharma fields. Since end of 2001, ABF provides its services to corresponding industry, academic and governmental institutions. We can offer skills of a staff (10 employees), almost all of them with an academic background, with a wide range of know-how, allowing flexible working approaches. Our aim is to provide excellent, high quality services; meeting or exceeding our customers expectations. Our service goes beyond sample analysis, we help customers to evaluate and interpret data.

abf diagnostics GmbH

PHARMA SUPPLIER & TRADE

abf diagnostics develops, manufactures and markets products and solutions for the collection, storage, transport and preparation of biological traces and samples. We supply products for advanced pre-analytics in forensics, toxicology and medical or veterinary diagnostics. In our business unit Digital Imaging and Detection we are marketing contact-less methods for the detection, identification and documentation of forensic and biological/chemical traces.

advanceCOR GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Peptide/Protein, Drug Development, Inflammation

advanceCOR is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. They concentrate on innovative biological drugs in indications with unmet medical needs. One innovative drug, Revacept is currently in phase II clinical development for the treatment of stroke and acute coronary and cerebral vascular syndromes. Revacept is a lesion-specific inhibitor of atherothrombosis. Further preclinical candidates are under development, i.e. COR-2 and COR-3. COR-2 is a biological which prevents foam cell formation in atherosclerotic plaques. COR-3 is a recombinant protein which binds to atherosclerotic plaques and then bi-specifically binds to circulating progenitor cells. advanceCOR is financed by the MIG AG, KfW Bank, Bayernkapital, HTGF and Bio^M AG. The founders and management of advanceCOR bring together knowledge and reputation in research and clinical medicine together with biotech experience.



Contact:
Dr. Max Scherer

Goethestr. 20
D-80336 München
Phone: +49 (0) 89 535395
E-Mail: max.scherer@abf-lab.com
Internet: www.abf-lab.com

abf diagnostics GmbH

Contact:
Dr. Franz Aberl

Raiffeisenstraße 34
D-85402 Kranzberg
Phone: +49 (0) 8166 9958 14
Fax: +49 (0) 8166 9958 13
E-Mail: info@abfdiagnostics.com
Internet: www.abfdiagnostics.com



Contact:
Prof. Dr. Götz Münch

Fraunhoferstr. 9a
D-82152 Martinsried
Phone: +49 (0) 89 2000 204-10
Fax: +49 (0) 89 2000 204-20
E-Mail: info@advancecor.com
Internet: www.advancecor.com



Contact:
Dr. Dr. Mohammad Naraghi

Berger Straße 8 - 10
D-82319 Starnberg
Phone: +49 (0) 8151 9987-001
Fax: +49 (0) 8151 9987-499
E-Mail: info@aenova-group.com
Internet: www.aenova-group.com



Contact:
Prof. Dr. Gottfried Brem

Larezhausen 2
D-86567 Hilgertshausen
Phone: +49 (0) 8250 9279040
Fax: +49 (0) 8250 9279049
E-Mail: info@agrobiogen.de
Internet: www.agrobiogen.de



Contact:
Dr. Stefan Schwab

Cauerstr. 4
D-91058 Erlangen
Phone: +49 (0) 9131 85-29452
Fax: +49 (0) 9131 85-29449
E-Mail: info@agrolytix.com
Internet: www.agrolytix.com

Aenova Holding GmbH

PHARMA & CHEMICAL INDUSTRY, CMO

With a planned turnover of around EUR 760 million in the current financial year, the Aenova Group is one of the leading companies in the global pharmaceutical and healthcare industry. The group's portfolio of services covers the entire value chain for the development and production of all the main dosage forms and product groups in the field of medicines and dietary supplements. The Aenova Group's high standards of quality, innovative technologies and clear vision for the future have enabled it to become European market leader in the business-to-business field. The company, which has its headquarters near Munich, operates 28 sites in eleven countries throughout the world. More than 4400 employees contribute to the group's success.

Agrobiogen GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Transgenic Animals, Gene Transfer, Genomics, Xenotransplantation, Automation

Agrobiogen focuses on and is experienced in the application of molecular-genetic techniques in livestock animals (especially molecular-genetic diagnostics and gene transfer). Many transgenic rabbit lines and several cattle clones have been established. As a service for other biotech companies transgenic farm animals are generated using conventional microinjection procedures and nucleus transfer. Detection of pathogens like BVDV, as well as parentage control of animals, SNP genotyping and analysis of DNA markers are offered as a service for breeders, veterinarians and companies. Agrobiogen has developed a simple labour-saving system for collection of tissue samples and extraction of DNA from millions of animals for high-throughput analysis.

Agrolytix GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Agrolytix is your competent partner around the themes of microencapsulation and micronization. The company specializes in the areas of agrochemicals and cosmetics. We are happy to assist in the development and production of your new products or offer you our technologies as services.

Alcon Pharma GmbH Division Vision Care

PHARMA & CHEMICAL INDUSTRY

Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. The three Alcon businesses - Surgical, Pharmaceutical and Vision Care - offer the widest spectrum of eye care products in the world. Alcon is the second largest division of the Novartis Group, with pro-forma sales of USD 10.5 billion in 2013. Headquartered in Fort Worth, Texas, USA, Alcon has more than 25,000 employees worldwide, operations in 75 countries and products available in 180 markets. For more information, visit www.alcon.com.

ALGORA Gesellschaft für Medizinstatistik und Vertriebssysteme mbH

CRO

Keywords: Infectious Diseases, Oncology

Algora is a niche CRO successfully operating on clinical trials in Germany. Services include phase II-IV trials as well as large observational studies and range from protocol development to final study reports. Algora manages complete study projects or delivers individual services, such as clinical monitoring, data management or statistical analysis. Experienced in oncology since the first days of the company in 1989, Algora always had a focus on innovative therapies, leading to close relationships to university hospitals and medical societies. Since 1995 another focus developed in large pediatric studies. Customers are pharmaceutical and medical device companies, independent research groups, and other CROs.

Altmann Analytik GmbH & Co. KG

PHARMA SUPPLIER AND TRADE

Keywords: Analytical Chemistry, Laboratory

Consumables for Chromatography (HPLC & GC), Spectroscopy (lamps & flow cells) and Sample Prep (syringe filters, vials and caps). For more than 30 years Altmann Analytik from Munich, Germany, has been your competent and independent partner for instrumental analytics. Our main areas are Chromatography, Spectroscopy, and Sample Prep. We provide more than 140,000 different lab supply products from more than 30 different high-quality manufacturers, such as Agilent Technologies, Chiral Technologies, Grace, Hamilton, Macherey Nagel, Merck, Millipore, PerkinElmer, Thermo Fisher, Waters, Whatman and YMC. Our products can be found and purchased online.



Contact:
Jan Thore Föhrenbach

Bauhofstr. 16
D-63762 Großostheim
Phone: +49 (0) 6026 941-0
Fax: +49 (0) 6026 941-393
E-Mail: info@cibavision.de
Internet: www.alcon-pharma.de



Contact:
Dr. Karl Fehnle

Münchner Str. 11
D-85540 Haar
Phone: +49 (0) 89 613727-0
Fax: +49 (0) 89 613727-20
E-Mail: cro@algora.de
Internet: www.algora.de



Contact:
Tobias Thelen

Rupert-Mayer-Str. 46
D-81379 München
Phone: +49 (0) 89 724805-90
Fax: +49 (0) 89 724805-91
E-Mail: info@altmann-analytik.de
Internet: www.altmann-analytik.de



Contact:
Dr. Corinna Jacob

Riesstraße 24
D-80992 München
Phone: +49 (0) 89 149096-0
Fax: +49 (0) 89 149096-2000
E-Mail: corinna.jacob@amgen.com
Internet: www.amgen.de



Contact:
Susanne Sporer

Staffelseestr. 2
D-81477 München
Phone: +49 (0) 89 895277-0
Fax: +49 (0) 89 895277-205
E-Mail: susanne.sporer@amgen.com
Internet: www.amgen.de



Contact:

Am BioPark 11
D-93053 Regensburg
Phone: +49 (0) 941 2000 1240
Fax: +49 (0) 941 2000 1241
E-Mail: contact@assay.works
Internet: www.assay.works

AMGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Nephrology, Bone/Joint Diseases, Oncology

Amgen GmbH is an affiliate of Amgen Inc. (Applied Molecular Genetics). The US based company discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, osteoporosis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

AMGEN Research (Munich) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Immune Therapy, Drug Development, Antibody, Oncology

Amgen Research (Munich) GmbH, former Micromet, puts novel concepts in immunotherapy to work. Using proprietary technologies, the company is building a strong pipeline of innovative drug candidates for the treatment of cancer, inflammation and autoimmune disease. It has established a powerful drug development platform: BiTE™ ("Bispecific T cell engagers"), a unique drug format that leverages the outstanding cytotoxic potential of T cells to precisely eliminate pathogenic cells. Amgen Research (Munich) is an affiliate of Amgen Inc. (Applied Molecular Genetics Inc.). The US based company discovers, develops, manufactures and delivers innovative human therapeutics.

Assay.Works GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Oncology, Neurology, Inflammation, Hematology, Small Molecules, Drug Development

Our mission is to accelerate our partner's research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities. We combine scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results.

AmplexDiagnostics GmbH Gesellschaft für molekularbiologische Diagnostik

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Infectious Diseases, PCR, Clinical Diagnostics

AmplexDiagnostics GmbH is a privately held company for the development, production and distribution of In Vitro Diagnostics. Our aim is the improvement of the potential of the PCR-technology by implementing the main advantages of this technology into the diagnosis of bacterial infections. Founded in 2002 - Amplex developed its first product (hyplex® StaphyloResist) and entered the market already in 2003. Additional systems for the direct detection of multidrug-resistant bacteria (like VRE, ESBL, KPC and NDM-1) are completing our portfolio of PCR-screening tests for nosocomial infections causing „bugs“. Beside this we offer several PCR-based screening tests for sexual transmitted diseases, EHEC or TBC.

AMS Advanced Medical Services

CRO

Keywords: Pharmacology, Medical Writing

AMS is a privately owned, independent mid-size CRO and a competent partner to the pharmaceutical and healthcare industry since 1997. Today over 250 employees work in the business areas Medical Science, Clinical Research and Marketing & Sales. As an experienced CRO, AMS offers 360° customer support in Clinical Trials phase II - IV and non-interventional studies, Data Entry, Data Management, Biostatistics, Pharmacovigilance/Clinical Safety and Medical Writing. In addition we offer Quality Management including the conduction of Audits and provide support in Regulatory Affairs and Market Authorization. AMS invented the first Internet-Pharmaschool with trainers and techniques offering tailor-made training concepts for staff in both clinical research and sales. AMS is a full-service CRO with significant experience in multiple therapeutic areas and strong medical expertise. The Medical Science Team of AMS combines years of experience in the global clinical development and benefit assessment of pharmaceuticals with the extensive knowledge in the field of pharmaceuticals and medical devices. We are an interdisciplinary team of more than 40 experts with profound experience in Biostatistics, Medical Writing, Health Economics, Public Health and Project Management. Our Team is supported by experts with over 15 years of experience in global clinical drug development. We are pioneers for the benefit assessment of pharmaceuticals since the German Act on the Reform of the Market for Medicinal Products came into effect in 2011. Due to our wide experience in methodological requirements we are also a strong European partner in the field of Health Technology Assessments (HTAs), Relative Effectiveness Assessments (rapid REAs) for pharmaceuticals and medical devices as well as method assessments for medical devices in Germany. Benefit from our extensive experience by choosing AMS as a competent and reliable partner for projects in the life cycle of your pharmaceutical or medical product.



Contact:
Dr. Lars Wassill

Werkstr. 2
D-83555 Gars-Bahnhof
Phone: +49 (0) 8073 91693-0
Fax: +49 (0) 8073 91693-33
E-Mail: info@amplexdiagnostics.de
Internet: www.eazyplex.com



Contact:
Dr. Gerlinde Jänel

Rosa-Bavarese-Str. 5
D-80639 München
Phone: +49 (0) 89 2000074-100
Fax: +49 (0) 89 2000074-400
E-Mail: Medical.Science@ams-europe.com
Internet: www.ams-europe.com



Contact:
Jens Klein

Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 579 5393-0
Fax: +49 (0) 89 579 5393-30
E-Mail: info@amsilk.com
Internet: www.amsilk.com

amYmed

Contact:
Prof. Dr. med. Reinhold P. Linke

Vinzenz-Schlüpfer-Straße 20a
D-81475 München
Phone: +49 (0) 89 745 022 73
Fax: +49 (0) 89 75 999 347
E-Mail: linke@amymed.de
Internet: www.amymed.de

AMSilk GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: New Materials, Industrial Biotechnology

AMSilk GmbH is the world's first industrial supplier of synthetic silk biopolymers and has its headquarters in Planegg near Munich, Germany. Sustainably produced using a patented biotechnological process, AMSilk high-performance biopolymers have the unique functional properties of the natural product they are based on. The organic high-performance material can be used in multiple ways, including in medical or technical products as well as cosmetic ingredients. AMSilk high-performance biopolymers give everyday products unique properties. Among other things, the polymers are biocompatible, breathable and especially robust. AMSilk high-performance biopolymers are distributed in the form of Silkbeads (microparticles), Silkgel (hydrogel) or Biosteel® (fibers). They are currently used in coatings for medical-technology products, in the textile industry and as an ingredient in personal care products.

amYmed GmbH Referenzzentrum für Amyloidkrankheiten

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Antibody Production Service, Devices, Antibody

The Reference Center of Amyloid Diseases specializes in the diagnosis of amyloid and amyloidosis, and its analysis and offers three types of service. We can provide you with a highly sensitive diagnosis at even the earliest stages of amyloidosis and a precise, fast classification of amyloid and amyloidosis, based on your submitted tissue samples.

The Reference Center of Amyloid Diseases can provide you with the respective panels of amyloid antibodies, "amY-kit", so you can classify the amyloids on tissues of your own patients in your institution if you possess immunohistochemistry facilities.

We also offer training courses for the efficient use of these antibodies, and seminars concerning all aspects of diagnosing the various amyloidoses and other protein storage diseases.

We are looking forward receiving your samples for amyloid typing. Achieve the same reliability in amyloid typing by using our antibodies.

apceth GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Gene Therapy, Cell Therapy, Autoimmune Diseases, Drug Development, Respiratory Diseases, Inflammation, Oncology

apceth - The cell engineering company!

PROPRIETARY TECHNOLOGY & PRODUCTS

- Clinical stage biopharmaceutical company
- Leader in the development of cell-based gene therapies
- Genetically engineered mesenchymal stem cell therapeutics
- Immunomodulation, major chronic diseases, cancer

CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION

- Reliable, experienced and high-performance partner
- Complex cell-based and gene therapy products (ATMPs)
- Process, product and assay development
- Clinical and commercial GMP manufacturing
- GMP-certified since 2010

APEX GmbH

CRO

Keywords: Pharmacology, Drug Development, Pharmacokinetics, Diabetes, Hepatology, Nephrology

- Our Concept... APEX is a highly efficient combination of investigator and CRO. Our aim is to provide our clients with a service which combines the access to patients of an investigator with the expertise to perform a complex, high quality research project of a CRO. We combine high level phase 1 data quality with the typical phase 2/3 study population.
- Our Service... Is the clinical performance of pharmacokinetic and proof-of-concept / PKPD studies.
- Our Study Population... are patients with impaired renal or hepatic function and patients with other chronic stable diseases (diabetes, hypertension, asthma etc.). Since the patients come into our clinic, rather than us having to go to them via their GP's, the data we generate are more complete and accurate, fewer patients are required and the project can be completed faster.
- Our Clients... are international pharmaceutical companies from medium sized to members of the world's top ten.



Contact:
Dr. med. Christine Günther

Max-Lebsche-Platz 30
D-81377 München
Phone: +49 (0) 89 7009608-0
Fax: +49 (0) 89 7009608-130
E-Mail: contact@apceth.com
Internet: www.apceth.com



Contact:
Dr. med. Gertraud Haug-Pihale

Landsberger Str. 476
D-81241 München
Phone: +49 (0) 89 896016-0
Fax: +49 (0) 89 896016-33
E-Mail: apexpkpd@aol.com
Internet: www.apex-research.com

aptaIT

Contact:

Dr. Raymund Buhmann

Zenettistr. 11

D-80337 München

Phone: +49 (0) 89 59918-123

Fax: +49 (0) 89 59918-125

E-Mail: info@aptait.de

Internet: www.aptait.de



Contact:

Karina Oppitz

Georg-Brauchle-Ring 64-66

D-80992 München

Phone: +49 (0) 89 4544-1057

Fax: +49 (0) 89 4544-1329

E-Mail: info@de.astellas.com

Internet: www.astellas.de

AptaIT GmbH

BIOTECH BIOINFORMATICS

Keywords: Immune Therapy, Personalized Medicine, Genomics, Informatics

AptaIT is a bioinformatics company dedicated to develop advanced and user-friendly software solutions for sequence driven biomedical research. Next-generation sequencing (NGS) currently transforms the procedures of modern drug discovery. AptaIT has developed intelligent software algorithms with an emphasis to discovery platforms of novel biologics by in vitro selection strategies or analysing the adaptive immune repertoire and response. THE SOFTWARE ENABLES - intelligent and efficient analysis of next-generation sequencing data. - profound quality control of synthetic nucleic acid libraries. - accelerated identification of ligands in combinatorial approaches. - comprehensive profiling of the adaptive immune repertoire. - improved patenting strategies by profound sequence information.

Astellas Pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Inflammation, Infectious Diseases, Immune Therapy, Autoimmune Diseases, Allergy, Antibiotics, Drug Development

Astellas Pharma Inc. was formed in April 2005 from a merger with Yamanouchi and Fujisawa. Astellas Pharma ist Japan's second largest pharmaceutical company and is headquartered in Tokio. It has operations in Europe, Asia, North and South America, South Africa and Japan. Astellas is focused on the following key therapeutic areas: Transplantation, urology, dermatology, anti-infectives, pain and oncology. Astellas employs approx. 3,300 people in Europe across Sales & Marketing, Research & Development and Manufacturing. Astellas has 21 Sales & Marketing affiliates, 3 manufacturing plants and 1 R&D site in Europe. Astellas Europe is headquartered just outside London in Chertsey. The German headquarters are based in Munich. Located here are Sales, Marketing and Medical. The product portfolio includes therapies in transplantation, urology, oncology, dermatology, asthma/COPD, cardiology, infectious diseases, gastroenterology and pain. Astellas Pharma GmbH employs approx. 380 people including 230 sales representatives.

Avergen Pharmaceuticals

BIOTECH THERAPEUTICS & DIAGNOSTICS

Avergen Pharmaceutical GmbH (APG) creates long-term value through internal and collaborative innovative drug discovery programs based on novel drug targets. APG is using a platform to identify and develop protein-protein interaction (PPI) inhibitors. APG is dedicated on its core competences in neurodegenerative disease and oncology research. APG is focused on drug development until phase II clinical studies. The location of the company in Munich enables the access to experienced experts in the field of drug discovery and development, as well as business development and commercialization.

Axolabs GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: RNAi & Antisense, Antisense/Nucleotides, Aptamer Technology, Pharmacokinetics, Pharmacology

Axolabs is a preclinical research organization for oligonucleotide therapeutics. Based on the foundations of the former Roche Center of Excellence for RNA Therapeutics, we leverage our world-leading know-how and 14+ years of experience to provide high-end preclinical solutions and consultancy tailored to your specific needs. Oligonucleotide Manufacturing: High-throughput up to large scale, sequence/ structure optimization, drug substance production for GLP-Tox, process development, regulatory documentation; Analytics and Bioanalytics: HPLC, UPLC, MS, CAD, CE, DSC, thermophoresis etc., pharmacokinetics and biodistribution, ADME and DMPK; Pharmacology: Lead identification and optimization, in vivo efficacy and early safety, delivery.

baseclick GmbH

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Nanobiotechnology, Chip/Array Technology, New Materials, Fine Chemicals/Reagents, Clinical Diagnostics

baseclick GmbH is an ISO9001:2015-certified company located in Neuried, Germany, and was founded in 2008 with the shareholders of BASF SE, Ludwigshafen and the LMU Munich. The core of the baseclick technology is the „click reaction,“ a Cu-catalyzed cycloaddition allowing virtually unlimited and highly efficient functionalization of nucleotides, small synthetic oligonucleotides and large gene fragments. The Scripps Research Institute patented the click chemistry of the inventor B. Sharpless, Nobel laureate 2001. Beside our own patents, baseclick holds an exclusive worldwide license for the use of this technology in the field of nucleic acids and offers this technology just as products like cell proliferation kits, modified oligonucleotides, FISH products, click reagents and many more.



Avergen Pharmaceuticals

Contact: Dr. Murat Yildiz

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 9627 9914
E-Mail: murat.yildiz@avergen.com
Internet: www.avergen.com



Contact:
Dr. Roland Kreutzer

Fritz-Hornschuch-Str. 9
D-95326 Kulmbach
Phone: +49 (0) 9221 82762-0
Fax: +49 (0) 9221 82762-99
E-Mail: info@axolabs.com
Internet: www.axolabs.com



Contact:
Dr. Thomas Frischmuth

Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 89 9699 3401
Fax: +49 (0) 89 9699 4696
E-Mail: info@baseclick.eu
Internet: www.baseclick.eu



Contact:

Elsenheimerstraße 7
D-80687 München
Phone: +49 (0) 89 7857674-0
Fax: +49 (0) 89 7857674-100
E-Mail: basilea.info@basilea.com
Internet: www.basilea.com



BAVARIAN NORDIC

Contact:
Derek Beggs

Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 255446-030
Fax: +49 (0) 89 255446-333
E-Mail: derek.beggs@bavarian-nordic.com
Internet: www.bavarian-nordic.com



Contact:
Lutz Knabe

Edisonstr. 4
D-85716 Unterschleißheim
Phone: +49 (0) 89 31701-0
Fax: +49 (0) 89 31701-177
E-Mail: info_de@baxter.com
Internet: www.baxter.de

Basilea Pharmaceutica Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Antibiotics, Allergy, Dermatology, Infectious Diseases, Oncology

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland. The company currently focuses on antibiotics and antifungal as well as oncology and dermatology drugs, targeting the medical challenge of rising resistance and non-response to current treatment options in the hospital and specialty care settings. Basilea Pharmaceutica Deutschland was founded 2007 in Munich. Skin diseases are an area of high medical need. Patients are suffering from disfiguring conditions such as hand eczema. Alitretinoin (Toctino®), a vitamin A derivative offers a significant quality of life improvement in the treatment of adults with severe chronic hand eczema unresponsive to topical corticosteroid.

Bavarian Nordic GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Vaccines, Drug Development

Bavarian Nordic (BN) is a leading international biopharmaceutical company developing innovative vaccines to prevent and treat infectious diseases. The company is capable to meet the growing demand for safe 3rd generation smallpox vaccines due to its proprietary vaccine technology MVA-BN®. BN was founded in 1994 and is headquartered in Kvistgaard, Denmark with subsidiary operations in Martinsried and Berlin, Germany. BN recently founded in the US an operating company, BN ImmunoTherapeutics Inc., for research and development of cancer vaccines. The company employs about 180 people and is listed on the Copenhagen Stock Exchange. More than 450 healthy and immune compromised subjects so far vaccinated with MVA-BN®, suggest an excellent safety and efficacy profile of the vector.

Baxter Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Nephrology, Autoimmune Diseases, Oncology, Pain, Immune Therapy, Vaccines, Tissue Engineering/Cell Culture

Baxter International Inc. (NYSE: BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Beckman Coulter Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Nanobiotechnology, Automation, PCR

Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. Our diagnostic systems are found in hospitals and other critical care settings around the world and produce information used by physicians to diagnose disease, make treatment decisions and monitor patients. Scientists use our life science research instruments to study complex biological problems including causes of disease and potential new therapies or drugs. Hospital laboratories are our core clinical diagnostic customers. Our life science customers include pharmaceutical and biotechnology companies, universities, medical schools and research institutions. Beckman Coulter has an installed base of more than 200,000 clinical and research systems operating in laboratories around the world. Beckman Coulter has a leading position in Laboratory Automation. Research & Development as well as Production of our stand alone automation systems, the AutoMate 2500 Family (formerly known as OLA 2500), are located in Munich, Germany.

bene-Arzneimittel GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, Drug Development

bene-Arzneimittel GmbH has been producing high quality pharmaceuticals in Munich for 65 years. As a traditional and innovative family business, people are always at the center of our actions. Our branded products are available in 30 countries with the highest standards of quality and compatibility. More than 100 employees are constantly working to develop new products, active ingredients, dosage forms and preparations for our most important goal: human health!

Bernina Plus GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Liposomes, Nanobiotechnology

Bernina develops smart oral drug delivery systems for therapeutic peptides. The proprietary technology is based on artificial envelopes created by lipids. In addition, these nano-particulate natural and synthetic lipids are used in coating and drug elution processes.



Contact:

Sauerbruchstr. 50
D-81377 München
Phone: +49 (0) 89 579589-0
Fax: +49 (0) 89 579589-3503
E-Mail: info@beckmancoulter.de
Internet: www.beckmancoulter.de



Contact:

Dr. Günter Auerbach

Herterichstraße 1-3
D-81479 München
Phone: +49 (0) 89 74987-0
Fax: +49 (0) 89 74987-200
E-Mail: contact@bene-arzneimittel.de
Internet: www.bene-arzneimittel.de



Bernina Plus

Contact:

Dr. Felix Gropp

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 52388-740
Fax: +49 (0) 89 52388-333
E-Mail: gropp@berninaplus.de
Internet: www.berninaplus.de



Contact:
Michael Ewers

Kobelweg 95
D-86153 Augsburg
Phone: +49 (0) 821 74881-0
Fax: +49 (0) 821 74881-420
E-Mail: info@betapharm.de
Internet: www.betapharm.de



Contact:
Dr. Kai Lamottke

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 820106-30
Fax: +49 (0) 89 529178
E-Mail: lamottke@bicoll-group.com
Internet: www.bicoll-group.com



Contact:
Dr. Silke Martin

Herzog-Heinrich-Str. 2
D-80336 München
Phone: +49 (0) 89 5399-0
Fax: +49 (0) 89 5399-4015
E-Mail: biobank@blutspendedienst.com
Internet: www.biobank.de

betapharm Arzneimittel GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, Drug Development

Betapharm was founded in 1993 in Augsburg. betapharm delivers generic drugs and is one of the leading generic companies in Germany. In 2006 the company was bought by globally active Dr. Reddy Laboratories, Hyderabad, India. With 75 employees Betapharm generates revenues of about EUR 180m.

Bicoll GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Medicinal Chemistry, Oncology, Infectious Diseases, Natural Compounds, Small Molecules, Nutraceuticals

Bicoll is a biopharmaceutical company, offering pre-clinical support in the area of Drug Discovery from Natural Products and Medicinal Chemistry. To speed up drug discovery processes, Bicoll offers its drug like compound library BILOBAC N, consisting of already fractionated plant extracts, to global clients in drug discovery and related innovative fields. BILOBAC N provides enhanced probability of biological activity and reduced complexity of fine fractions, thus it's ready to use in client's screening systems. With innovative strategies and a proprietary technology platform, Bicoll is able to rapidly select only the best leads with superior drug-like profiles for further development. Subsequent medicinal chemistry and custom synthesis complete Bicoll's seamless substantial services.

BIOBANK der Blutspender Blutspendedienst des BRK

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Autoimmune Diseases, Cardiovascular Diseases, Diabetics, Metabolic Diseases, Oncology

With its »Blood Donor BIOBANK«, the Bavarian Red Cross Blood Donor Service offers a unique resource for biomarker research: the world's first blood donor based biobank. A large pool of more than 400,000 active blood donors enables the identification of several thousands of diseased BIOBANK participants per year. Their serial, pre-diagnostic blood samples are a unique resource for investigating markers associated with the onset and progression of diseases. With a collection of more than 4 m plasma samples processed and stored using highly standardized, qualified processes (ISO9001:2008 certification) the »Blood Donor BIOBANK« is one of the largest biobank projects worldwide.

BioClinica GmbH

CRO

Former „CoreLab Partners“ is an imaging core lab, managing the complete imaging segment of clinical trials for the global pharmaceutical, biotechnology and medical device industries. Our expertise spans Phase I through IV and all major therapeutic areas. We are specialized in oncology trials but also do cardiovascular, musculoskeletal, CNS and medical device studies. Our radiologists, nuclear physicians and medical oncologists interpret data from all major modalities, including CT, MRI, X-ray, SPECT, Ultrasound, PET and PET/CT in a centralized and independent way. We assist in planning, tracking and implementation of studies and provide medical expertise, regulatory know-how and validated technologies. In 2013 BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, announced that JLL Partners and Ampersand Capital Partners, two leading middle market private equity firms, have completed their acquisition of BioClinica and CoreLab Partners and have combined the two companies under the name BioClinica. This merger brings together two of the most experienced and trusted authorities in medical imaging management for clinical trials and creates a new standard in imaging core lab services, cardiovascular safety monitoring, and eClinical trial management solutions.

Biogen GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Rheumatoid Arthritis, Autoimmune Diseases, Dermatology, Neuro-Degeneration, Neurology, Drug Development

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Building on its heritage in biologics, Biogen also manufactures and commercializes high-quality biosimilars. The German affiliate is located in Ismaning.



Contact:
Dr. Michael Kersten

Landsberger Str. 155
D-80687 München
Phone: +49 (0) 89 202 444 97-0
Fax: +49 (0) 89 2024 4497-9
Internet: www.bioclinica.com



Contact:
Stefan Schneider

Carl-Zeiss-Ring 6
D-85737 Ismaning
Phone: +49 (0) 89 99617-0
Fax: +49 (0) 89 99617-199
E-Mail: stefan.schneider@biogen.com
Internet: www.biogen.com



Contact:
Markus Siegers

Weißenburgstr. 22
D-93055 Regensburg
Phone: +49 (0) 941 5699 6947
Fax: +49 (0) 941 5699 2168
E-Mail: biogents@biogents.com
Internet: www.biogents.com



Contact:
Dr. Philipp Krubasik

Robert-Koch-Str. 2
D-82152 Planegg
Phone: +49 (0) 89 895574-0
Fax: +49 (0) 89 895574-825
E-Mail: info@biomax.com
Internet: www.biomax.com

Biogents AG

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Infectious Diseases, Natural Compounds, Devices, Agrobiotechnology

Biogents develops, produces & sells innovative trapping systems against mosquitoes & flies, especially against dangerous vectors such as *aedes aegypti*, *aedes albopictus* & sand flies. These systems are already being used by leading health organisations (e.g. CDC, USA), several armed forces (e.g. „Bundeswehr“, Germany), other governmental bodies & public entities (incl. quarantine departments, research institutes & universities). Several consumer versions are marketed since 2009. The technology is protected by two granted patents and was awarded in 2007 by the world bank with money from the Bill & Melinda Gates Foundation. Biogents also offers a fee-for-service business for insect repellents and attractants. The company was started in 2003 as a spin-off from the University of Regensburg.

Biomax Informatics AG

BIOTECH BIOINFORMATICS

Keywords: Informatics, Data Management and Biostatistics, Biomarker Discovery & Development, Data Management

Biomax provides computational solutions for better decision making and knowledge management in the life science industry. They focus on integrating information to enable a knowledge-based approach to develop innovative life science products. Their BioXM™ Knowledge Management Environment combines software products and knowledge resources to help customers eliminate the coding process, slash the implementation time of complex projects, harness the information overload and distill critical insights from data. The Viscovery® data mining software complements the BioXM system with tools to identify and validate diagnostic biomarkers. Biomax's worldwide customers include companies and research organizations in healthcare, drug discovery, diagnostics, fine chemicals, food and plant production.

Biomed Labordiagnostik GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Analytical Chemistry, ELISA/EIA, PCR, Clinical Diagnostics

Our core competence is the manufacture and distribution of CE marked products for clinical chemistry and quality control according to IVD Guidelines. Our area of activities covers also Infectious Disease Diagnostics. We are currently extending our focus to the Molecular Diagnostics field, for which we aim to develop and to market new products leveraging on our years of experience at home and abroad. Our success is tied to a continuous increase of know-how, an extensive expertise in the healthcare marketplace and specialized system solutions in the field of Laboratory Diagnostics. We work tightly with our customers ascertaining their requirements in relation to new and existing products and create solutions optimized to their needs.

Biomer

BIOTECH NEW MATERIALS AND COMPOUNDS

Biomer develops and produces raw materials such as PHB (polyhydroxybutyrate) which can be processed and used in the same way as classic thermoplasts, but are fully biodegradable. Articles made of Biomer formulations can be disposed of by composting. Being made from renewable feed stocks they do not add to the carbon dioxide concentration of the atmosphere even when they are burned. The core competence covers the production of biopolymers in microorganisms and formulation of the extracted polymers into resins for use by plastics processors.

Biometric GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Analytical Chemistry

Biometric GmbH is a laboratory for microbiological and chemical analysis dealing with the analysis of water, hygienic control and providing microbiological analyses of pharmaceutical products, medical devices, cosmetics and food.



Contact:
Claudia Caspers

Bruckmannring 32
D-85764 Oberschleißheim
Phone: +49 (0) 89 3157000
Fax: +49 (0) 89 3153242
E-Mail: info@biomed.de
Internet: www.biomed.de



Contact:
Dr. Urs Hänggi

Forst-Kasten-Str. 15
D-82152 Krailling
Phone: +49 (0) 89 12765-136
Fax: +49 (0) 89 12765-137
E-Mail: mail@Biomer.de
Internet: www.biomer.de



Contact:
Sabine Zirngibl-Brandl

Im Gewerbepark B49
D-93059 Regensburg
Phone: +49 (0) 941 454 41
Fax: +49 (0) 941 461 68 31
E-Mail: info@biometric-gmbh.de
Internet: www.biometric-gmbh.de



Contact:
Thomas Jaik

Kerschensteinerstr. 11-15
D-92318 Neumarkt
Phone: +49 (0) 9181 231-90
Fax: +49 (0) 9181 231-265
E-Mail: info@bionorica.de
Internet: www.bionorica.de



Contact:

Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 700763-0
Fax: +49 (0) 6131 9084 - 390
Internet: www.biontech.de

BIONORICA SE

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Analytical Chemistry, Oncology, Respiratory Diseases, Pain, Neurology

Bionorica SE is one of the leading companies in the area of phytopharmaceuticals worldwide. The product range focuses mainly on diseases of the respiratory tract, urinary tract, gynaecological disorders and on medications for the treatment of pain. As an essential Bionorica follows the principle of phytoneering as gold standard in modern phytotherapy. Phytoneering combines the huge potential of natural active substances (phytos) with the knowledge and methodology of modern pharmaceutical research (engineering) in order to develop efficient and safe preparations. The expressed goal is to discover new active substances in order to develop effective drugs with minimized side effects. Bionorica has established an impressive network of scientists working in about 490 renowned universities, institutions and organisations worldwide.

BioNTech Small Molecules GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Medicinal Chemistry, Analytical Chemistry, Small Molecules, Autoimmune Diseases, 3D-Structural Analysis, Molecular Modelling, Inflammation

Former 4SC Discovery GmbH has been a 100% subsidiary of 4SC AG offering integrated drug discovery services, from hit finding and chemical lead optimisation through to early development candidates. 4SC AG (4SC, FSE Prime Standard: VSC) announced in April 2016 the sale of the operations of its subsidiary 4SC Discovery GmbH (4SC Discovery) to newly incorporated BioNTech Small Molecules GmbH (BioNTech Small Molecules). The sale comprises all key operating assets of the subsidiary. 4SC Discovery will retain its preclinical research projects. 4SC will continue using the epigenetic schemes and the underlying intellectual property for itself, and in addition plans to out-license other projects. BioNTech Small Molecules is a wholly-owned subsidiary of Mainz, Germany-based BioNTech AG (BioNTech)

Biontex Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Nanobiotechnology, Gene Therapy, RNAi & Antisense, Liposomes, Gene Transfer, Fine Chemicals/Reagents

Biontex Laboratories GmbH was launched in 1995 as an innovative biotech company in the field of genetic engineering, having been one of the technology leaders in the field of transfection since 1998. The company's operations focus on transfection, a field covering the introduction of genetic material (transfection) and proteins (proteofection) into eukaryotic cells. Biontex aims to continuously improve the success of this technology by advancing their synthetically produced carrier systems for nucleic acids and proteins and developing a variety of high-quality genetic engineering products. Current research focuses on the development of completely new strategies for maximising the transfection efficiency for all cell types in vivo or in vitro by utilising synthetic carrier components free from immunological effects.

Bio-Rad Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Chip/Array Technology, Peptide/Protein, Proteomics, Genomics, Gene Transfer, Laboratory, Antibody Production Service

Bio-Rad was founded in 1952 by the late David Schwartz and his wife Alice. In the 1950s, Bio-Rad introduced the first analytical grade ion exchange resins for laboratory research applications, launching the company's Life Science Group. In 1957, Bio-Rad incorporated and in 1958 relocated its headquarters to Richmond, California. By 1966 the company sold its stock to the public and expanded internationally with its first overseas office in Germany, namely in MUNICH. Over the years, Bio-Rad has evolved into a global enterprise that manufactures and distributes a broad range of products around the world. Today, Bio-Rad products are used in hospitals, universities, major research institutions, biotechnology companies, reference laboratories, pharmaceutical firms, and classrooms around the world. Bio-Rad's key competencies include separation, purification, and analysis, and the company is a leader in electrophoresis, protein assays, gel image analysis, quality controls, diabetes monitoring, autoimmune testing, blood typing, and BSE and chronic wasting disease testing.



Contact:
Dr. Roland Klösel

Landsberger Str. 234
D-80687 München
Phone: +49 (0) 89 324799-50
Fax: +49 (0) 89 324799-52
E-Mail: contact@biontex.com
Internet: www.biontex.com



Contact:
Sonja Fischer

Heidemannstr. 164
D-80939 München
Phone: +49 (0) 89 31884-0
Fax: +49 (0) 89 31884-100
E-Mail: info@bio-rad.de
Internet: www.bio-rad.com



Contact:
Dr. Josef Scheiber

Garmischer Str. 4/V
D-80339 München
Phone: +49 (0) 89 1896582-80
Fax: +49 (0) 89 1896582-99
E-Mail: josef.scheiber@biovariance.com
Internet: www.biovariance.com



Contact:
Dr. Ralf Bäuerle

Obere Hauptstr. 10 b
D-85386 Eching
Phone: +49 (0) 89 3799666-6
Fax: +49 (0) 89 3799666-99
E-Mail: info@biozol.de
Internet: www.biozol.de



Bristol-Myers Squibb

Contact:
Eszter Viragh

Arnulfstr. 29
D-80636 München
Phone: +49 (0) 89 12142-0
Fax: +49 (0) 89 12142-392
E-Mail: info@b-ms.de
Internet: www.b-ms.de

bioVariance GmbH

BIOTECH BIOINFORMATICS

Keywords: Personalized Medicine, Informatics, Data Management, Biomarker Discovery & Development, Toxicology, Pharmacogenomics, NGS

BioVariance as premium provider for bioinformatics services generates insights into complex biomedical datasets that lead to testable hypotheses for our customers. We bring your data into the right context by linking DNA, RNA, proteins, metabolites & more with known biological interactions and phenotypes, generating insights to the big picture of human biology and pharmacology. We use this as fundament for our analyses helping our customers to advance projects quicker and more targeted. Our analytis capabilities are supported by biomedical software development capabilities so that we can implement our pipelines very efficiently and also deploy them to our customers.

BIOZOL Diagnostica Vertrieb GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody, Peptide/Protein, ELISA/EIA, Proteomics, Small Molecules, Clinical Diagnostics

BIOZOL Diagnostica Vertrieb GmbH markets and distributes products for immunology, cell biology, molecular biology, biochemistry and human and veterinary diagnostics, such as antibodies, recombinant proteins, ELISA/EIA, detection kits, biochemicals and further reagents for cell culture, flow cytometry, immunohistology and cytogenetics. The company represents almost 50 different worldwide known suppliers in Germany. Biozol offers additionally different types of services such as free product search.

Bristol-Myers Squibb GmbH & Co. KGaA

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology

Bristol-Myers Squibb is a global BioPharma company firmly focused on its Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines help millions of people in their fight against diseases such as cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, rheumatoid arthritis and after kidney transplant.

BSL BIOSERVICE Scientific Laboratories Munich GmbH

CRO

Keywords: Toxicology, Pharmacology

BSL BIOSERVICE is an internationally active Contract Research Organization. We are offering a broad range of biological safety and activity testing services for (Bio-)Pharmaceuticals, Chemicals, Medical Devices, Agrochemicals and Food. A high degree of customer orientation, high quality and flexibility are core values of our corporate philosophy. A highly experienced team of scientists and regulatory experts guarantees acceptance by national and international authorities and supports customers from early research until finalization of preclinical studies. BSL BIOSERVICE has been accredited with DIN EN ISO 17025 as well as with AAALAC and is certified in accordance with GLP and GMP. We are listed by the World Health Organization (WHO) and have successfully been audited by the FDA.

Carl Zeiss Microscopy GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, Microscopy, Tissue Engineering/Cell Culture,

Carl Zeiss Microscopy GmbH offers a broad range of modern and innovative microscope systems and solutions for different fields such as biotechnology, biomedical and clinical research as well as routine and industrial applications. Carl Zeiss Microimaging employs about 1,750 staff worldwide and has its direct sales force in 130 countries. The company's headquarter is in Jena. At its Munich site Carl Zeiss Microscopy GmbH is focusing on software development, systems for laser microdissection and its application as well as digital slide and automation technology. In addition, in Munich the company is maintaining a unique facility hosting a modern application center and an up-to-date laboratory for biomedical and clinical research, molecular analysis and imaging. Practical courses, workshops and training are held on a regular basis and customer services are offered.

CASCAT GmbH

CHEMICAL INDUSTRY

CASCAT researches and develops processes for the production of chemicals based on chemical-enzymatic reactions. One focus is the use of renewable resources as a base. The own implementation of these processes as well as working with partners in this case represents the preferred choice of the company. In addition, the consultation of third parties in matters of biotechnology, biocatalysis, renewable resources, sustainability and bioeconomy is a main focus.



Contact:

Behringstr. 6 / 8
D-82152 Planegg
Phone: +49 (0) 89 899650-0
Fax: +49 (0) 89 899650-11
E-Mail: info@bioservice.com
Internet: www.bioservice.com



We make it visible.

Contact:

Dr. Renate Burgemeister

Kistlerhofstr. 75
D-81379 München
Phone: +49 (0) 89 909000-800
Fax: +49 (0) 89 909000-820
E-Mail: microscopy@zeiss.com
Internet: www.zeiss.com/microscopy



Contact:

Europaring 4
D-94315 Straubing
Internet: www.cascad.de



Contact:
Gerwin Winter

Joseph-Wild-Str. 20
D-81829 München
Phone: +49 (0) 89 451519-010
Fax: +49 (0) 89 451519-019
E-Mail: info@celgene.de
Internet: www.celgene.de

cellasys

Contact:
Dr. Joachim Wiest

Ohmstrasse 8
D-80802 München
Phone: +49 (0) 89 2000110-74
Fax: +49 (0) 89 2000110-76
E-Mail: info@cellasys.com
Internet: www.cellasys.com



Contact:
Dr. Karin Schütze

Am Neuland 1
D-82347 Bernried
Phone: +49 (0) 8158 9064010
Fax: +49 (0) 8158 9042318
E-Mail: info-celltool@celltool.de
Internet: www.celltool.de

Celgene GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Drug Delivery, Hematology, Small Molecules, Drug Development

Celgene is a globally acting biopharmaceutical company, founded in New Jersey (USA) in 1986. Celgene is mainly active in developing and distributing drugs in hematology, oncology and immunotherapy. Since 2006, Celgene operates a German subsidiary in Munich-Riem. For further information visit: www.celgene.de

cellasys GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Toxicology, Tissue Engineering/Cell Culture, Drug Development, Biochips, Chip/Array Technology, In-Vitro-Diagnostics

cellasys delivers system solutions for microphysiometry. These include services such as contract research, research & development, and production & maintenance. Furthermore we offer consulting services in the area of application development, data analysis and data interpretation. Our microphysiometric systems monitor different parameters directly from living cells. These parameters include extracellular acidification (pH), cellular respiration (pO₂) and morphology (impedance).

CellTool GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Devices

CellTool is a company that develops, manufactures and distributes innovative systems for non-contact and marker-free recognition, quantitative characterization and gentle sorting of living cells based on Raman spectroscopy. CellTool systems are especially designed to meet the requirements of biologists and physicians. They are extremely user friendly. Cell handling and cell measurements are highly automated. In combination with innovative microfluidics cells can be characterized in a physiological environment keeping them viable for downstream applications. Capabilities are fast diagnosis, patient-specific drug screening or individual cell therapy

Centronic GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Medicinal Chemistry, Analytical Chemistry, Clinical Diagnostics

Centronic GmbH is a German manufacturer, with a certified Quality Management System according to EN ISO 9001:2008 and ISO 13485:2003/AC: 2009, and distributor of a big range of high qualitative clinical chemistry reagents in fluid and lyophilised form for the determination of enzymes, electrolytes, substrates, lipids and proteins. The product range is completed by a wide range of immunoturbidimetric reagents and corresponding controls, Latex reagents, controls-calibrators, food chemistry reagents, cleaning solutions for several analysers and our registered additive for waterbaths Prothermal. The products are distributed worldwide. Our team consists of highly engaged scientists from different special fields with an experience of many years in the area of clinical chemistry.

Certara Spain SL Zweigniederlassung Deutschland

BIOTECH BIOINFORMATICS

Keywords: Pharmacokinetics, Drug Development, Medicinal Chemistry, Molecular Modelling, Data Management and Biostatistics, Informatics, Data Management

Certara is dedicated to improving human health through a broad spectrum of software products and scientific consulting services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by uniting industry leaders Tripos®, provider of innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery; Simcyp™, a research-based company providing predictive pharmacokinetic and pharmacodynamics tools, workshops, and consultancy services; and Pharsight® Corporation, provider of software and scientific consulting services to improve productivity and decision-making in preclinical and clinical drug development.



Contact:
Dr. Johannes Betz

Am Kleinfeld 11
D-85456 Wartenberg
Phone: +49 (0) 8762 7243-00
Fax: +49 (0) 8762 7243-12
E-Mail: info@centronic-gmbh.com
Internet: www.centronic-gmbh.com



Contact:
Dr. Fabian Böes

Martin-Kollar-Str. 17
D-81829 München
Phone: +49 (0) 89 451030-0
Fax: +49 (0) 89 451030-30
E-Mail: fabian.boes@certara.com
Internet: www.certara.com



Oskar Tropitzsch

Contact:
Michael Schäffler

Waldershofer Str. 51
D-95615 Marktredwitz
Phone: +49 (0) 9231 9619-0
Fax: +49 (0) 9231 9619-60
E-Mail: info@cfmot.de
Internet: www.cfmot.de



Contact:
Dr. Andrea Kofler

Hochriesweg 14
D-83131 Nussdorf
Phone: +49 (0) 8035 9849-28
Fax: +49 (0) 8035 9849-30
E-Mail: chrombios@chrombios.com
Internet: www.chrombios.com

Cfm Oskar Tropitzsch GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Antibiotics, Agrobiotechnology, Drug Delivery, Pharmacology, Drug Development, Natural Compounds

Cfm Oskar Tropitzsch is your reliable partner for:

- Small scale (API) manufacturing (nonGMP/cGMP)
- Contract synthesis (nonGMP/GMP)
- Small molecules (> 700 substances)
- Phytochemicals (> 1000 substances)
- Pharmaceutical raw materials
- Excipients
- Chemical specialities (Curare, Picric acid incl. DMF)
- Natural toxins - synthetically produced
- Toxins
- HPAPs - Payloads for ADCs.
- Sourcing for all kind of chemicals in small scale
- Sourcing for APIs

ChromBios GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Founded in 1998, ChromBios is focused on the field of Molecular Cytogenetics (fluorescence in situ hybridisation, FISH). The company's aims are to provide service and products for chromosome analysis tailored to the needs of the customers. We offer "FISH service" such as chromosome analysis with "chromosome painting", mapping of clones, characterisation of cancer cell lines and animal models in genome research. We especially focus on multi colour karyotyping human tumour cells and other transformed cell lines (for example for patent applications). Chrombios also offers multi colour chromosome painting of mouse cells to identify translocations in mouse tumours and to characterise mouse ES cells. Apart from human and mouse, we also provide service in the characterization of chromosomes from other animal model species including rat, hamster, cat, and various live stock animals.

ChromoTek GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Oncology, Antibody, Proteomics

ChromoTek GmbH, founded in 2008, is a biotech company focused on the discovery and development of novel nanoprobe and cell based assays for biomedical research and early drug development. During the last years ChromoTek has developed innovative research tools including the GFP-Trap® and RFP-Trap®, two versatile pull-down reagents for biochemical analysis of fluorescent fusion proteins. In April 2011 ChromoTek successfully introduced its first cell based assay for early drug development, the U2OS Cell Cycle Chromobody®. This real-time High-Content Analysis (HCA) screening assay enables to monitor the complete cell cycle in live cells for the first time. In addition ChromoTek developed the Fluorescent 2-Hybrid (F2H)-Assay to analyze protein-protein interactions in vivo in real time.

Cinfa Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

We approach biopharmaceuticals from a completely different angle: the pharmacists' perspective. Because their role is crucial to product success. We act autonomously and with flat, agile hierarchies. And we're backed by the economic power and know-how of Cinfa, the long-established and successful pharmaceutical company based in Pamplona, Spain.

The first wave of product candidates includes biosimilars in the areas of oncology and inflammatory diseases and form the basis of Cinfa Biotech's product portfolio.

Cipla Europe NV

PHARMA & CHEMICAL INDUSTRY

Cipla Europe NV, a 100% subsidiary of Cipla Limited, has presence in several countries in Europe through its partners and own network. Cipla is focused on offering a new pharma concept built on layers of value such as newer products, concepts, formats, information and services to help healthcare providers across Europe.

Cipla offers a range of products in Europe —Respiratory, HIV, Vaccines, OTC, API, Plain Generics and Hospital products.



Contact:
Dr. Marion Jung

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 124 148 8 - 0
Fax: +49 (0) 89 124 148 8 - 11
E-Mail: info@chromotek.com
Internet: www.chromotek.com



Contact:

Nymphenburger Strasse 3c
D-80335 München
Phone: +49 (0) 89 54 54 62-0
E-Mail: info@cinfabiotech.com
Internet: www.cinfabiotech.com



Contact:

Inselkammerstraße 4
D-82008 Unterhaching
Phone: +49 (089) 6242208 10
Fax: +49 (089) 6242208 29
E-Mail: europe@cipla.com
Internet: www.cipla.com



Contact:
Prof. Dr. Andre Koltermann

Semmelweisstraße 3
D-82152 Planegg b. München
Phone: +49 (0) 89 710 661-0
Fax: +49 (0) 89 710 661-122
E-Mail: biotech@clariant.com
Internet: www.clariant.com



Contact:

Pionierstr. 2
D-82152 Krailling
Phone: +49 (0) 89 8638933-0
Fax: +49 (0) 89 8638933-99
E-Mail: info@clinical-trial-care.de
Internet: www.clinical-trial-care.de

Clariant Produkte (Deutschland) GmbH, Group Biotechnology

PHARMA & CHEMICAL INDUSTRY

Keywords: New Materials, Agrobiotechnology

Clariant is an internationally active specialty chemical company based in Muttenz, Switzerland. Clariant focuses on creating value by investing in future profitable and sustainable growth, which is based on five strategic pillars: Increase profitability, reposition of portfolio, add value with sustainability, foster innovation and research & development, and intensify growth in emerging markets. The main focus of Clariant's Group Biotechnology is on bio-catalysis and bio-refining. The company develops sustainable products and processes for bio-based chemicals and fuels. Clariant has developed a process which uses enzymatic hydrolysis followed by fermentation to produce cellulosic ethanol from agricultural residues.

Clinical Trial Care GmbH

CRO

Keywords: Dermatology, Metabolic Diseases, Nephrology, Pain, Rheumatoid Arthritis

Clinical Trial Care GmbH founded in 2001 is a CRO located in the southwest of Munich (Krailling) and provides the full scope of clinical and biometric services required for the conduct of clinical trials of phase II-IV, post marketing surveillance as well as non-interventional or epidemiologic studies. The very experienced, flexible and successful team ensures expert support and a responsive commitment. The CRO is headed by Dipl. Psych. Andreas Behr (CEO) with a long standing history of clinical research.

Clinipace GmbH

CRO

Keywords: Drug Development, Pharmacovigilance, Regulatory Affairs, Data Management and Biostatistics, Clinical Trial Management and Monitoring, Medical Writing

Clinipace Worldwide, a global digital clinical research organization (dCRO), specialized in serving the strategic product and clinical development needs of emerging and mid-tier biopharmaceutical and medical device firms. Our core competencies are

- Concepts for Drug & Medical Device Development
- Regulatory & Medical-Scientific Services
- Clinical Operations
- Data Management & Biostatistics
- QMS Services & Auditing
- TEMPO eClinical Platform

We maintain offices on four continents, including centralized North American, South American, and European hubs. The combination of our service portfolio, our technology-driven approach and our flexible & highly trained teams enables the adaptation to the specific-requirements of each project.

Clinrex GmbH

CRO

Clinrex was founded in 2004 by Dr. Dagmar Chase to offer consulting services and training in the areas GCP, Quality Management and Project Coordination for clinical trials. The set-up and handling of DSMBs / DMCs is also one of Clinrex' core competencies.

GCP/Quality Management Consulting:

- Assessment of systems or studies regarding GCP compliance
- Inspection preparedness
- SOP development/SOP streamlining
- GCP gap analyses
- Interface sponsor/CRO
- Investigator Initiated Trials

Training:

- All areas of GCP and project management of clinical trials
- Smart Training® or customised in-house training
- Training for sponsors, CROs, investigators and study nurses



Contact:

Landsberger Str. 408
D-81241 München
Phone: +49 (0) 89 9999-7733
Fax: +49 (0) 89 9999-7744
E-Mail: contact-eu@clinipace.com
Internet: www.clinipace.com



Clinrex GmbH
your clinical research experts

Contact:

Dr. Dagmar Chase

Rosenkavalierplatz 12
D-81925 München
Phone: +49 (0) 89 9292 87-0
Fax: +49 (0) 89 9292 87-50
E-Mail: info@clinrex.com
Internet: www.clinrex.com



Contact:
Dr. Hans Wolf

Landshuter Allee 8-10
D-80637 München
Phone: +49 (0) 89 5455 8355
Fax: +49 (0) 89 5574 43
E-Mail: germany@clintec.com
Internet: www.clintec.com

Compass GmbH

Contact:

Kolpingring 8
D-82041 Oberhaching
Phone: +49 (0) 89 673 4688 10
Fax: +49 89 673 4688 19
E-Mail: info@compass.de
Internet: www.compass.de

ClinTec GmbH

CRO

Keywords: Medical Writing, Oncology, Drug Development, Regulatory Affairs, Cardiovascular Diseases, Neurology

ClinTec International is a privately owned medium sized CRO with a global reach and a strong presence in the emerging markets of Asia Pacific, Middle East & Africa and Eastern & Central Europe. With flexible resourcing services across 80 countries, ClinTec provides clinical research personnel and support services to the pharmaceutical, biotechnology and medical device industry. ClinTec has a wealth of experience in managing clinical trials in all major therapeutic categories including oncology, neurology, autoimmune diseases, orphan drugs and diabetes. ClinTec International is well placed to conduct clinical research on a worldwide basis through our carefully selected and internationally trained staff.

Compass GmbH

PHARMA SUPPLIER AND TRADE

Keywords: Logistics

Compass is a young and dynamic company in the south of Munich. As an independent service provider in the pharmaceutical setting our core business is to deal with all kinds of pharmaceutical registrations. Based on our 20 years of experience in the pharmaceutical industry we want to guarantee that the bought products are available in highest quality and as fast as possible for your sales staff and for your customers. We support you therefore in the selection of the best possible contract manufacturer and accompany you and the product up to the successful conclusion of first production

conoGenetix biosciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Pain, CNS, Peptide/Protein, Drug Development

conoGenetix is a privately owned biopharmaceutical company focused on the development of new peptide therapeutics for the treatment of autoimmune diseases. conoGenetix was founded in 2002 by Dr. Andreas Klostermann and Dr. Jörg Stockhaus and is located in Martinsried, Germany. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads that modulate ion channel targets causatively involved in the generation of autoimmune diseases. conoGenetix runs a program targeting severe autoimmune disorders like Multiple Sclerosis (MS), Rheumatoid Arthritis (RA) and Vasculitis. Several peptides called cgtx-peptides within this program are in preclinical development. The leading indication for the cgtx-peptides will be Vasculitis; a fatal disease strongly related to Rheumatoid Arthritis. Vasculitis is a rare disease and will be a market door opener for conoGenetix.

Conreso GmbH

CRO

Keywords: Clinical Trial Management and Monitoring, Data Management and Biostatistics, veterinary clinical trials

Conreso, established in 1990, BVMA member, offers a wide range of medical and clinical research services, from phase II to late phase and epidemiological studies. A particular strength, the Conreso monitoring quality, is considered by its clients to be unrivalled. Conreso shows an impressive record of successful FDA inspections and significant contributions to important new product licenses. Having recruited more than 30.000 patients between 0 and 17 years of age proves the company's unique expertise in pediatric trials. Further areas of particular expertise are oncological and vaccine studies. Quality and service of Conreso are awarded by a constant repeat business rate of 90%. The Conreso department of veterinary medicine provides all types of veterinary studies.



Contact:
Dr. Andreas Klostermann

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 547 2695-0
Fax: +49 (0) 89 547 2695-9
E-Mail: info@conogenetix.de
Internet: www.conogenetix.de



Contact:
Jürgen Schäfer

Neuhauser Str. 47
D-80331 München
Phone: +49 (0) 89 236650-0
Fax: +49 (0) 89 236650-50
E-Mail: info@conreso.com
Internet: www.conreso.com



Contact:
Dr. Michael Wiggenhorn

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 5424498-0
Fax: +49 (0) 89 5424498-22
E-Mail: contact@coriolis-pharma.com
Internet: www.coriolis-pharma.com



Contact:
Wolfgang Schläger

Carl-Wery-Str. 42
D-81739 München
Phone: +49 (0) 89 9210930
Fax: +49 (0) 89 913466
E-Mail: wolfgang.schlaeger@covance.com
Internet: www.covance.com

Coriolis Pharma

CRO

Keywords: Drug Delivery, Peptide/Protein, Vaccines, Antisense/Nucleotides

Coriolis Pharma is a globally operating independent service provider for research and formulation development of (bio)pharmaceutical drugs (proteins, peptides, monoclonal antibodies, RNA/DNA etc.) and vaccines. An interdisciplinary team of highly qualified scientists with many years of experience in the development of (bio)pharmaceuticals provides cutting-edge service and know-how related to the formulation development of biopharmaceuticals, supported by an expert scientific advisory board. This may involve for example formulation development of (pre-)clinical material through to commercial products, lyophilization processes, stability testing (light obscuration, Micro-Flow imaging and AF4/HF5 under cGMP), supply of pre-clinical material, and analytical services using innovative analytical technologies.

Covance Clinical and Periapproval Services GmbH

CRO

Keywords: Regulatory Affairs, Oncology, Pharmacology, Medical Writing, Laboratory, Clinical Trial Management and Monitoring, Drug Development

Covance Inc., a global contract research organization (CRO), is the world's most comprehensive drug development company. We are dedicated to advancing healthcare and delivering Solutions Made Real® by providing high-quality nonclinical, preclinical, clinical & commercialization services to pharmaceutical and biotechnology companies to help reduce the time and costs associated with drug development. Because of our broad experience and deep knowledge, we are in a unique position to provide insights to our client partners that go above and beyond testing. We also offer laboratory testing services to the chemical, agrochemical and food industries and are a market leader in toxicology services, central laboratory services, discovery services and a top global provider of clinical trial services.

Creative Instruments GmbH

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Automation, Devices

Creative Instruments develops and manufactures customized solutions for laboratory automation, automation analysis for diagnostics and biotechnology as well as for measurement technology. The focus is on precision engineering, chemical and liquid handling, particularly in the optical detection and related evaluation. With a team of highly qualified and motivated specialists from the fields of physics, biology, chemistry, electronics, mechanics, optics and software, we are your partner for projects right from the design through to small series production, commissioning and maintenance. The certified and innovative company develops in close cooperation with customers tailored solutions to implement processes faster, more economically and precisely.

CRELUX GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Peptide/Protein, 3D-Structural Analysis, Drug Development

CRELUX is a leading expert in premium drug discovery solutions for pharma, biotech and research organizations. Our services are highly individualized for our customers. We have been delivering customized solutions in drug discovery, hit finding,- validation and optimization, X-ray crystallography, biophysical screening, fragment based screening and protein supply to global pharma and biotech for more than a decade. CRELUX is part of the WuXiAppTec family and as such integrated in global R&D services.

CRI – The Clinical Research Institute GmbH

CRO

Keywords: Devices, Medical Writing, Clinical Trial Management and Monitoring, Data Management and Biostatistics, Logistics, Pharmacovigilance, Regulatory Affairs

CRI-The Clinical Research Institute GmbH is a full-service Contract Research Organization for phase III and IV clinical trials as well as for observational clinical projects (clinical registries). We perform clinical projects within Europe but we also have reliable partners in USA, Australia and Japan to offer services in those regions in addition. We offer special experience in large-scaled non-commercial trials (IITs) and in studies with medical device companies. In addition, we support medtech companies in scientific marketing challenges or technical solutions for all aspects of clinical research.



Contact:

Trifthofstr. 58
D-82362 Weilheim
Phone: +49 (0) 881 927067-60
Fax: +49 (0) 881 927067-61
E-Mail: info@creative-instruments.de
Internet: www.creative-instruments.de



Contact:

Dr. Michael Schäffer

Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 700760-0
Fax: +49 (0) 89 700760-222
E-Mail: info@crelux.com
Internet: www.crelux.com



Contact:

Brigitte Skudelny

Arnulfstraße 19
D-80335 München
Phone: +49 (0) 89 9901649-0
Fax: +49 (0) 89 9901649-800
E-Mail: info@cri-muc.eu
Internet: www.cri-muc.eu



Contact:
Christine Wurm

Rüdesheimer Straße 15/1
D-80686 München
Phone: +49 (0) 89 21019-10
Fax: +49 (0) 89 21019-150
E-Mail: jorge.garcia@cromsource.com
Internet: www.cromsource.com



Contact:
Vesna Stamenkovic

Konrad-Adenauer-Allee 1
D-86150 Augsburg
Phone: +49 (0) 821 450807-4
Fax: +49 (0) 821 450807-6
E-Mail: info@crosnt.com
Internet: www.crosnt.com

CROMSOURCE GmbH

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Medical Writing, Devices, Drug Development, Clinical Trial Management and Monitoring, Data Management and Biostatistics

CROMSOURCE is an ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions. A well-established full-service CRO, CROMSOURCE is unique in offering an end-to-end guarantee covering trial timelines, enrolment and contract price. This guarantees our clients that their trials are delivered on time and within the contract price with no CRO initiated change orders. CROMSOURCE supports the full spectrum of clinical development via our Pharmaceutical, Medical Device, and Staffing Solutions divisions.

CROS DE GmbH

CRO

Keywords: Pharmacovigilance, Medical Writing, Data Management and Biostatistics

CROS NT is an international Contract Research Organisation (CRO) specialized in clinical data services. Founded in 1992, CROS NT has completed over 800 studies and remains focused on biometrics services including clinical data management, biostatistics (analysis and programming), pharmacovigilance, medical writing and life science technology. CROS NT can also offer expert consultancy services on trial design, CDISC standards, DSMB review and regulatory submissions. With offices in Italy, Germany and the UK, CROS NT has retained 100% of its customers due to advanced internal governance and client relationships built on trust.

CryoShop

OTHER SERVICES

Keywords: Logistics

SUPPLIER FOR LIQUID NITROGEN EQUIPMENT CryoShop is Munich based consulting and trading company specialising in the field of cryogenic and cold storage applications. We are supporting, serving and supplying customers in the healthcare and medical research sector. Over the years we developed an expertise in projects for ultra-cold and cryogenic preservation and storage of biological specimen. Furthermore our ‚cryo‘ experienced technical crew offers services, support and maintenance, when and wherever needed. We are a reliable and skilled partner for liquid nitrogen and cold storage equipment for biotech, pharmaceutical and research companies. CryoShop is offering value added cryogenic solutions; according to our customers individual requirements it is our aim to recommend the most suitable products/solution. Our portfolio allows us to provide products and solutions along the cryopreservation (standardized) workflow: from preanalytical sample preparation, controlled rate (cell)freezing, temperature controlled transport, cryogenic archiving to controlled/automated thawing devices. Furthermore we care about your staff's safety while working in deep cold environments, offering special cryogenic personal protective equipment as well as training courses.



Contact:

WerkStadt Sendling / Haus 2
Flößergasse 4
D-81369 München
Phone: +49 (0) 89 63 899 012
Fax: +49 (0) 89 892 94 31
E-Mail: einfachcool@cryoshop.de
Internet: www.cryoshop.de



Your reliable supplier for liquid nitrogen equipment



- Cryopreservation storage, transport and supply equipment
- Cryogenic protective equipment and training courses
- Crogenic labelling solutions
- Cryovials and Cryoboxes



Sample preparation

ice-free bench top cooling devices



Freezing

controlled rate freezing systems



Transport

cold-temperature stability devices for short and long distances



Deep cold storage

cryogenic and ultra-low storage freezers -190°C, -80°C



Thawing

automated, consistent and reproducible thawing devices



Contact:

Dr. Huber Heinrichs

Merianstraße 26
D-90409 Nürnberg
Phone: +49 (0) 700 - 1447 1447
Fax:
E-Mail: info@curadis.eu
Internet: www.curadis.eu



Contact:

Dr. Silke Ostermann

Trimburgstr. 2
D-81249 München
Phone: +49 (0) 89 20335359
Fax: +49 (0) 89 80919380
E-Mail: info@cso-pharma.eu
Internet: www.cso-pharma.eu



Contact:

Dr. Dietmar Scheddin

Gottlieb-Keim-Str. 60
D-95448 Bayreuth
Phone: +49 (0) 921 1511-254
Fax: +49 (0) 921 1511-255
E-Mail: info@cytox.de
Internet: www.cyttox.de

Curadis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

The pharmaceutical start-up company located in Erlangen/Regensburg researches and develops steroidal medicines for breast cancer and benign enlargement of the prostate gland. Curadis GmbH was founded in 2008 in Erlangen and has S-Refit AG of Regensburg as one of its investors. The company is developing a novel substance for breast cancer and a substance for prostate cancer

CSO Pharma Consulting GmbH Compliance – Safety – Organisation Development

CRO

Keywords: Pharmacology, Data Management, Regulatory Affairs, Pharmacovigilance, , Medical Writing, Laboratory

CSO Pharma provides reliable pharmacovigilance services, professional medical affairs & medical science support and successful QM/GxP consulting. Our organization is build around our customers requirements and objectives. We do not only support you as experienced service provider but always serve you as your personal business partner. Successful delivery of your projects is a personal matter for us at CSO Pharma. We run our own quality management system and offer our customers reliable services and processes based on international standards. As a professional partner CSO Pharma supports the implementation of your own Quality Management/ GxP system and you can benefit from our extensive experience from audits and inspections and our comprehensive knowledge of present legal requirements.

CYTOX, biologische Sicherheitsprüfungen

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, ELISA/EIA, Toxicology, Tissue Engineering/Cell Culture

CYTOX provides biological testing service for the medical device and pharmaceutical industry by using in vitro toxicological testing procedures according to ISO 10993 as well as FDA-compliant processes. Next to classical 2D cell culture testing systems we use organotypical 3D cell culture systems especially in the area of skin irritation testing and REACH applications.

DAIICHI SANKYO EUROPE GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Cardiovascular Diseases, Drug Development, Oncology

Daiichi Sankyo is a global pharmaceutical company that focuses on researching and marketing of innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of more than EUR 9.3 billion in fiscal year 2013, Daiichi Sankyo is one of the world's 20 leading pharmaceutical companies. The company's world headquarters is in Tokyo, and its European base is located in Munich. Daiichi Sankyo has established affiliates in 12 European countries since it set up European production facilities and marketing offices in 1990. The company's research activities focus on the areas of cardiovascular diseases, hematology, diabetes, anti-infectives and cancer.

Data Analysis Solutions DA-SOL GmbH

BIOTECH BIOINFORMATICS

Keywords: Informatics, Biomarker Discovery & Development, Personalized Medicine, Molecular Diagnostics, Drug Development, Data Management and Biostatistics, Data Management

DA-SOL is a services and consulting company providing advanced multi-variate bioinformatics, biostatistics, chemometrics and data mining. Based on extensive experience in large scale industry projects and fostered by proprietary algorithms, DA-SOL develops innovative, tailored data analysis solutions for its clients and provides project support as well as training on all levels. Gene expression, proteomics, metabolomics, spectroscopy, imaging and other data – DA-SOL helps its clients to conduct their studies most efficiently and to harvest the full potential of their data. Focus areas are the analysis of process data, the development of medical diagnostics and the integration of diverse biomedical or pharmaceutical data.

Dauids Biotechnologie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Allergy, Immune Therapy, Antibody, Proteomics, ELISA/EIA, Tissue Engineering/Cell Culture, Antibody Production Service

Dauids Biotechnologie is a German custom manufacturer for antibodies since 1996.

- Polyclonal antibodies and monoclonal antibodies.
- Antibodies and other proteins are produced in HEK and CHO cells after transient transfection as well as in standard E.coli cells.
- Chromatographic and affinity purification services for purification of protein without a tag and with a tag.
- Cell-based natural killer cell assays for detection of active molecules and for control of human therapies.



Contact:

Zielstattstr. 48
D-81379 München
Phone: +49 (0) 89 7808-0
Fax: +49 (0) 89 7808-202
E-Mail: service@daiichi-sankyo.eu
Internet: www.daiichi-sankyo.eu



Contact:

Dr. Jürgen von Frese

Moosstr. 36
D-82266 Inning am Ammersee
Phone: +49 (0) 8143 9977293
Fax: +49 (0) 8143 9977294
E-Mail: info@da-sol.de
Internet: www.da-sol.de



Contact:

Dr. Michael Davids

Roentgenstr. 3
D-93055 Regensburg
Phone: +49 (0) 941 948 228
Fax: +49 (0) 941 946 8119
E-Mail: info@dabio.de
Internet: www.davids-bio.de

DEFINIENS®

the tissue phenomics company

Contact:
Dr. Florian Leiss

Bernhard-Wicki-Straße 5
D-80636 München
Phone: +49 (0) 89 231180-0
Fax: +49 (0) 89 231180-90
E-Mail: fleiss@definiens.com
Internet: www.definiens.com



Contact:
Dr. Frank Pfannenschmid

Unter den Schwibbögen 23
D-93047 Regensburg
Phone: +49 (0) 941 2986615
Fax: +49 (0) 941 6963846
E-Mail: info@delphitest.de
Internet: www.delphitest.de

Definiens AG

BIOTECH BIOINFORMATICS

Keywords: Drug Development, Microscopy, Personalized Medicine, Oncology, Toxicology, Biomarker Discovery & Development, Clinical Diagnostics

Definiens is the leading provider of image analysis and data mining solutions for Quantitative Digital Pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans, and allows the correlation of this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and support better decisions in research, diagnostics and therapy. Definiens' vision is to open new fields of research, to advance personalized medicine and to significantly improve the quality of patients' lives.

DelphiTest GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Laboratory, Clinical Diagnostics, Genomics, PCR, Analytical Chemistry

The company's core technology capitalizes on the revolutionary development of DNA analysis, DNA sequencing and DNA fragment analysis. Delphitest GmbH focussed on family relationship testing especially for private customers but also for courts, lawyers, medical doctors, youth welfare offices and embassies. We developed new techniques and tests, e.g. paternity tests for dogs, sibling tests etc. In addition, we offer genetic tests for hereditary diseases like Chorea Huntington, Alzheimers Disease or Canavan Syndrome and a genetic blood group test. Delphitest provides its high level of competence in DNA techniques to scientific partners like universities, hospitals or pharmaceutical companies in Europe.

Denk Pharma GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

In a global world it is difficult to know where a product is manufactured. Therefore DENK PHARMA has created something unique. All DENK PHARMA products are:

- Manufactured in Germany
- Quality controlled in Germany
- Registered in Germany

DENK PHARMA was founded in Munich, Germany in 1948. We have a strong focus on export markets and presently supply our DENK PHARMA premium medicine to over 50 countries around the world. In Germany our products are sold through co-marketing agreements with other companies. DENK PHARMA premium medicine is registered and approved for the German market by the German Health authorities. You are guaranteed exactly the same quality of medicine as a patient in Germany. The DENK PHARMA production facility is state-of-the-art and of course meets the latest requirements with respect to GMP and ISO.

DiaServe Laboratories GmbH

BIOTECH DEVICES & REAGENTS

DiaServe is a primary manufacturer of human and animal blood derived raw materials for diagnostic industry. Based on this raw materials DiaServe also offers tailor-made in vitro controls/calibrators for medical laboratories. The company was established in 1997 with a mission to identify, develop and manufacture in vitro diagnostics mainly on OEM basis for diagnostic manufacturers and clinical laboratories.

Dojindo EU GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Fine Chemicals/Reagents

Dojindo produces over 500 well-known products used by research organizations over the world. Many of these products were developed jointly between Dojindo staff and outside researchers. Dojindo strives to expand its ability to analyze the future direction of science by maintaining continued interest in new research activities as well as improving its information-gathering network. Dojindo is ready for this shortened product cycle because our creative researchers are working continuously to meet tomorrow's research needs.



Contact:
Stephan Huber

Prinzregentenstraße 79
D-81675 München
Phone: +49 (0) 89 2300 29-0
Fax: +49 (0) 89 2300 29-480
E-Mail: pharma@denkpharma.de
Internet: www.denkpharma.de



Contact:
Dr. Ulf Henseling

Seeshaupter Str. 27
D-82393 Iffeldorf
Phone: +49 (0) 8856 8036-05
Fax: +49 (0) 8856 8036-07
E-Mail: contact@diaserve.de
Internet: www.diaserve.de



Contact:
Takatoshi Ezoe

Leopoldstr. 254
D-80807 München
Phone: +49 (0) 89 3540-4805
Fax: +49 (0) 89 3540-4806
E-Mail: info@dojindo.eu.com
Internet: www.dojindo.eu.com



Contact:
Dr. Franz Kerek

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
Fax: +49 (0) 89 856625-56
E-Mail: info@donatur.de
Internet: www.donatur.de



Contact:
Dr. Reinhard Nibler

Fürstenriederstr. 105
D-80686 München
Phone: +49 (0) 89 56823726
Fax: +49 (0) 89 92185265
E-Mail: mail@dr-nibler.de
Internet: www.dr-nibler.de

DoNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Rheumatoid Arthritis

DoNatur GmbH develops new therapeutics from herbal extracts with traditionally confirmed therapeutic efficiency. The comprehensive analysis of the genuine extracts, the isolation and structural characterization of the active substances and the test of their pharmacological activities constitutes the main competence of the company. Over the last years DoNatur has successfully developed a new immunomodulatory acting natural substance which has been proved highly efficacious for the therapy of rheumatic diseases.

Dr. Nibler & Partner

CRO

Keywords: Medical Writing, Pharmacology, Devices, Drug Development

Legal requirements for pharmacovigilance are continuously rising. The fulfillment turns out to be a major burden for small and medium sized enterprises. We provide a complete pharmacovigilance full-service solution:

- 24-hours availability for receipt of adverse event reports by phone, fax or e-mail
- Literature screening and -review
- Data entry and MedDRA coding
- Follow-up by medically qualified personnel (MD, RN)
- Scientific assessment by experienced physicians
- Authority reporting either electronically or on paper
- SUSAR reporting
- Preparation of periodic reports: PSUR and ASR
- Preparation and maintenance of risk management plans
- Implementation and optimization of your pharmacovigilance system
- SOP preparation or revision
- Audits and guidance through inspection

Dr. R. Pflieger GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Dermatology, Antibiotics, Pharmacokinetics, Pharmacology, Drug Delivery

Dr. R. Pflieger GmbH is a medium sized German pharmaceutical company located in Bamberg (Bavaria) with a staff of 300 employees. Established in 1945 as a private company, it is nowadays exclusively owned by the Doktor Robert Pflieger Foundation, which aims are the exclusive sponsoring of charitable and social projects and the support of medical research. The company is currently selling about 35 medicinal products with emphasis in urology, gynaecology and dermatology and has GMP approved production facilities. The international business is focused on the antimuscarinic drug trospium chloride which was developed by the Dr. R. Pflieger and is approved for treatment of overactive bladder.

Dust BioSolutions GmbH

BIOTECH AGRO FOOD ENVIRONMENT

Keywords: New Materials, Biocement, Bacteria, Chemistry, Mining, Construction

Dust BioSolutions is an industrial biotechnology company that improves sustainability and profitability of its clients through the application of a natural process that solidifies permeable materials. Its international and multidisciplinary team has developed a technology platform around microbiologically induced calcite precipitation, a bio-geochemical process where bacteria precipitate calcium carbonate within the soil matrix. A first product offers various industries a customised solution to control dust more cost-efficiently and environmentally friendly than existing alternatives. Dust BioSolutions is continuously working on other applications of the technology and an expansion of its product portfolio.



Contact:
Dr. Peter Topfmeier

Dr.-Robert-Pflieger-Str. 12
D-96045 Bamberg
Phone: +49 (0) 951 6043-0
Fax: +49 (0) 951 6043-29
E-Mail: info@dr-pflieger.de
Internet: www.dr-pflieger.de



Contact:
Martin Spitznagel

Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 339 800-510
Fax: +49 (0) 89 339 800-519
E-Mail: info@dustbiosolutions.com
Internet: dustbiosolutions.com



Contact:
Dr. Dirk Scholl

Lochhamerstr. 15
D-82152 Martinsried
Phone: +49 (0) 89 897 4544-0
Fax: +49 (0) 89 897 4544-11
E-Mail: info@dynamic-biosensors.com
Internet: www.dynamic-biosensors.com



Contact:
Rebekka Fründt

Semmelweisstraße 3
D-82152 Planegg
Phone: +49 (0) 89 3249 3670
E-Mail: info@electrochaea.com
Internet: www.electrochaea.com



Contact:
Dr. Peter Frischmann

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7093 9316
Fax: +49 (0) 89 7093 9440
E-Mail: info@ellabiotech.com
Internet: www.ellabiotech.com

Dynamic Biosensors GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antibody, Proteomics, Small Molecules, Peptide/Protein, Chip/Array Technology, Drug Development, Devices

Dynamic Biosensors offers solutions for label-free molecular interaction analysis and beyond. The proprietary switchSENSE® technology combines unrivaled analytical content with superior sensitivity. Apart from standard binding parameters (affinity and kinetics; even in the sub-picomolar range), switchSENSE® allows much deeper insights into the analyte. This includes determination of the absolute size of the molecule, analysis of conformational changes, characterization of complex binders, including affinity vs. avidity, as well as thermodynamic characterization. Overall, by combining the advantages of a dynamic molecular measurement with the benefits of a chip-based biosensor system, switchSENSE® offers a new level of information and flexibility in biosensing.

Electrochaea GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

On the basis of biocatalysis, Electrochaea offers a power-to-gas key technology which has been patented internationally. It cost-effectively recycles CO₂ and simultaneously produces storable and usable biomethane from surplus electrical energy. The first industrial scale plant operates successfully in Denmark. Plants of more than one gigawatt of capacity are targeted by 2025. 20 employees work for Electrochaea in Denmark and at the head office in Munich. CEO is Mich Hein.

ELLA Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, PCR, Chip/Array Technology, RNAi & Antisense, Genomics, Antisense/Nucleotides

Our focus is the synthesis of special oligoribonucleotides for selected projects in diagnostics, chip technologies, genesynthesis and further topics - following quality standards which you would appreciate and expect in your own lab. The guidelines for the synthesis standards can be defined by our customers themselves. Through our validated technology platform, our experienced interdisciplinary team and our resolute attitude towards the highest quality in our products we offer tangible advantages to our customers and partners.

EMFRET Analytics GmbH & CoKG

BIOTECH DEVICES & REAGENTS

emfret Analytics GmbH (founded 2002) is focussing on production, characterization, derivatization and supply of monoclonal antibodies in biomedical research, namely vascular biology.



Contact:
Susanne Nieswandt

Am Morgenroth 6
D-97246 Eibelstadt
Phone: +49 (0) 9303 984 964
Fax: +49 (0) 700 3637 3800
E-Mail: service@emfret.com
Internet: www.emfret.com

EMP Genetech

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Peptide/Protein, Biomarker Discovery & Development, Antibody Production Service, Personalized Medicine, Clinical Diagnostics, Drug Development

EMP Genetech Recombinant Proteins from Human Cells Improving your Research Activities. EMP Genetech provides non-GMP services in recombinant protein production and the development of stable high producer cell lines. Protein purification to customer given purity is also conducted, as well as cell banking. We work with industrial and academical clients. Since 2000, the company has developed several dozen recombinant biomolecules.

EMP Genetech's Services:

- Gene Cloning
- Development of Stable High Producer Cell Lines
- Recombinant Protein Production
- Process Development
- Generation of Cell Banks
- Protein Purification
- Experience since 2000

EpiGene GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Genomics

EpiGene GmbH, founded in 1999, is a genomics-based research and development company focusing on applications in plant protection. The core competences comprise the molecular characterization of plant-pathogen interactions and the development of high throughput systems for molecular diagnostics of involved genetic factors. In addition, research efforts include investigations of the mode of action of plant protective agents at the molecular level and the identification of mutations or differentially expressed genes in pathogens as potential new targets.



Contact:
Dr. Franz X. Welser

Hebbelstr. 61
D-85055 Ingolstadt
Phone: +49 (0) 841 3796013
Fax: +49 (0) 841 8817185
E-Mail: info@empgenetech.com
Internet: www.empgenetech.com

EPIGENE

Contact:
Dr. Friedrich G. Felsenstein

Hohenbachernstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
Fax: +49 (0) 8161 4990-89
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.epigene.de



Contact:
Dr. Friedrich G. Felsenstein

Hohenbachernstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
Fax: +49 (0) 8161 4990-89
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.EpiLogic.de

ethris

Contact:
PD Dr. Carsten Rudolph

Semmelweisstrasse 3
D-82152 Planegg
Phone: +49 (0) 89 8955 788-0
Fax: +49 (0) 89 8955 788-18
E-Mail: info@ethris.com
Internet: www.ethris.com

eticur)
GESUNDHEITSVORSORGE FÜRS BABY

Contact:
Felix Raslag

Landsberger Str. 406
D-81241 München
Phone: +49 (0) 89 12 59 81-0
Fax: +49 (0) 89 12 59 81-19
E-Mail: info@eticur.de
Internet: www.eticur.de

EpiLogic GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Genomics

EpiLogic is a new European wide operating company involved in product development based on genomic analysis of fungal pathogens propagated by wind in agricultural crops (at present: cereals and vine). Pathogen analysis of virulence and fungicide sensitivity are used as decision support for breeding, choice of cultivar and fungicide management to ensure sustainable agriculture. A genotype bank of several pathogens is currently being set up to offer high quality inoculum for selection in laboratory, greenhouse and field. Additionally, methods are under development for analysing and culturing new pathogens.

ethris GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Dermatology, Bone/Joint Diseases, Gene Therapy, Gene Transfer, Tissue Engineering/Cell Culture, Drug Development

Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners.

eticur) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Based on the idea that umbilical cord blood contains multipotent adult stem cells, the cord blood is prepared and stored for potential later use. These cells might in future play an important role in therapies including regenerative medicine. Our priority is to grant the most secure storage, highest quality and extensive testing by highly qualified personnel. eticur) grants the storage of stem cells following the highest quality-standards of the Federal Board of Physicians and the Institute for Sera and Vaccine (Paul-Ehrlich-Institute). eticur) cooperates with the Department of Transfusion Medicine and Haemostaseology of the University Hospital of Erlangen.

Eurofins BioPharma Product Testing Munich GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Pharmacology, Small Molecules, Bioanalytics, Laboratory

Eurofins BioPharma Product Testing is the largest network of harmonized bio/pharmaceutical GMP product testing laboratories worldwide providing comprehensive laboratory services for the worlds largest (bio-)pharmaceutical and medical device companies. Our service offerings are fully comprehensive and include testing of drug substance, final product, intermediates, and starting materials for both small and large molecule drug products as well as testing of medical devices . With a global capacity of more than 65,000 square meters and facilities located in Australia, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, UK and the US, our network of GMP/GLP laboratories operates under the same strict quality procedures.



Contact:
Bettina von Klitzing-Stückle

Behringstr. 6/8
D-82152 Martinsried
Phone: +49 (0) 89 899650-0
Fax: +49 (0) 89 899650-11
E-Mail: info-munich@eurofins.com
Internet: www.eurofins.de

The Largest Global Footprint of Harmonized Testing Labs...

Right In Your Backyard.



www.eurofins.com/biopharma

With the largest network of harmonized bio/pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing is everywhere you are.

While delivering a true local lab experience, our international presence ensures personal quality service backed by a unique global breadth of harmonized capabilities to solve all your testing challenges.

For the most complete range of global testing services, harmonized quality systems and LIMS, you'll never need to look further than your own backyard.

Services

Chemistry/Biochemistry
Cell Banking Services
Facility & Process Validation
GMP Manufacturing

Method Development & Validation
Microbiology
Molecular & Cell Biology
Raw Materials Testing

Release Testing
Stability Testing & Storage
Viral Clearance & Viral Safety
Professional Scientific Services ®

Facilities

Australia	Germany	Spain
Belgium	Ireland	Sweden
Denmark	Italy	UK
France	Netherlands	US



Contact:
Dr. Jutta Huber

Anzinger Straße 7a
D-85560 Ebersberg
Phone: +49 (0) 8092 8289-0
Fax: +49 (0) 8092 21084
E-Mail: info-eu@eurofins.com
Internet: www.eurofinsgenomics.com



Contact:
Dr. Dirk Ullmann

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 4524465-0
Fax: +49 (0) 89 4524465-20
E-Mail: info@evotec.com
Internet: www.evotec.com

Eurofins Genomics

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, NGS, PCR, Antisense/Nucleotides

Eurofins Genomics is an international provider of genomic services around the core business lines next generation sequencing, genotyping, gene expression, custom DNA sequencing, oligonucleotides, siRNA and gene synthesis.

Evotec Munich GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Oncology, Genomics, Proteomics, Small Molecules, Inflammation, Metabolic Diseases

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com.

EXCELLA GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Medicinal Chemistry, Analytical Chemistry, Small Molecules, Oncology

Excella GmbH has been serving the pharmaceutical industry for more than 35 years with high quality API's and finished dosage forms. Recent investments have directed our focus towards high containment products (including OEB5) and a one-stop-shopping approach. Excella supplies products to the generic industry but also manufactures for big pharma life cycle end products and develops processes for innovative API's and novel solid dosage forms. Services offered range from early product development through registration support to state-of-the-art manufacturing. Excella's Feucht site has an excellent track record with the FDA and other regulatory agencies since 1983 and is Safebridge certified.

EXCELLA
PHARMA SOURCE

Contact:
Dr. Johann Peter Mörsdorf

Nürnberger Str. 12
D-90537 Feucht
Phone: +49 (0) 9128 404-0
Fax: +49 (0) 9128 4045-81
E-Mail: info@excella-pharma-source.de
Internet: www.excella-pharma-source.de



#RESEARCHNEVERSTOPS

BUILDING INNOVATIVE DRUG DISCOVERY PARTNERSHIPS

Flexible scientific and commercial solutions from Target ID to Pre-clinical Candidate in a world-class infrastructure



Target ID and validation



Hit identification



Compound management



Medicinal chemistry



ADME-Tox and DMPK



Proteomics and biomarker science



Cell and protein production



In vitro pharmacology



In vivo pharmacology



Integrated services



Contact:
Dr. Mikkel Noerholm

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 416172-70
Fax: +49 (0) 89 416172-69
E-Mail: munich@exosomedx.com
Internet: www.exosomedx.com



Contact:
Erika Weber

Lochhamer Schlag 21
D-82166 Gräfelfing
Phone: +49 (0) 89 8956 62-0
Fax: +49 (0) 89 8956 62-101
E-Mail: LM.info@fei.com
Internet: www.fei.com



Contact:
Albert Stumpf

Aubinger Str. 30
D-82166 Gräfelfing
Phone: +49 (0) 89 895 300-24
Fax: +49 (0) 89 895 300-25
E-Mail: info@fermcom.de
Internet: www.fermcom.de

Exosome Diagnostics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Diabetics, CNS, PCR, Genomics, Clinical Diagnostics

Exosome Diagnostics is developing biofluid based molecular diagnostic tests for use in personalized medicine applications. Exosomes and other microvesicles are shed into all biofluids, including blood, urine, and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. The Company is commercializing in vitro diagnostic tests for use in companion diagnostic applications and real-time monitoring of disease. The Company is located in New York, USA and Munich, Germany and is backed by an international consortium of leading VCs

FEI Munich GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Automation, 3D-Structural Analysis, Microscopy, Devices

Industry-leading FEI life sciences workflows offer a proven path to results for structural and cell biology researchers. Our commitment to innovation has resulted in many industry firsts, placing customers at the forefront of advanced research capabilities. With our comprehensive range of flexible workflows including hardware, software, and consumables researchers at any level can move from questions to answers quickly and easily. Our teams of scientists understand customers disciplines, challenges, and goals, enabling us to build long-term partnerships that advance biological research. More customers achieve results and recognition working with FEI than with any other solution provider.

FermCom Bio-VNT Biologische Verfahrenstechnik und Netzwerk-Technologie

BIOTECH DEVICES & REAGENTS

Keywords: Devices

FermCom Bio - VNT is a research and development company focused on biotechnology and network applications. FermCom Bio - VNT is in development of an innovative in-situ online-analysis system by using a high-technology bioreactor. The use of bio-chips allows to miniaturize online real-time-analysis. FermCom's field of activity is development a new compact system for non-invasive process-monitoring in the area of biotechnology, fermentation- and environment-analytics.

FGK Clinical Research GmbH

CRO

Keywords: Drug Development, CRO/CMO, Clinical Trial Management and Monitoring, Regulatory Affairs, Medical Writing, Data Management and Biostatistics

FGK Clinical Research is a European CRO with headquarters in Munich offering full services for all phases of clinical trials. Our more than 100 highly qualified medical, scientific and regulatory experts can guide you through the clinical trial process, from planning and approval to the final report. FGK has subsidiaries in the UK, Hungary, Poland and Czech Republic. Our international client base includes biotechnology, medical device, and pharmaceutical companies. With our „all services through one company“ philosophy we are able to offer tailored approach to meet the specific requirements of each sponsor. FGK has extensive experience in all major therapeutic areas allowing it to effectively design, manage, and analyze development programs and clinical trials.



Contact:
Martin Krauss

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 893 119-0
Fax: +49 (0) 89 893 119-20
E-Mail: info@fgk-cro.com
Internet: www.fgk-cro.com

YOU NEED FULL COMMITMENT FOR BEST RESULTS. IN EVERY PHASE.

- ▶ We offer the complete range of clinical development and consulting services
- ▶ We work for pharmaceutical, biotechnology and medical device companies
- ▶ We are present in Munich, Budapest, London, Prague & Warsaw

fgk-cro.com

Dr. med. Edgar J. Fenzl
+49 89 893 119-22
edgar.fenzl@fgk-cro.com

Dipl.-Stat. Martin Krauss
+49 89 893 119-25
martin.krauss@fgk-cro.com

Heimeranstrasse 35 · 80339 Munich · Germany



The Clinical Trial Optimizer



Contact:
Dr. Edgar J. Fenzl

Heimeranstraße 35
D-80339 München
Phone: +49 (0) 89 893 119-0
Fax: +49 (0) 89 893 119-20
E-Mail: info@fgk-pv.com
Internet: www.fgk-pv.com



Contact:
Iris Margraf

Fraunhoferstr. 15
D-82152 Martinsried
Phone: +49 (0) 89 864667-100
Fax: +49 (0) 89 864667-110
E-Mail: info@formycon.com
Internet: www.formycon.com

FGK Pharmacovigilance GmbH

CRO

Keywords: Data Management and Biostatistics, Pharmacovigilance, Regulatory Affairs, Drug Development, Clinical Trial Management and Monitoring, Medical Writing

FGK Pharmacovigilance GmbH is a service provider offering the full range of services related to continuous monitoring of risk-benefit of authorized medicinal products including:

- Management of Adverse Events and Signals and of risk minimization activities including assessment of effectiveness of these activities
- Preparation of periodic safety update reports, ad hoc safety reports or statements specifically tailored to requests of CAs
- Safety profile characterization and planning of PV activities to increase knowledge about the safety profile of the medicinal product

With broad therapeutic and risk management experience of its personnel FGK PV guarantees an early recognition of potential risks and timely planning of risk minimization activities to avoid these risks while keeping the product on the market. With our daughter company, FGK Representative Service Ltd, we also provide legal representation services to our non-European customers (www.fgk-rs.com).

Formycon GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development

Formycon AG is developing biosimilars for global markets. Biosimilars are identical preparations of biopharmaceuticals whose patents have expired. Its active ingredient is similar to the active ingredient of the established reference product. Biosimilars are cost effective and equivalent alternatives to the precursor biopharmaceutical products. Formycon has a leading position for those products that run out patent protection after 2020 (so-called 'Third Wave' of biosimilars). Formycon's current team has many years of experience in the development of biopharmaceuticals. Already in the years 2008 and 2011, two protein-based products have been licensed to major pharmaceutical companies. Formycon has particular expertise in this area, and develops high-quality biosimilars, which meet the high requirements of the regulatory authorities in Europe and the United States. Currently Formycon has three products in development, the first biosimilar candidate was already out-licensed to Santo Holding GmbH for future commercialization.

Freeline Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Freeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of gene therapies for bleeding and other debilitating disorders based on a next-generation AAV gene therapy platform developed by Amit Nathwani, Professor of Hematology at UCL and CSO of Freeline Therapeutics. The German branch located in Munich was established around the Adeno-Associated Virus (AAV) manufacturing platform developed by Rentschler Biotechnologie GmbH (Rentschler) and acquired by Freeline. The focus of the Munich site is to further advance the AAV platform technologies and large-scale manufacturing processes as well as to develop a broad analytical toolbox for gene transfer vector characterization.

FRIZ Biochem Gesellschaft für Bioanalytik mbH

BIOTECH DEVICES & REAGENTS

Keywords: Chip/Array Technology, Infectious Diseases, Devices, Clinical Diagnostics

FRIZ Biochem develops and produces highly reliable user-friendly and inexpensive biochip systems for applications in medical diagnostics, food testing and pharmaceutical research. Key products are DNA-chips with direct electrical read-out where SNPs (single nucleotide polymorphism) can unambiguously be detected and time-consuming labeling of the target-DNA is no longer necessary. This enables a broad range of simple and fast analyses making the system ideal for biological medical studies. The company's proprietary combination of micro arrays, electrical detection and semiconductor technology opens the way to compact multiplex analyses directly at a PC without the expensive instrumentation commonly needed.

GBA-Laborgruppe

BIOTECH & PHARMA ANALYTICS

LPU Labor für Pharma- und Umweltanalytik GmbH (Martinsried and Gräfelfing, Germany) as well as Phytos Labor für Arzneimittelanalytik GmbH & Co. KG (Neu-Ulm, Germany) build the pharmaceutical division of GBA Laboratory Group. As an analytical full-service provider operating under cGMP, the three pharmaceutical laboratory sites offer scientific and technical solutions for international customers from both, the private industry and research institutions. GBA Laboratory Group supports its clients in development and validation, approval process and quality control during every step in the product lifecycle. Gas and liquid chromatography, mass spectrometry, capillary electrophoresis as well as microbiological testing and development of tests for in-vivo-in-vitro correlation belong to the core competencies of GBA Laboratory Group. All analytical work is embedded in a long-term experience of all aspects of regulatory affairs.



Contact:
Dr. Markus Hörer

Semmelweisstraße 3
D-82152 Planegg

E-Mail: infode@freelinetx.com
Internet: www.freelinetx.com



Contact:
Dr. Gerhard Hartwich

Floriansbogen 2 - 4
D-82061 Neuried
Phone: +49 (0) 89 7244 09-25
Fax: +49 (0) 89 7244 09-10
E-Mail: info@frizbiochem.de
Internet: www.frizbiochem.de



Contact:

Am Haag 4
D-82166 Gräfelfing

Internet: www.gba-group.de



Performing Mechatronics
Made in Bavaria

Contact: Harry Flint

Fellnerstrasse 2
D-85656 Buch am Buchrain
Phone: +49 (0) 8124 5310-0
Fax: +49 (0) 8124 5310-20
E-Mail: info@gbn-systems.com
Internet: www.gbn-systems.com



GE imagination at work

Contact:
Michael Kaleja

Oskar-Schlemmer-Str. 11
D-80807 München
Phone: +49 (0) 7667 833-559
Fax: +49 (0) 7667 833-616
E-Mail: michael.kaleja@ge.com
Internet: www.gelifesciences.com

GBN Systems GmbH

BIOTECH & MEDTECH DEVICES & REAGENTS

Quality, Functionality and Efficiency For over 20 years our challenge is to meet the outstanding demands of our clients in the fields of medical technology, biotechnology, the semi-conductor industry and automation technology. From the very start our experienced team of electro technology engineers and precision mechanics develops and manufactures a wide product range. From customized components to complete assemblies and machines including a fulfillment from initial vision to serial end production. Let your idea, vision turn into a serial product. Use the GBN Systems engineering- and manufacturing competence since 1989 for „Performing Mechatronics - Made in Bavaria“. The Facilities are centrally located facilities near Bavarian capital and airport of Munich. This enables business partner to find the logistically ideal sparring for expansions in southern Germany, Austria and Switzerland. Key competencies in : Concept, development, prototyping, validation, certification, pre-series, main-serial production, quality management, fulfillment, logistics.

GE Healthcare Europe GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Fine Chemicals/Reagents, Devices, Analytical Chemistry, Genomics, Proteomics

GE Healthcare Life Sciences provides a broad range of products and services for biomolecule separations at all scales.

Chief products include:

- ÄKTAdesign™ chromatography systems and BioProcess™ media
- Filtration systems and devices
- Wave Bioreactor™ and mixers
- Cell separation for isolating and purifying cells, viruses, and sub-cellular particles
- Fast Trak™ BioPharma Services.

Our products are used in the manufacture of the majority of all FDA-approved biopharmaceuticals on the market. GE Healthcare Life Sciences is a part of GE Healthcare, a General Electric company with more than 42,000 employees, providing transformational medical technologies that are shaping a new age of patient care.

Genedata Bioinformatik GmbH

BIOTECH BIOINFORMATICS

Genedata is a bioinformatics company that specializes in developing software systems for the comprehensive analysis of genomes, transcriptomes, proteomes, metabolomes, and biochemical compounds. By working closely with key partners, the company combines its extensive product portfolio with expert scientific consulting services to offer tailor-made solutions for specific applications and multiple therapeutic areas. The company's solutions are key for moving the focus of life science research from high-throughput data acquisition to high-content data interpretation. Founded in 1997 as a spin-off from Novartis, the company is headquartered in Basel (Switzerland) with branch offices in Munich (Germany), San Francisco (USA), Boston (USA), and Tokyo (Japan).

Genedia AG Biotec Services and Products

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antisense/Nucleotides, Genomics, Medicinal Chemistry

Genedia AG Biotec Services and Products is a provider of DNA testing services including private DNA paternity testing, legal DNA paternity testing as well as other relationship testing services (full or half sibling testing, grandparents testing, aunt or uncle testing, 1st cousin testing, maternity testing as well as twin testing). An other area is DNA genealogy and anthropology, which includes ancestral origin DNA population test, Y-Chromosome Analysis, mt-DNA analysis. The forensic area includes DNA identification and banking services forensic testing services especially stain analysis. DNA molecular testing of diseases (Factor V and II, MTHFR, CFTR-Mutation). DNA testing of animals.

Genetic ID (Europe) AG Labor für gentechnische Analysen

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: ELISA/EIA, Genomics, PCR, Laboratory, Transgenic Plants, Agrobiotechnology

Genetic ID is a global leader in testing for the presence of genetically modified organisms (GMOs) in food and agricultural products. In addition Genetic ID also offers Allergen screening. Founded in 1996, Genetic ID Inc. maintains global headquarters in USA, as well as premier testing laboratories in Japan and Germany, offices in Brazil, and the Global Laboratory Alliance of affiliated laboratories and representatives spanning five continents. We develop technologies that address all aspects of the GMO-testing segment and provide all clients with the technology, services and information they need to operate in the increasingly high-tech global marketplace.



Contact:
Dr. Peter Haberl

Fürstenrieder Straße 281
D-81377 München
Phone: +49 (0) 89 4581901-0
Fax: +49 (0) 89 4581901-5
E-Mail: peter.haberl@genedata.com
Internet: www.genedata.com



Contact:
Dr. Hildegard Haas

Candidplatz 13
D-81543 München
Phone: +49 (0) 89 543448-0
Fax: +49 (0) 89 543448-20
E-Mail: info@genedia.de
Internet: www.genedia.de



Contact:
William F. Thompson

Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 821 747 76-30
Fax: +49 (0) 821 747 76-39
E-Mail: info@genetic-id.de
Internet: www.genetic-id.de



Contact:
Dr. Korbinian Grote

Bayerstr. 85a
D-80335 München
Phone: +49 (0) 89 599 766-0
Fax: +49 (0) 89 599 766-55
E-Mail: info@genomatix.de
Internet: www.genomatix.de



Contact:

Staffelseestraße 6
D-81477 München
Phone: +49 (0) 89 780 179 40
Fax: +49 (0) 89 780 179 44
E-Mail: info@gen-plus.de
Internet: www.gen-plus.de

Genomatix GmbH

BIOTECH BIOINFORMATICS

Keywords: Genomics, Devices, NGS, Informatics, Data Management and Biostatistics

Genomatix is one of the world's leading suppliers of technologies to analyze and interpret genomic data. As well as laying the groundwork for microarray experiments and NGS data sequencing analyses, our hardware, software & service solutions help answer the typical questions posed by systems biology. Our approach: combine multiple lines of evidence to perform an integrated meta-analysis. Instead of looking at single strands of information separately, we access an exceptionally large pool of data from different sources. This wealth of data is continually expanding, so it is continually up to date. This meta-analysis leads to more relevant results, more precise scientific knowledge and a better chance of understanding the molecular contexts of gene regulation and expression.

Gen-Plus GmbH & Co KG

CRDO

Keywords: Drug Development

Gen-Plus was founded in 1999 and is since then engaged in research and development of innovative formulation concepts for challenging drug substances. Today Gen-Plus is a state-of-the-art contract research and development organization fully equipped and capable of meeting our customers' ambitious goals in formulation development. Experienced and skilled experts are our key factor of success.

Gen-Plus offers following contract services:

- Wide experience in special formulation concepts and technologies for solid and semi-solid dosage forms to increase bioavailability, stability and consumer convenience
- Sophisticated formulation technologies for oral films (ODF) and transdermal patches (TTS)
- GMP facility enabling manufacturing of investigational medicinal products for proof of concept studies in humans
- Competence Center for in vitro liberation & dissolution (USP I,II,IV,V) and performance of customized permeation tests
- Drug Development of high potent drug substances in tailor-made containment systems
- Development of formulations containing controlled substances (narcotics). – All necessary conditions as well as all legal requirements for handling narcotics are fulfilled

Gilead Sciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Gilead Sciences is dedicated to providing accelerated solutions for patients and the people who care for them. The evolution of Gilead – from a promising biopharmaceutical company to a leader in the international development and commercialisation of medicines for life-threatening infectious diseases (viral, fungal and bacterial infections) – is testament to what the company has achieved through disciplined science, visionary thinking and diversified planning. Gilead's headquarter is based in Foster City, California with additional operations in San Dimas, California. Sales and marketing organisations are located in the following cities: Athens, Greece; Cambridge, UK; Lisbon, Portugal; Madrid, Spain; Istanbul, Turkey; Munich, Germany; Paris, France; Dublin, Ireland; Milano, Italy.

GILYOS GmbH

CRO

Keywords: Small Molecules, Peptide/Protein, Antibody, Nanobiotechnology, Drug Development

GILYOS is a research-oriented, highly specialized contract service partner in the field of pharmaceutical freeze-drying. Services include, but are not limited to, formulation development for pharmaceuticals (protein, peptide), freeze-drying cycle development, optimization of processes including Quality-by-Design and scale-up from laboratory to production. GILYOS offers a variety of analytical methods to fully characterize drug formulations (liquid and solid state), with special focus on the examination of the physicochemical properties of materials. Moreover, the company offers a full range of consulting services, including technical support for freeze-dryers and sales of equipment.

gimbio mbH Gesellschaft für Informationsmanagement in der Biotechnologie

BIOTECH BIOINFORMATICS

Keywords: Automation, Data Management

Development and application of innovative online measurement systems for biotechnical process state variables. Gimbio-Society for Information Management in biotechnology-sees itself as a company offering innovative products and solutions in bioprocess technology, especially for companies in the food, brewing or biotechnology industry. The guiding principle of the company is, in addition to the information gathering and processing, the development and application of innovative online measurement systems for biotechnical process state variables for the purpose of process design, modeling and simulation, with the ultimate goal of optimizing underlying bioprocesses.



Contact:
Dr. Andrea Kücherer-Ehret

Fraunhoferstr. 17
D-82152 Martinsried
Phone: +49 (0) 89 899890-0
Fax: +49 (0) 89 899890-90
E-Mail: info@gilead-sciences.de
Internet: www.gilead.com



Contact:
Dr. Margit Gieseler

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 907056-78
Fax: +49 (0) 931 907056-79
E-Mail: info@gilyos.com
Internet: www.gilyos.com



Contact:
Markus Fellner

Lise-Meitner-Str. 30
D-85354 Freising/Weihenstephan
Phone: +49 (0) 8161 986 4480
Fax: +49 (0) 8161 986 5661
E-Mail: info@gimbio.de
Internet: www.gimbio.de



Contact:
Dr. Christian Hautmann

Lessingstr. 14
D-80336 München
Phone: +49 (0) 89 209 120-0
Fax: +49 (0) 89 209 120-30
E-Mail:
mail@gkm-therapieforschung.de
Internet: www.gkm-therapieforschung.de



Contact:
Claudia Kubacki

Prinzregentenplatz 9
D-81675 München
Phone: +49 (0) 89 360 440
Fax: +49 (0) 89 360 448000
E-Mail: service.info@gsk.com
Internet: www.glaxosmithkline.de

GKM Gesellschaft für Therapieforschung mbH

CRO

Keywords: Pharmacovigilance, CRO/CMO, Medical Writing, Regulatory Affairs, Data Management and Biostatistics, Clinical Trial Management and Monitoring

GKM Gesellschaft für Therapieforschung mbH is a privately owned full service Contract Research Organisation for planning and conducting clinical trials phase II-IV as well as for post-marketing-surveillances. Since 1981, GKM is a reliable partner for pharmaceutical, biotech and medical device companies. GKM provides flexible services with expert knowledge and dedication to your projects in accordance with ICH-GCP and other applicable national and international guidelines. More than 30 years experience: cost-effective quality combined with the latest standards and technologies.

GlaxoSmithKline GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

Keywords: Antibiotics, Vaccines, CNS, Dermatology, Respiratory Diseases, Urology

GSK is a research-based, globally operating healthcare company committed to improving the quality of human life by enabling people to do more, feel better and live longer. GSK is setting milestones in healthcare prevention with a comprehensive portfolio of vaccines and additionally in respiratory, urological and dermatological therapies. Via our affiliate ViiV Healthcare, we are also involved in the area of HIV. Beyond that, we are a leading manufacturer of consumer healthcare products. From clinical development to manufacturing and commercialization of our products, GSK is closely associated with Germany as a business and science location: GSK has facilities in Munich, Heidelberg, Dresden and Marburg, to name a few. We owe our success to the incredible dedication and commitment of our global workforce. We have more than 100,000 employees in 115 countries worldwide, including 3,600 employees in Germany. Social responsibility and sustainability are at the heart of our corporate philosophy. This is the reason why we place such great emphasis on promoting projects at a local level. Our global headquarter is based in London, UK.

GNA Biosolutions GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Nanobiotechnology, Clinical Diagnostics, Devices, Analytical Chemistry

GNA Biosolutions has developed a laser-based, optothermal system to provide the world's fastest DNA diagnostics. The technology is based on nanoparticles within the sample solution. These nanoparticles can be heated up with a laser, and they cool down immediately after irradiation. As a result, the heating and cooling ramps are a million times shorter than in conventional thermocyclers, leading to ultra-fast DNA amplification (Laser PCR®). The optical characteristics of the nanoparticles can also be utilized for a fluorescence-free detection (Nanostove®) that minimizes any upstream sample preparation. GNA's Pharos400 instrument will perform integrated Laser PCR® and Nanostove® read-out. The assay pipeline comprises tests for infectious diseases, with a focus on screening incoming patients for resistant micro-organisms directly during the admission. GNA was incorporated in 2010 as a spin-off from Ludwig-Maximilians-Universität, Munich and its chair for Photonics and Optoelectronics



Contact:
Dr. Lars Ullerich

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 998 207-180
Fax: +49 (0) 89 998 207-188
E-Mail: info@gna-bio.com
Internet: www.gna-bio.com

THINK BEYOND. CHOOSE PASSION!

full-service CRO: international, smart, accurate

TAILORED TO YOUR NEEDS

- clinical trials
- non-interventional studies
- value dossiers

- drugs
- medical devices

INNOVATIVE CONCEPTS

- medical advising
- study planning

RELIABLE SERVICE

- medical writing
- regulatory
- project management
- biostatistics
- vigilance
- quality assurance
- data management
- monitoring
- GCP training

www.gkm-therapieforschung.de

 **GKM**
Gesellschaft für
Therapieforschung mbH



Contact:
Christian Heese

Gollierstr. 70
D-80339 München
Phone: +49 (0) 89 7264960-0
Fax: +49 (0) 89 7264960-29
E-Mail: info@gwk-munich.com
Internet: www.gwk-munich.de



Contact:
Dr. Dr. Stefan Bertsch

Professor-Messerschmitt-Str. 3
D-85579 Neubiberg
Phone: +49 (0) 89 6008761-0
Fax: +49 (0) 89 6008761-24
E-Mail: bertsch@hematris.de
Internet: www.hematris.de



Contact:

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 95001711
Fax: +49 (0) 89 9612087
E-Mail: Liming.Ge@hepacult.de
Internet: www.hepacult.de

GWK Präzisionstechnik GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Chip/Array Technology, Automation, Analytical Chemistry, Devices

GWK Precision Technology offers laboratory equipment and medical devices. Based in Munich we are a team of 20 specialists and serve industries since 1991. We provide special know-how in technical fields (precision mechanics, optics, image processing, sensors, microfluidics, cutting techniques, lateral flow, 3D-prototyping) and system techniques (automation, handling, electronics and machine control) as well as the certification of equipment and production systems.

Hematris Wound Care GmbH

MEDTECH

Keywords: Devices

Hematris Wound Care GmbH develops, manufactures and markets products in the area of wound care. Our major initial focus is the marketing of hemostatic products to control bleeding. We are experts in the field of hemostasis and wound healing. Our vision is to build up an attractive company together with our investors in this business area.

hepacult GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Tissue Engineering/Cell Culture, Drug Development, Analytical Chemistry

hepacult develops and markets cell culture technology based on human liver cells and other human organs. The cell culture technology is used to prognose the metabolism of novel drugs and for the in vitro simulation of liver dysfunctions. With their cutting edge cell and tissue products hepacult provides to the scientific community and pharmaceutical industry an outstanding in vitro test system coming close to the human in vivo conditions. Animal experiments can be replaced to a large extent. Results gained during the preclinical stage with hepatocytes show a better prognostic value. Partially even the cost-intensive clinical experiments on humans and related risks to humans can be reduced.

Hepa Wash GmbH

MEDTECH

Keywords: Devices, Hepatology


Hepa Wash is a medical device company committed to the development and commercialization of its novel liver and kidney support device for the treatment of patients with life-threatening liver and/or kidney disease. Main features of the Hepa Wash® extracorporeal technology are its highly efficient albumindialysis and its innovative albumin regeneration circuit. The technology proves to be several times more effective than currently available alternatives and has the potential to significantly increase the survival rates in liver patients. The company has established an EN ISO 13485 certified quality management system regarding the development, design and production of the hemodialysis device and the necessary treatment fluids. The therapy is market approved within the European Economic Area (CE-marking) in compliance with the Medical Device Directive 93/42 EEC Annex II.3.

Hexal AG

PHARMA & CHEMICAL INDUSTRY

Keywords: 3D-Structural Analysis, Pharmacokinetics, Peptide/Protein, Drug Development

Hexal is the leading German generic manufacturer and belongs to the worldwide Sandoz Group with its headquarters in Holzkirchen, Bavaria. Hexal brings biosimilars to the German market. Biosimilars are highly-differentiated products, based on very complex biological molecules. Biologics, or biopharmaceuticals, are medicines produced from living organisms using biotechnology techniques. Many biologics are recombinant proteins and are manufactured using „recombinant DNA“ technology, a process that involves inserting a specific gene into a host cell to produce a particular protein. These complex state-of-the-art molecules represent a distinct regulatory class of medicine compared to „traditional“, chemically synthesized medicines. In Germany Hexal employs more than 4.000 people at six sites. The company was founded in 1986 and merged with Sandoz in 2006.




Contact:
PD Dr. Bernhard Kreymann

Agnes-Pockels-Bogen 1
D-80992 München
Phone: +49 (0) 89 4111842-0
Fax: +49 (0) 89 4111842-09
E-Mail: info@hepawash.com
Internet: www.hepawash.com



Contact:
Helmut Fabry

Industriestr. 18
D-83607 Holzkirchen
Phone: +49 (0) 8024 908-0
Fax: +49 (0) 8024 908-1290
E-Mail: service@sandoz.com
Internet: www.hexal.de



Contact:

Maximilianstraße 34
D-80539 München
Phone: +49 (0) 89 255 437-0
Fax: +49 (0) 89 255 437-157
E-Mail: info@hmnc.de
Internet: www.hmnc.de



Contact:
Ditte Heimberg

Am Forst 6
D-85560 Ebersberg
Phone: +49 (0) 8092 2092-0
Fax: +49 (0) 8092 2092-28
E-Mail: info@hti-bio-x.com
Internet: www.hti-bio-x.com

HMNC Brain Health GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Medicinal Chemistry, Personalized Medicine, Laboratory, Biomarker Discovery & Development

HMNC is a Munich-based biotech company specialised in research and development of new drugs against depression and anxiety disorders, that was founded in December 2010. HMNC highly contributes to the improvement of treatment strategies against depression and anxiety disorders by pushing the development of new chemical compounds, gene tests and biomarkers. The objective of HMNC is to enable a more precise characterization of patients suffering from depression or anxiety disorders by means of gene tests and biomarkers, leading to an improved identification of those patients who will benefit from specific personalized treatments. Such compounds already exist but have not been marketed due to a lack of suitable gene tests and biomarkers. HMNC is in possession of such laboratory markers and is conducting clinical studies to prove that personalized treatment of depression based on laboratory markers is a progressive innovation with high market potential. HMNC invests in research projects and patents in order to develop profitable therapy concepts in cooperation with investors.

HTI bio-X GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation

HTI bio-X GmbH is an engineering supplier for products and technical service. We are developing customized solutions of instruments and automations. Our product portfolio covers e.g. consumables and instruments for DNA-synthesis. The biomagnetic workstation X-Tract facilitates magnetic beads applications. The main focus is a system of instruments and modules for the automation of laboratory processes. The X-TubeProcessor is based on the X-Capper for capping and of screw cap tubes. This device is expandable with many modules e.g. for labelling, barcode reading, filling reagents or powder into individual tubes or dispensing of reagents into all tubes. The X-TubeProcessor is usable for a wide range of tubes. The system will be combined with modules regarding to the market requirements.

HumediQ

BIOTECH BIOINFORMATICS

Keywords: Informatics, Personalized Medicine, Devices

humediQ was founded in 2010 and has currently 10 employees. We see our mission in the development, production and sales of medical-technical systems – both software and hardware. The focus is on quality assurance systems in radiotherapy. Our vision is to develop high-quality medical devices. To achieve our product goals (transfer of scientific research results into clinical routine integration of innovation into clinical practice), we work closely together with hospitals and research institutions and form a highly qualified and motivated team.

Hyglos GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Peptide/Protein, Infectious Diseases, Proteomics

Hyglos' core competency is to exploit the principles of bacteriophage biology and the expert use of the proprietary phage-protein technology for diagnostics, antimicrobial and research applications. Hyglos' products and services are supplied to well known pharmaceutical and biotech companies as well as research institutes. Hyglos product portfolio includes the endotoxin detection assays EndoLISA® & EndoZyme®, EndoTrap®, EndoGrade®, reagents for food diagnostics, Bacteria Capture Kits. Furthermore, Hyglos offers customized services using state-of-the-art technology; Endotoxin Detection Service, Endotoxin removal Service, From Gene to Protein Service. Hyglos GmbH is certified according to ISO 9001:2008 and ISO 13485:2003 + AC:2007.

Hyperthermics Regensburg GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Hyperthermics Regensburg GmbH is a biotechnology company developing applications of hyperthermophilic organisms in renewable energy solutions and in industrial processes. In these applications hyperthermophilic microorganisms are the "software". In the initial phase we are focusing on developing applications together with international industrial partners. In an operational phase we will focus our research activities towards "software development and update".



Contact:
Dr. Margarete Martinez

Herrenwiesstr. 12
D-82031 Grünwald
Phone: +49 (0) 89 649 56 28 4
Fax: +49 (0) 89 649 5628 5
E-Mail: info@humediq.com
Internet:www.humediq.com



creative bioscience solutions

Contact:
Dr. Wolfgang Mutter

Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9060-0
Fax: +49 (0) 8158 9060-210
E-Mail: info@hyglos.de
Internet:www.hyglos.de



Contact:
Prof. Dr. Michael Thomm

Am BioPark 9
D-93053 Regensburg
Phone: +49 (0) 173 8908929
E-Mail:
michael.thomm@biologie.uni-regensburg.de
Internet:www.hyperthermics.com



Contact:
Prof. Dr. Markus Veit

Fraunhoferstraße 9
D-82152 Martinsried
Phone: +49 (0) 89 520 46 17-0
Fax: +49 (0) 89 520 46 17-59
E-Mail: info@i-dras.com
Internet: www.i-dras.com



Contact:
Dr. Susanne Seifert

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 800 001111-28
Fax: +49 (0) 800 001111-29
E-Mail: info@ibidi.de
Internet: www.ibidi.de

i.DRAS GmbH international Drug Regulatory Affairs Services

CRO

Keywords: Devices, Regulatory Affairs, Toxicology, Pharmacology, Medical Writing, Analytical Chemistry, Drug Development

i.DRAS is a service provider for international drug regulatory affairs. i.DRAS offers support and services for human and veterinary medicinal products from the preclinical/early clinical development stages to the first submission of the MA dossier throughout post marketing activities, covering the whole product life cycle. Services provided cover CTAs and MAAs and all respective documentations to be filed (IB, IMPD, CTD, NtA) for new and established drug substances and the corresponding drug products, including herbal and biological/biotechnological medicinal products. If requested i.DRAS takes over the project management for complex projects with further partners who may be assigned through us or our clients. The same applies to borderline medicinal devices and such incorporating an ancillary drug substance.

ibidi GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Chip/Array Technology, Tissue Engineering/Cell Culture, Nanobiotechnology, Devices

ibidi - cells in focus ibidi develops, produces, and distributes innovative laboratory products, instruments, and reagents for live cell analysis and cell-based assays specifically for high-end microscopy. An extensive line of cell-culture biochips - μ -Slides, μ -Dishes, and μ -Plates- offers solutions for immunofluorescence and basic cell culture, plus complex assays, such as angiogenesis, chemotaxis, wound healing, shear stress, and flow. The instrument line includes stage top incubators, a unique perfusion system that provides continuous flow for the simulation of blood vessels, and a system for monitoring, measuring, and controlling the O₂ concentration in biological samples. The Fuse-It reagents allow for fast and efficient transport of mRNA and other particles into cells.

ImevaX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Vaccines, Infectious Diseases

ImevaX develops highly specific vaccines against pathogens which cause chronic infectious diseases. With our technology, we identify immune modulatory bacterial factors that we then use to develop effective vaccines against infections of global relevance. Our lead candidate is a vaccine against *Helicobacter pylori*, which colonizes the stomach and is the cause of ulcer disease and gastric cancer in humans. Using an immunological screening approach, our research team was able to identify the factor responsible for the down-regulation of the immune system. Presentation of an inactivated form of this factor to the immune system led to the production of inactivating antibodies, resulting in a full recovery of the immune response. In 2011, ImevaX was awarded by the prestigious GO-Bio program of the German Ministry of Research and Education (BMBF), which provides essential funding for the preclinical development. As part of this program, further bacterial pathogens are analyzed to identify immune modulatory factors that are useful as vaccines against chronic infections. During the present funding period, our most advanced project, the *Helicobacter pylori* vaccine is envisioned to become phase I ready (IND/IMPD stage).

ImevaX

Immune Evasion Vaccines

Contact:

Grillparzerstr. 18
D-81675 München
Phone: +49 (0) 89 4140 2477
Fax: +49 (0) 89 4140 4139
E-Mail: info@ImevaX.com
Internet: www.imevax.com



ibidi[®]
cells in focus

ibidi Slides, Dishes, and Plates

The Choice for Scientists
Who Care About Their Image



Contact:
Dr. Eva Laußermair

Bunsenstr. 7a
D-82152 Martinsried
Phone: +49 (0) 89 452 4667-0
Fax: +49 (0) 89 452 4667-410
E-Mail: info@imgm.com
Internet: www.imgm.com



immatics

Contact:
Dr. Nikola Wiegeler

Fraunhoferstr. 18 b
D-82152 Martinsried
Phone: +49 (0) 89 540415-0
Fax: +49 (0) 89 540415-905
E-Mail: info@immatics.com
Internet: www.immatics.com

IMGM Laboratories GmbH

BIOTECH

Keywords: Pharmacogenomics, Pharmacogenetics, Chip/Array Technology, Laboratory, PCR

IMGM Laboratories, founded in 2001, are a GLP and DIN EN ISO / IEC 17025 certified contract service provider for genomic services. Our four service pillars cover biomarker discovery, pharmacogenetics, metagenomics and bio-distribution studies of nucleic acid compounds. We provide vast experience in Expression Profiling, Mutation Analysis and SNP detection based on Next Generation Sequencing, Microarray and qPCR. IMGM offer a fast and reliable service complemented by consultancy and comprehensive bioinformatics analysis. In close collaboration with the Center of Human Genetics and Laboratory Medicine, Martinsried, our clinical partner, we offer a complete pathology workflow containing the molecular characterization of cancer samples from histology to mutation detection and fusion transcript identification; comprehensive analysis of the human microbiome from different sources (eg. stool, skin, saliva) and high resolution HLA-typing by NGS as part of clinical studies under GCP. Our customer base is formed by biotech companies and start-ups, academic groups as well as bio-pharmaceutical companies across the globe.

immatics biotechnologies GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Genomics, Proteomics, Peptide/Protein, Vaccines, Immune Therapy, Oncology

immatics biotechnologies is a clinical-stage biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer. immatics' lead product, IMA901 for renal cell carcinoma, completed Phase III patient recruitment in Nov. 2012. immatics' pipeline also includes IMA910, in Phase II for colorectal cancer, and IMA950 which is being developed for glioma. immatics' technology platform rapidly generates defined therapeutic cancer vaccines which are based on multiple tumour-associated peptides (TUMAPs) with the ability to specifically stimulate the immune system against cancer cells. These vaccines – comprising multiple peptides confirmed to be naturally presented by real tumour tissue – offer the prospect of greater effectiveness than existing cancer vaccine approaches. immatics' products are 'drug like' with stable, off-the-shelf formulations and robust easily scalable manufacturing. immatics is based in Tuebingen and Munich, Germany, and has raised EUR 108 million (US\$ 140 million) in private equity in three financing rounds.

Q F S B Y F X T F Z O Y Z F N C H V F V G G P Z K G T E C W Z T D
Q D G X L W X H W F Z D T T Z A D B X N Q H K X S I X P W Q P K S
E I U G V O W H V A F J K U Z E K I P Y K G Y X B J J R H O V M L
T I W A E B U X Y Q D F K P X N P U B P M G C N U P E J X P W E W
I C R C O R P F P O N R A T E C T S A E L A L S U P W O M T E R Z
O J Z A A Z E C A Q D C M C I M X N F J U U E F P B P H S D I C R K
M O N I V F Y B N C O M Y M U U N I C A Y T I O N S H D H S Q R K
R T S Z A D I L V G X C Z G E M E F K U G X S E H R X V I U C E S
M M V A Y U T P J B Z B L A D F S Z N V I N L V E S T Y O R J D M Z Q U G K
Z M V R J U Q E Z Z Q C O P C N W L J C O B Y I V J D M Z Q U G K
N T I Y D A G L A X S Y D Q E W V T G D K V P S P H L J V E K Q R
C O P C B L A D F S Z N V I N L V E S T Y O R J D M Z Q U G K W W
N P A G J U V R Z N S K Z W H C E R X E C E S C B M U N T T C S I
O T I E N N J S J H Y X D B T R E L N A K T I B O N D S M L M D C
Z Q B L K G V J N N S P K P O A L C N E L H S Z U K W B N G P R K
U Q M C X I I F P K S K K B U T B R I R V A J L A B E F H B P J U
F V X B I R E N K K H P H M O R Z O P J J S C Q A W L R K J E N H
Q T K H R N K P O Z V T T B N J S A C H O V V Y O Z W N I A V I S
G L I N P F F L A C O U V X L G D S C G P F O L Z B R I C B D N B
C K Y O C S M N I E Q T O H A O C N M A L V F U E Q F L A Q O K I
V K H F O Z H J F H D K F U Y C X A R I P L L F N O K S K K B U T
B R I R V F I N A A N F C I P A L F V X B I R E N K D O R C N L K
P S P Q F S B Y F X T F Z O Y Z F N C H V F V G G P Z K G T E C W
Z T D Q D G X L W X T R F A N S T A C T B I O Q N S X G I X P W Q
P K S E I U G V O W H V A F J K U Z E K I P Y K G Y X B J J R H O
V M L T I W A E B U X Y Q D F K P X N P U B P D G A U P L X L H J
J V W K Q R Z M V R J U Q E Z Z Q C O K M F Z B J D O P C N W L J
C O B Y I V J D M Z Q U G K W W N P A G J U K R Z N O P Z W H C

EXPERTS IN LIFE SCIENCE COMMUNICATIONS

Corporate Communications

- > Strategy
- > Editorial Work
- > Media Relations
- > Media Events
- > Crisis Communications
- > Corporate Website

Investor Relations

- > IR Consulting
- > IR Website
- > IR Outsourcing
- > IR Events
- > Financial PR
- > Financial Reporting

Financial Transactions*

- > IPOs
- > Secondaries + PIPEs
- > Private Financings
- > Investor Targeting
- > Roadshows
- > Feedback Report



Contact:

Am Klopferspitz 19a
D-82152 Planegg-Martinsried

E-mail: info@immunic.de
Internet: www.immunic.de



Contact:

Wolfgang Mayer

Karlstrasse 46
D-80333 München
Phone: +49 (0) 89 5432177-89
Fax: +49 (0) 89 5432177-92
E-Mail: info@immumed.de
Internet: www.immumed.de

Immunic AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Immune Therapy

Immunic AG is a young biotech company based in the Munich biotech hub Martinsried that develops pharmaceuticals in the immunology space, in particular for autoimmune diseases or diseases that have an important immunology component in its pathogenesis. Mission of Immunic AG: Immunic AG is a start-up biotech company focused on the development of immune modulators to block TH17- and TH1-mediated immune and autoimmune responses. The final aim is to develop these drug candidates to clinical proof of concept.

Immumed GmbH Gesellschaft für angewandte Immunologie

BIOTECH PRECLINICAL SERVICES

Keywords: Laboratory, Inflammation, ELISA/EIA, Clinical Diagnostics

Applied Immunology – Testing Services

We offer testing services for human, mouse or rat samples:

- Analysis of cytokines, chemokines and phosphoproteins
- Cell-characterization
- Cell-separation
- Cytotoxicity

Our team is specialized in measuring multiplex-parameter analysis with Luminex-Technology in various samples like serum, cell cultures, saliva, urine. We perform every application for flow-cytometry analysis, for example cell phenotyping, intracellular cytokine detection or cytotoxicity assays as well as positive or negative selection of cells with magnetic-bead technology.

immunoGlobe Antikörpertechnik GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Laboratory, Antibody Production Service, Antibody

immunoGlobe® GmbH is a privately owned company, established in 1997.

Core competences are

- Manufacturing of novel research antibodies,
- Full service custom antibody production and purification,
- Marketing of own and licensed antibodies through a global network of OEM partners, wholesalers, and distributors.

Specializations:

Through sophisticated schemes of immunization, affinity purification & depletion on multiple proteins or peptides immunoGlobe® has specialized in the generation of highly specific antibodies against:

- any combination of (de)phosphorylation states of neighboring double-phosphorylation sites
- neo-epitopes (e.g. cleavage sites)
- isoforms, variants, and point mutations

Epitope mapping services with single amino acid precision complete the service catalog.

Implen GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Nanobiotechnology, Genomics, Chip/Array Technology, Automation, Devices

Implen is a privately held corporation that is a leading supplier for spectroscopy instruments and consumables for the non-destructive analysis of ultra low volume samples. The company focuses on biological, chemical, and pharmaceutical laboratories in industry and research.



Contact:
Dr. Matthias Reinhard

Rudolf-Diesel-Str. 8A
D-97267 Himmelstadt
Phone: +49 (0) 9364 810-610
Fax: +49 (0) 9364 810-613
E-Mail: info@immunoglobe.com
Internet: www.immunoglobe.com



Contact:
Martin Sahiri

Schatzbogen 52
D-81829 München
Phone: +49 (0) 89 7263718-0
Fax: +49 (0) 89 7263718-54
E-Mail: info@implen.de
Internet: www.implen.de



Contact:
Patrick McManus

Robert-Koch-Allee 29
D-82131 Gauting
Phone: +49 (0) 89 8935 69-0
Fax: +49 (0) 89 8935 69-22
E-Mail: request@inamed-cro.com
Internet: www.inamed-cro.com



Contact:
Susanne Brehm

Stefan-George-Ring 6
D-81929 München
Phone: +49 (0) 89 993 913-0
Fax: +49 (0) 89 993 913-160
E-Mail:
reza.khosravani@incresearch.com
Internet: www.incresearch.com

Inamed GmbH

CRO

Keywords: [Drug Delivery](#), [Medical Writing](#), [Respiratory Diseases](#)

Inamed GmbH - „THE Respiratory CRO“ INAMED was founded in 1998 and is an experienced, independent, privately owned and managed CRO with its headquarters located at the periphery of Munich, and with its roots in basic research and clinical medicine. We are an international contract research organization with true respiratory expertise. Complementing our solid experience in conducting clinical trials, INAMED's team of inhalation and clinical experts provides our sponsors with a unique spectrum of services. Besides our clinical trial operations at all phases of development and our fully staffed, in-house Phase I-IIa unit with twenty beds, INAMED performs in-vitro studies in our own labs and is the only CRO in continental Europe able and approved to perform radio-labeling studies. Our studies deliver the highest quality data and can enhance your clinical trials and development projects for drugs and inhalation devices. INAMED offers an opportunity for sponsors to get their products to market more successfully.

INC Research GmbH

CRO

Keywords: [Data Management and Biostatistics](#), [Medical Writing](#), [Vaccines](#), [Inflammation](#), [CNS](#), [Oncology](#), [Pharmacovigilance](#)

INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The company's Trusted Process® methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions.

Innovation and Entrepreneur Center Würzburg



- ⊙ **renting of lab and office space**
- ⊙ **coaching of start-ups**
- ⊙ **consulting on financing**
- ⊙ **support of the management**
- ⊙ **networking / business contacts**

INFORS HT

Contact:
Dr. Burkhard J. Feigel

Dachauer Str. 6
D-85254 Einsbach
Phone: +49 (0) 8135 8333
Fax: +49 (0) 8135 8320
E-Mail: infors.de@infors-ht.com
Internet: www.infors-ht.com



virion\serion

Contact:
Andrea Aelker

Friedrich-Bergius-Ring 19
D-97076 Würzburg
Phone: +49 (0) 931 3045-0
Fax: +49 (0) 931 3045-100
E-Mail: dialog@virion-serion.de
Internet: www.virion-serion.de



Contact:

Sonnenstraße 24-26
D-80331 München

E-Mail: contact@ingeneron.com
Internet: www.ingeneron.com

Infors GmbH

BIOTECH DEVICES & REAGENTS

INFORS HT is your specialist for bioreactors, incubation shakers and bioprocess control software. You benefit from sophisticated systems, in which your cell lines or microorganisms develop their full potential in a reproducible way, thus contributing to your success.

For your applications, we offer the right solutions:

- Fermentation of microorganisms (bacteria, fungi and yeasts)
- Cell culture (mammalian cells, insect cells, plant cells and algae)
- Biofuel (biodiesel and bioethanol)
- Parallel bioprocesses
- Custom-made bioreactors and incubation shakers
- Bioprocess control software
- Qualification of bioreactors and incubation shakers

Closeness to the customer, high quality, innovation and flexibility are our greatest strengths.

Institut Virion\Serion GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Clinical Diagnostics](#), [ELISA/EIA](#), [Autoimmune Diseases](#), [Infectious Diseases](#), [Respiratory Diseases](#), [Automation](#)

Institut Virion\Serion GmbH is a German in-vitro diagnostic company with more than 30 years of experience in the international market. The extensive high-quality product portfolio for the diagnosis of infectious diseases contains SERION ELISA classic tests recommended for quantified antibody detection in human serum, plasma, and, if necessary, in cerebrospinal fluid, against various viral, bacterial, fungal and parasitic infections. SERION ELISA antigen tests enable a direct antigen detection of pathogens. Our Complement Fixation Tests are featuring more than 50 different antigens. The latest developments of our particle-based SERION Multianalyt™ products allow simultaneous antibody detection against multiple antigens using flow cytometry. Parallel to immunoassays we have introduced the Immunomat™ for automated processing and analysis of SERION ELISA classic and SERION ELISA antigen tests.

InGeneron GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Cell Therapy](#)

InGeneron is elevating the field of regenerative medicine by translating robust science into proven patient benefit. Our purpose is to set new therapeutic standards by enabling physicians to use the patients own regenerative cells at point of care. With the initial focus on key orthopedic and wound healing indications, we will make regenerative cell therapies broadly accessible across multiple medical fields.

iOmx Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, RNAi & Antisense, Immune Therapy

iOmx Therapeutics is a novel immuno-oncology target discovery and drug development company. Its founders have developed a high-throughput siRNA-based screening approach that allows a comprehensive identification of ligands on human cancer cells that inhibit CTL-mediated tumor cell killing. To date, this screening technology has been applied to multiple tumor entities. More than twenty novel targets have been identified which form the basis of the company's pre-clinical product portfolio. For more details, please refer to: <http://www.iomx.de/> or Follow us on: <https://www.linkedin.com/company/iomx-therapeutics>.

Intana Bioscience GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Microscopy, Antibody, Peptide/Protein, Small Molecules

Intana Bioscience GmbH, founded 2008, is a privately owned service provider company. Understanding the selectivity profile and the binding characteristics of a candidate drug has been shown to be essential for downstream optimization. Intana Bioscience GmbH offers interaction analysis based on a single molecule sensitive spectroscopic approach called fluorescence cross correlation spectroscopy (FCCS). FCCS can be applied in cellular lysates to determine the binding and rate constants of biomolecular interaction and represents a highly efficient approach to develop selective inhibitors for targeted therapies. Customers benefit from short assay development time, in depth interaction analysis and assay conditions that mimic the natural environment of a drug.

Iris Biotech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Peptide/Protein, Drug Development, Drug Delivery, Medicinal Chemistry, Combinatorial Chemistry, Natural Compounds

1. Starting materials for peptide synthesis, peptidomimetic and medicinal chemistry: protected amino acids, coupling reagents, linkers and resins, natural and unusual amino acids and natural compounds with physiological properties.
2. Technologies for Drug Delivery: more than 900 different carriers used in polymer therapeutics products (PEGylating reagents, PASylation, PGA Poly(glutamic acid) and multi-functional dendrimers).
3. Reagents for Life Sciences and Diagnostics: substrates, inhibitors, cross-linker, immunologic tools, carbohydrates, dyes and fluorescent labels.
4. We carry out custom synthesis in all areas above. Our strengths are compounds with one or several chiral centers.



Contact:
Angelika Geier

Fraunhoferstraße 13
D-82152 Planegg-Martinsried

Internet: www.iomx.de



Contact:
Dr. Frank Becker

Lochhamer Str. 29 a
D-82152 Martinsried
Phone: +49 (0) 89 895 572-80
Fax: +49 (0) 89 895 572-81
E-Mail: info@intana.de
Internet: www.intana-bioscience.de



Contact:
Dr. Thomas Bruckdorfer

Waldershofer Str. 49-51
D-95615 Marktredwitz
Phone: +49 (0) 9231 9619-73
Fax: +49 (0) 9231 9619-99
E-Mail: info@iris-biotech.de
Internet: www.iris-biotech.de



Contact:
Dr. Andrea Kottke

Leopoldstraße 254-256
D-80807 München
Phone: +49 (0) 89 890 831-0
Fax: +49 (0) 89 890 831-491
E-Mail: info@isarna-therapeutics.com
Internet: www.isarna-therapeutics.com



Contact:
Christian Wiest

Zielstattstr. 13
D-81379 München
Phone: +49 (0) 89 700 7449-0
Fax: +49 (0) 89 700 7449-90
E-Mail: info@ithera-medical.com
Internet: www.ithera-medical.com



Contact:
Nicola Scharrer

Lichtenbergstr. 1
D-85748 Garching
Phone: +49 (0) 89 329 8986 60
Fax: +49 (0) 89 329 8986 66
E-Mail: info@itm.ag
Internet: www.itm.ag

ISARNA Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: RNAi & Antisense, Biomarker Discovery & Development, Drug Development

Isarna Therapeutics has an unmatched commitment to developing TGF- β inhibitors that stimulate the human immune system to effectively fight cancer and other diseases. We are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

iThera Medical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Drug Development, Devices, Cardiovascular Diseases, Inflammation, Oncology

iThera Medical develops and markets a novel in-vivo biomedical imaging technology, "MSOT" = multi-spectral opto-acoustic tomography. MSOT utilizes the photo-acoustic effect to visualize and quantify anatomical, functional and molecular information of living tissue. Today, MSOT allows the early and reliable validation of new substance efficacy in drug discovery (e.g., for oncology, neurology and cardiovascular problems). For the future, MSOT also promises to become a valuable tool for clinical diagnostics.

ITM Isotope Technologies Munich AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Drug Development, Industrial Biotechnology, Personalized Medicine, Oncology

ITM Isotopen Technologien München AG is a privately held group of companies dedicated to the development, production and global supply of innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals. Since its foundation in 2004, the ITM Group has established the GMP manufacturing and a robust global supply network. ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development addressing a range of cancers such as neuroendocrine cancers or bone metastases. ITM's main objectives are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side-effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology

Kantar Health GmbH Clinical Research

CRO

Keywords: Regulatory Affairs, Data Management and Biostatistics, Clinical Trial Management and Monitoring, Medical Writing, Oncology, Pharmacovigilance, Logistics

Kantar Health GmbH Clinical Research conducts phase I-IV clinical trials, retrospective and prospective non-interventional studies, patient reported outcomes and pharmacoeconomic studies. Our operations span local agencies in over 45 countries worldwide. Kantar Health combines more than 30 years of CRO expertise in drug research including development of innovative web-based applications (InTrial® and InDrugs®). Our services include: protocol and CRF design, eCRF solutions, feasibility and site selection, investigators training, handling of legal and ethical requirements, monitoring and site management, project management, implementation of risk management programs, data management, medical coding, pharmacovigilance, quality assurance, statistical planning and analysis, medical writing.

KANTAR HEALTH

Contact:
Mercedes Apecechea

Landsberger Str. 284
D-80687 München
Phone: +49 (0) 89 5600 1005
Fax: +49 (0) 89 5600 1400
E-Mail: info@kantarhealth.com
Internet: www.kantarhealth.com



*Creating new ideas
is your business.*

*Protecting these ideas
is ours.*

HUBER & SCHÜSSLER
Patentanwälte und Rechtsanwälte





Contact:
Dr. Klaus Hellmann

Geyerspergerstr. 27
D-80689 München
Phone: +49 (0) 89 580 082-0
Fax: +49 (0) 89 580 082-7777
E-Mail: info@klifovet.com
Internet: www.klifovet.com



Contact:
Dr. Michael Miller

Ferdinand-Zwack-Str. 39
D-85354 Freising
Phone: +49 (0) 8161 205957
E-Mail: info@kmbioservices.de
Internet: www.kmbioservices.de

KLIFOVET AG

CRO

Keywords: [Veterinary clinical trials](#), [Pharmacovigilance](#), [Regulatory Affairs](#), [Drug Development](#), [Data Management and Biostatistics](#), [Clinical Trial Management and Monitoring](#)

Munich/ Germany-based KLIFOVET AG is the provider of high quality services for the Animal Health and Animal Nutrition Industry acting as a CRO, CMO and regulatory consultancy for the registration and marketing of all kind of veterinary medicinal products and feed additives. Klifovet has recently been awarded as the Best CRO by AnimalPharm. Our services include:

- Project management for the complete product development phase - from the idea to the marketed product
- Regulatory strategic consultancy, dossier writing, negotiations with the authorities
- CRO: Planning and conduct of veterinary clinical safety and efficacy studies in all target animal species
- Full life cycle management incl. pharmacovigilance and QPPV services - CMO support for EU QP release

We handle EU, US or other projects with our dedicated partners. We provide nearly 20 years of experience, well organized logistics, a highly motivated team, and a comprehensive net of co-operators and skilled investigators throughout Europe, North America and other continents. We handle large multinational projects as professionally as national ones, complying to national, EMA, EFSA, FDA/USDA or other national standards.

kmbs

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: [Genomics](#), [PCR](#)

kmbs is your service partner for organismic studies e. g. in Conservation Biology, Zoology, Phylogeny, Taxonomy, and Molecular Biology to clear up specimens' identities by means of molecular/genetic analyses (Sample preparation, PCR, DNA sequencing, Gene Fragment analysis) for purposes like resolving species relationships, detecting sibling species, delimiting species boundaries, investigating population structure and integrity, a.s.o. In addition, we are experienced in making microscopic preparations, carrying out outdoor services like mapping species inventories or searching for special organisms within a given habitat including the collection of organisms on demand, and acting as project manager and consultants.

Laboklin GmbH & Co KG – Unternehmensbereich Labogen

BIOTECH THERAPEUTICS & DIAGNOSTICS

Our laboratory provides a complete testing service for veterinary surgeons to meet the diagnostic needs of your practice. You can find all important information and our laboratory profiles and screens (microbiology, haematology, allergy, pathology and genetic testing). Furthermore you can download submission forms or order sample collection material. If you are registered you are able to locate your samples, the stage of investigation and much more.

Labor Friedle GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Medicinal Chemistry, Allergy

Labor Friedle GmbH is an accredited analytical laboratory for analytics of chemical residues like heavy metals, pesticides, mycotoxins and radioactivity testing. Our scope includes furthermore food ingredients, nutrient content analytic, examination of human biological matrices, microbiological and molecular biological examinations and examination of indoor air pollutions.

Labor L+S AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Laboratory, Clinical Diagnostics, Allergy, Medicinal Chemistry, Molecular Diagnostics, Analytical Chemistry

The Labor L+S AG is one of the leading European CROs for analytics and consulting for pharmaceuticals and medical devices. More than 1000 customers trust in the companys experience. The range of services covers microbiology, molecular-biology, biochemistry as well as physics and chemistry on raw materials and on finished products. In addition, services in industrial hygiene and clinical-microbiological diagnostic are offered. In a state of the art plant with 10,000 sqm of laboratory space, 450 experts handle more than 250,000 samples/a. Establishment of new methods is a key strategic factor of the companys success, triggered by customers requests and changes in regulatory requirements from FDA or European agencies. Both agencies successfully inspect on a regular basis.

LABOKLIN
LABOR FÜR KLINISCHE DIAGNOSTIK GMBH & CO. KG

Contact:
Dr. Elisabeth Müller

Steubenstr. 4
D-97688 Bad Kissingen
Phone: +49 (0) 971 7202-0
Fax: +49 (0) 971 68546
E-Mail: mueller@laboklin.de
Internet: www.laboklin.com



Contact:
Albrecht Friedle

Von-Heyden-Str. 11
D-93105 Tegernheim
Phone: +49 (0) 9403 967 98-0
Fax: +49 (0) 9403 967 98-20
E-Mail: info@labor-friedle.de
Internet: www.labor-friedle.de

LS|AG

Contact:
Denise Baumbach

Mangelsfeld 4, 5, 6
D-97708 Bad Bocklet
Phone: +49 (0) 9708 9100-0
Fax: +49 (0) 9708 9100-36
E-Mail: service@labor-ls.de
Internet: www.labor-ls.de



Contact:
Dr. Stefanie Zorbas-Seifried

Bunsenstr. 7a
D-82152 Martinsried
Phone: +49 (0) 89 899 480 780
E-Mail: szorbas-seifried@labpmm.de
Internet:
<https://invivoscribe.com/clinical-services>

leon-nanodrugs

Contact:
Dr. Wolfgang Beier

Kopernikusstr. 9
D-81679 München
Phone: +49 (0) 89 4142 4889-0
Fax: +49 (0) 89 4142 4889-88
E-Mail: info@leon-nanodrugs.com
Internet: www.leon-nanodrugs.com

LabPMM GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Molecular Diagnostics

LabPMM GmbH is an ISO 15189 accredited reference laboratory focused on Personalized Molecular Medicine and Personalized Molecular Diagnostics for customers throughout Europe and surrounding regions. Our test menu includes biomarkers that have demonstrated clinical utility; tests that provide data and information critical to making informed treatment decisions. These tests conform to a Standard of Care as defined by the World Health Organization and they are recommended by the National Comprehensive Cancer Network, LeukemiaNet, and other world opinion leaders in hematology-oncology. LabPMM is the only reference laboratory accredited and licensed to perform testing for FLT3 and NPM1 mutations the most important prognostic biomarkers for karyotype normal AML.

leon-nanodrugs GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Drug Development, Drug Delivery, Antibody, Peptide/Protein, Small Molecules, Combinatorics

Leon-nanodrugs GmbH (Munich) is a nanotechnology-based drug development company focused on development of novel oral and parenteral formulations and innovative drug combinations. More than half of all marketed therapeutic drugs are poorly soluble or practically insoluble in water. However, good water solubility is a pre-requisite that drugs are taken up into the body and distributed to the desired sites where they can unfold their therapeutic potential. This vital problem in drug development can be solved by using nanotechnology. The proprietary and patent-protected MicroJetReactor (MJR®) Technology by leon-nanodrugs is a bottom-up approach for nano- and microparticle synthesis. Basis of the process is a continuous solvent / non-solvent precipitation that is performed under precisely controlled process conditions. leon-nanodrugs GmbH is the exclusive licensee of the MJR® Technology platform for pharmaceutical applications and develops drug products based on nanoparticle & nanoemulsion approaches. The business concept includes contract development, co-development, partnerships and internal development projects in order to generate added value to established molecules and new chemical entities (NCEs). Build on its „network of expertise“, leon-nanodrugs can provide a 360 degree competence range - from concept to product approval. Leon's reformulation service partner in Europe is MJR PharmJet GmbH (Instillo Group) and in 2015, leon opened an US Office in New York and established cooperation with CoreRX in Clearwater/Florida in order to enhance its lab scale screening and formulation capabilities. Leon-nanodrugs proprietary MJR® Technology offers access to the next generation nano formulated drugs with added patient benefits and economical values for its partners and shareholders.

LEUKOCARE AG

BIOTECH DEVICES & REAGENTS

- LEUKOCARE provides proprietary formulation technologies and related development services for stabilization and protection of biologics
- LEUKOCARE technologies are employed in collaborations with partners in the field of vaccines, therapeutic proteins, and biologic device combination products.
- LEUKOCARE provides development services based on fee for service during implementation of its technologies.
- LEUKOCARE's technologies provide manifold benefits:
 - Improved shelf-life / stability / quality
 - Terminal sterilization of biologics
 - Significant production cost savings

LINDIS Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody

LINDIS Biotech was founded to develop ektomun[®], an innovative immunotherapeutic for the treatment of small cell lung cancer, melanoma and other neuroectodermal cancers that currently lack sufficient treatment options. The company is managed by Horst Lindhofer, inventor of the underlying trifunctional antibody technology and CEO of TRION Pharma.

LISANDO GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Lysando is a manufacturer of medical devices. Lysando AG and the R&D centre Lisando GmbH are owned by the TGI Group, which is specialised in environmentally supportive technologies and manufacturing.

- Achievements: In 2010 our team received the Food Safety Innovation Award for a novel method to detect bacterial contamination in food. In October 2012 LYSANDO AG has been rated with the best rating possible by Dun&Bradstreet.
- Cooperations: Lysando cooperates with various Universities and Institutes in Europe, Thailand, Japan and United States of America.



Contact:
Michael Scholl

Am Klopferspitz 19
D-82152 Martinsried/Munich
Phone: +49 (0) 89 7801665-0
Fax: +49 (0) 89 7801665-11
E-Mail: info@leukocare.com
Internet: www.leukocare.com



Contact:

Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 700 766 24
E-Mail: horst.lindhofer@lindisbiotech.com
Internet: www.lindisbiotech.com



Contact:
Markus Matuschka von Greiffenclau

Am BioPark 13
D-93053 Regensburg
Phone: +49 (0) 941 28096-208
E-Mail: info@lisando.com
Internet: www.lisando.com



Contact:
Prof. Dr. Matthias Schieker

Truhenseeweg 8
D-82319 Starnberg
Phone: +49 (0) 8151 5590291
Fax: +49 (0) 8151 917922
E-Mail: info@livimplant.de
Internet: www.livimplant.de



Contact:
Dr. Caroline Freye-Minks

Mühlweg 2 a
D-82054 Sauerlach
Phone: +49 (0) 8104 616-20
Fax: +49 (0) 8104 616-48
E-Mail: service@loewe-info.com
Internet: www.loewe-info.com



Contact:
PD Dr. Ludwig Deml

Am BioPark 13
D-93053 Regensburg
Phone: +49 (0) 941 6309 197-0
Fax: +49 (0) 941 6309 197-9
E-Mail: info@lophius.com
Internet: www.lophius.com

LivImplant GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Inflammation, Bone/Joint Diseases, Cell Therapy, Tissue Engineering/Cell Culture

LivImplant GmbH develops and sells innovative cell based therapies for lesions and diseases of tendons, joints, cartilage and bones, focusing on stimulating the self-healing powers of the body by applying stem cells and growth factors. As a spin off from the Experimental Surgery and regenerative Medicine department of the Ludwig-Maximilians-University of Munich (www.experimed.de) and a close collaboration with the Veterinary Clinic of the University of Giessen LivImplant benefits from the latest scientific proceedings. First applications are available for curing lameness with horses and dogs.

Loewe® Biochemica GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Agrobiotechnology, ELISA/EIA

LOEWE is committed to the development and production of high quality reagents for the detection of plant diseases caused by bacteria, fungi, nematodes, and viruses. Furthermore we offer contract testing services for all kinds of crops and ornamentals (ELISA techniques, Immuno Fluorescence Antibody Assays, Blotting, and PCR).

Lophius Biosciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Immune Therapy, Infectious Diseases

Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases. The company's developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics. With its T-Track® CMV leading product, Lophius offers a highly sensitive, reliable and standardized CE-marked in vitro diagnostic solution to measure the functionality of CMV-specific cell-mediated immunity. T-Track® CMV assists clinicians in the risk stratification of CMV disease in immunocompromised patients, toward an improved and individualized patient management.

Luye Pharma

PHARMA & CHEMICAL INDUSTRY

Keywords: Pharmacology, Drug Delivery, Medicinal Chemistry

Luye Pharma Group Ltd. announced the completion of its acquisition of the transdermal drug delivery systems (TDS) business from Swiss company, Acino in November 2016. The acquired business is a global leader in niche transdermal markets and will greatly enhance Luye's developmental efforts in R&D, manufacturing, international registration, and market promotion of new formulation products to international standards, thereby helping to pave the way for Luye's expansion into the global markets. The acquired business is one of the largest independent TDS manufacturers in Europe, with a product portfolio primarily focused on more sophisticated and higher margin specialty patch categories such as CNS, pain and hormone spaces under several successfully commercialised and hard-to-make formulations such as Rivastigmine, Buprenorphine, Fentanyl and fertility control patch. Luye Pharma is a leading Chinese pharmaceutical enterprise driven by innovation and primarily focuses on therapeutic areas such as Central Nervous System, Oncology, Cardiovascular, and Metabolic diseases. Since inception, Luye Pharma has adopted innovation and globalization as its core growth drivers. As one of the pioneering Chinese pharmaceutical enterprises to have conducted clinical trials in international markets, Luye Pharma currently has 5 innovative products at various stages of clinical research with significant breakthroughs in the U.S.

MAB Discovery GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody

MAB Discovery, based in Munich, Germany, is a provider of high quality IND ready monoclonal antibodies obtained from an unique immunization approach exploiting the natural immune system in combination with a sophisticated B-cell cloning and cultivation technique. Early functional testing allows the identification of highly potent monoclonals which eliminates the need for further time consuming affinity maturation. The diversity of the immune responses not only guarantees unprecedented epitope coverage but also ensure success against targets heretofore considered intractable. We offer simple and straightforward business terms by eschewing the traditional IP license approach.



Contact:

Am Windfeld 35
D-83714 Miesbach
Phone: +49 (0) 8025 2867-0
Fax: +49 (0) 8025 2867-28
E-Mail: info@luyepharma.eu
Internet: www.luyepharma.eu



Contact:

Dr. Stephan Fischer

Forstenrieder Str. 8-14
D-82061 Neuried
Phone: +49 (0) 89 990 178-0
Fax: +49 (0) 89 990 178-199
E-Mail: info@mabdiscovery.com
Internet: www.mabdiscovery.com



Contact:

Bunsenstr. 7
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 954 7795 60
E-Mail: info@magforce.com
Internet: www.magforce.de



Contact:

Dr. Michael Gierend

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 895286-0
Fax: +49 (0) 89 895286-66
E-Mail: info@medicomp-cro.de
Internet: www.medicomp-cro.de

MagForce AG

MEDTECH

Keywords: Oncology, Nanobiotechnology

MagForce AG, listed in the entry standard (MF6) of the Frankfurt Stock Exchange, together with its subsidiaries MT MedTech Engineering GmbH and MagForce USA, Inc., is a leading medical device company in the field of nanomedicine in oncology. The headquarters of the MagForce AG are in Berlin. The departments of Clinical Development, Commercial, Intellectual Property and Legal are located at the Munich site. The group's proprietary NanoTherm® therapy enables the focal treatment of solid tumors through the intratumoral generation of heat via activation of instilled superparamagnetic nanoparticles by an alternating magnetic field applicator. The nanoparticles are instilled into a tumor via a minimal invasive procedure and remain at the site of injection due to their aminosilane coating. Based on the amount and location of the instilled nanoparticle depots and the applied magnetic field strength the company's therapy planning software simulates the temperature distribution within the treatment area prior patient treatment. NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide certification (CE mark) as medical devices for the treatment of brain tumors.

medicomp GmbH

CRO

medicomp GmbH was founded in 1985 and has developed ever since into a full service CRO. We offer a wide range of services for phase I-IV trials, PMS and medical devices: medical and biometrical planning, protocol and CRF design, project management, data management, monitoring, statistical analysis and medical writing. medicomp is a member of the Bundesverband Medizinischer Auftragsinstitute (BVMA), which implies regular independent system audits. Furthermore, medicomp is a founding member of Pharmaceutical Service Network (PSN), a network of independent European CROs, which allows us to offer services for studies conducted on a European scope in collaboration with our partners.

Medigene AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Personalized Medicine, Cell Therapy, Vaccines, Hematology, Dermatology, Immune Therapy

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies with focus on hematological malignancies. Through scientific innovation and targeted use of resources, Medigene strives to create sustainable value that will benefit both patients and shareholders.

Medpace Germany GmbH

CRO

Keywords: Cardiovascular Diseases, Metabolic Diseases, Oncology

Medpace, established in 1992, is a full-service Contract Research Organization (CRO), who partners with leading pharmaceutical and biotech organizations to bring promising new drugs to market. Medpace combines comprehensive regulatory consulting with efficient clinical trial management to provide sponsors with exceptional support in drug development. Proven leaders in medical and scientific research monitor every project. Medpace physicians have first-hand experience working with regulatory agencies to successfully guide projects through the complexities of the regulatory process. The medical expertise and regulatory guidance provided by Medpace leads to reduced costs and increased efficiencies for our valued customers.

MedPharmTec GmbH

CRO

Keywords: Medical Writing, Pharmacovigilance, Clinical Trial Management and Monitoring, Data Management and Biostatistics, Regulatory Affairs

MedPharmTec GmbH is a Pharmaceutical Contract Service Organisation providing expert assistance in drug development, clinical research (phase II through IV), medical information, regulatory affairs and drug safety to pharmaceutical and biotechnology companies. Our clinical research services range from protocol planning, CRF design, trial management, monitoring and auditing up to data management, biometrics and report writing. Further areas of MedPharmTec activities include medical information, i.e. medical and scientific translations, Labeling Compliance Service, writing/designing of brochures, publications and scientific literature searches as well as consulting and services in terms of regulatory affairs and drug safety.

medigene

Contact:
Julia Hofmann

Lochhamer Str. 11
D-82152 Martinsried
Phone: +49 (0) 89 2000 33-0
Fax: +49 (0) 89 2000 33-2920
E-Mail: medigene@medigene.com
Internet: www.medigene.com

MEDPACE

Contact:
Dr. Alfred Fraunhofer

Theresienhöhe 30
D-80339 München
Phone: +49 (0) 89 895 5718-0
Fax: +49 (0) 89 895 5718-100
E-Mail: info.de@medpace.com
Internet: www.medpace.de

MEDPHARMTec

Contact:
Dr. Horst H. Langenbahn

Olschewskibogen 7
D-80935 München
Phone: +49 (0) 89 354 998-0
Fax: +49 (0) 89 354 998-199
E-Mail: office@medpharmtec.de
Internet: www.MedPharmTec.de



Contact:
Dr. Regina Bichlmaier

Semmelweisstr. 3
D-82152 Martinsried
Phone: +49 (0) 89 899363-0
Fax: +49 (0) 89 899363-11
E-Mail: info@mymetabion.com
Internet: www.metabion.com



Contact:
Dr. Andreas Benesic

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 151 1799 7111
E-Mail: info@metaheps.com
Internet: www.metaheps.com



Contact:
Dieter Meyer

Paul-Gerhardt-Allee 42
D-81245 München
Phone: +49 (0) 89 829265-100
Fax: +49 (0) 89 829265-099
E-Mail: info@metronomia.net
Internet: www.metronomia.net

metabion

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Antisense/Nucleotides, Antibody Production Service, Other Diagnostics, NGS, Genomics, Proteomics

metabion is one of the globally leading suppliers of custom nucleic acids renowned for its focus on reliable supplies of consistently high quality products and services. Founded in 1997 in Munich/Martinsried, metabion keeps on expanding its product portfolio from the production of a wide range of synthetic DNA and RNA oligonucleotides according to customers' needs to the supply of standard life science products. Successfully translating highest quality standards into daily practice is the core of metabion's business philosophy and key to its popularity at the same time. Careful evaluation and implementation of new and promising technologies and products are complementing metabion's progressive and innovative approach within a healthy and sound business setup.

MetaHeps GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Drug Development

MetaHeps® – First technology to diagnose or exclude DILI (Drug-induced liver injury) in individual patients MetaHeps® is an unique service provider that generates a personalized cell model reflecting individual drug hepatotoxicity from a small patient blood sample. Customers are research driven pharmaceutical companies and global acting CROs, using Metaheps' services in clinical phases of drug development as well as postmarketing.

Metronomia Clinical Research GmbH

CRO

Keywords: veterinary clinical trials, Data Management and Biostatistics, Clinical Trial Management and Monitoring

Metronomia Clinical Research is a mid-size European CRO, providing full- or tailored services in clinical trials phase I - IV and NIS, with special focus on e-clinical, data management and biostatistics. Metronomia's mission statement is to improve and accelerate drug development by bringing together cutting-edge e-clinical technologies, well accepted study designs and pronounced customer orientation. Since more than 20 years our customers particularly esteem the high-quality and reliability of our data, our commitment to best service and outstanding flexibility, our stable project teams and the competitive cost-benefit ratio. Metronomia has a proven track record in all major therapeutic areas (core indications: oncology, dermatology, transplantation, nephrology and pulmonary diseases). additional Keywords: Consulting, e-clinical Services, Biostatistics.

Microcoat Biotechnologie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: ELISA/EIA, Clinical Diagnostics, In-Vitro-Diagnostics, Bioanalytics, PCR

Custom Development:

Development of diagnostic assays, test components and new test formats to market-ready kits. Immunological assays, molecular assays, sample and Matrix preparation protocols Contract manufacturing Diagnostik kit and component manufacturing Service. Standard kit formats comprise ELISA, ELISpot, bead-based formats, lateral-flow kits.

Production, modification and conjugation of antibodies and recombinant proteins, customized solid Phase coating, filling, freeze-drying, kit-assembly, ISO 9001 and 13485

Laboratory Services:

Bioanalytics, companion diagnostics and platform development support.

Biomarker Services:

PK/PD, immunogenicity, sample measurement, endotoxin and pyrogen testing, Assay validation, method and System benchmarking, GLP, GC(L)P, cGMP



Contact:

Am Neuland 3

D-82347 Bernried

Phone: +49 (0) 8158 9981-0

Fax: +49 (0) 8158 9981-10

E-Mail:

humanresources@microcoat.de

Internet: www.microcoat.de

Passion for Performance

 **Rentschler**
THE BIOPHARMA MANUFACTURER

CDMO for Biopharmaceuticals

Contract Development and Manufacturing Partner

- Full-service with quality excellence
 - Experts in mammalian cell culture
 - Development of cell lines, processes, analytics and formulations
 - Manufacturing with single-use and stainless steel technology
 - Global regulatory support
-
- We remain flexible in every way
 - We are listening to our clients
 - We find solutions where others don't even look
 - Our track record: Security for our clients, guidepost for our future

Rentschler Biotechnologie GmbH

Erwin-Rentschler-Str. 21 · 88471 Laupheim · Germany
info@rentschler.de · www.rentschler.de





Contact:
Dr. Martin Groher

Rupert-Mayer-Str. 44, Building 64.07
D-81379 München
Phone: +49 (0) 89 189 4253-30
E-Mail: info@micro-dimensions.com
Internet:micro-dimensions.com



Contact:
Dr. Erwin Soutschek

Floriansbogen 2 - 4
D-82061 Neuried
Phone: +49 (0) 89 54801-0
Fax: +49 (0) 89 54801-100
E-Mail: mikrogen@mikrogen.de
Internet:www.mikrogen.de

microDimensions GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Informatics, Microscopy, Automation, 3D-Structural Analysis, Molecular Diagnostics

microDimensions, founded in 2011 as a spin-off of the TU München, creates solutions for the analysis and visualization of microscopic image data. Biotech and Pharma companies use microDimensions' software to gain a significant speed-up of the processes within clinical studies where histology images are involved. In the field of biomarker analysis the solution of microDimensions plays an essential role for life science companies to mitigate the risk of drug development. The patent pending technology of microDimensions for hierarchical image registration can be used to correlate histology sections automatically: analysis of multiple biomarkers, volume measurements through the reconstruction of stacks of consecutive sections, automated scoring or fast stereology are potential applications.

MIKROGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Chip/Array Technology, Autoimmune Diseases, Automation, Infectious Diseases, ELISA/EIA, Clinical Diagnostics, PCR

Founded in 1989 MIKROGEN GmbH offers innovative solutions for medical laboratories. The companies scope is the development and production of clinical diagnostic test systems based on recombinant antigens, with the focus on bacterial, viral, parasitic and autoimmune diseases. MIKROGEN's core competencies covers genetic engineering and the scientific quality of research and development, which is reflected in various patent applications and publications in international journals. The key success factors of the company are consistent customer orientation, the strong product competence and highly skilled employees. MIKROGEN meets ongoing market demands by emphasising its activities on automation and standardisation in the in-vitro diagnostics, to improve processes in medical laboratories.

MLL Münchner Leukämie Labor GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Chip/Array Technology, Genomics, PCR, Hematology, Oncology

MLL Munich Leukemia Laboratory is working as a reference laboratory for the diagnosis of hematologic malignancies focussing on leukemia and lymphoma. All 132 coworkers (physicians, molecular biologists, biostatisticians, and technicians) have outstanding reputation in the field of comprehensive diagnostics. In parallel, cytomorphology, cytochemistry, immunophenotyping, cytogenetics, FISH, and molecular genetic techniques such as PCR as well as new techniques such as next-generation sequencing are performed. The seven day available work-flow is orientated to the clinical needs of patients and physicians. MLL serves as a reference laboratory for German and European leukemia studies and is a SME-member in the European Leukemia Network (ELN). Education programmes are provided for physicians and technicians.

Molecular Machines & Industries GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Molecular Diagnostics, Devices

Molecular Machines & Industries (MMI) is the leading provider of microscope based micromanipulation solutions for the life sciences, material sciences, and healthcare. We specialize in single cell handling, laser microdissection and optical tweezers for a wide range of clinical and research based applications. MMI is a high value partner for our customers providing worldwide unique competence in micromanipulation and single cell handling. Founded in 1998 by Prof. Dr. Stefan Seeger in Heidelberg, Germany, MMI moved in 2001 to Zurich, Switzerland. Since then, MMI emerged into the global market and today has established a broad instruments base all over the world.



Contact:
Prof. Dr. Dr. Torsten Haferlach

Max-Lebsche-Platz 31
D-81377 München
Phone: +49 (0) 89 990 17-0
Fax: +49 (0) 89 990 17-111
E-Mail: info@mll.com
Internet: www.mll.com



Molecular Machines & Industries

Contact:
Stefan Niehren

Breslauer Strasse 2
D-85386 Eching
Phone: +49 (0) 89 319 048 40
Fax: +49 (0) 89 319 048 59
E-Mail: info@molecular-machines.com
Internet: www.molecular-machines.com



Contact:
Dr. Oliver Sacher

Medical Valley Center, Henkestr. 91
D-91052 Erlangen
Phone: +49 (0) 9131 8156-68
Fax: +49 (0) 9131 8156-69
E-Mail: info@molecular-networks.com
Internet: www.molecular-networks.com



Contact:
Alena Haas

Karl-Weinmair-Str. 5
D-80807 München
Phone: +49 (0) 89 360 900 900
Fax: +49 (0) 89 360 900 901
E-Mail: dinfo@molekula.com
Internet: www.molekula.com

Molecular Networks GmbH

BIOTECH BIOINFORMATICS

Keywords: [Molecular Modelling](#), [Small Molecules](#)

Molecular Networks offers innovative chemoinformatics software products, consulting, development and research services to increase the quality and productivity of discoveries in chemical, pharmaceutical and biotechnology R&D. Founded in 1997, the company established international business relationships and Molecular Networks' technology is utilized in major industrial and academic discovery laboratories worldwide to design and optimize chemical products and processes. Molecular Networks' product portfolio comprises a variety of software tools, databases and decision support applications for the design and the synthesis of chemical compounds, the prediction of their chemical, physical and biological properties, their chemical reactivity and metabolic or environmental fate.

Molekula GmbH

BIOTECH DEVICES & REAGENTS

Keywords: [Antibiotics](#), [Analytical Chemistry](#), [New Materials](#), [Medicinal Chemistry](#), [Peptide/Protein](#), [Fine Chemicals/Reagents](#), [Drug Development](#)

Molekula is a leading supplier of fine chemicals and biochemicals and stands at the forefront of this constantly changing industry. Molekula is different - we specialise in hard-to-source chemicals using production laboratories across the world with a diligence and tenacity that sets us apart from any other chemical supply company. Having started in a rented facility just over ten years ago, Molekula now boasts sales locations all over Europe. We are constantly expanding, having recently developed our operations in the UK and Germany. Our catalogue, which was initially comprised of just 500 research chemicals, now holds over 8000 ex-stock products and our ability to source high-quality compounds quickly and easily means our product list is growing all the time.

MorphoSys AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: CNS, Oncology, Infectious Diseases, Antibody, Drug Development, Inflammation, Rheumatoid Arthritis

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic applications. By successfully applying HuCAL® and other proprietary technologies, MorphoSys has become a leader in the field of fully human therapeutic antibodies. With Ylanthia®, MorphoSys's next-generation antibody technology has been launched in 2011. Through its alliances with some of the world's largest pharmaceutical companies and by developing a proprietary portfolio of therapeutic compounds, MorphoSys has created a pipeline of more than 90 drug candidates, thereof over 20 in clinical studies. Three partnered programs are in phase 3 clinical studies. The proprietary development concentrates on antibodies in the area of inflammation and oncology.

MSD MERCK SHARP & DOHME GMBH

PHARMA & CHEMICAL INDUSTRY

Keywords: Cardiovascular Diseases, Diabetics, Oncology, Endocrinology, Infectious Diseases, Rheumatoid Arthritis, Hepatology

MSD SHARP & DOHME GMBH is the German subsidiary of Merck & Co., Inc., a research-driven, worldwide acting pharmaceutical company based in the US, which develops, produces and distributes medicines and vaccines in different therapeutic fields. MSD wants to contribute to medical care in order to guarantee and improve access to urgently needed medicines worldwide. Thus, MSD supports numerous poor countries with donations of pharmaceuticals. For more than 100 years MSD publishes the renowned „MSD-Manual“, a standard publication for physicians and pharmacists (www.msd.de/msdmanual/). Medical knowledge and advice for the public is published in the „MSD-Manual Handbuch Gesundheit“. MSD Germany has app. 1.200 employees. The company is situated in Haar near Munich.

morphosys
Engineering the Medicines of Tomorrow

Contact:
Anke Linnartz

Semmelweisstraße 7
D-82152 Planegg OT Steinkirchen
Phone: +49 (0) 89 89927-0
Fax: +49 (0) 89 89927-222
E-Mail: info@morphosys.com
Internet: www.morphosys.com



Contact:
Kurt Leidner

Lindenplatz 1
D-85540 Haar
Phone: +49 (0) 89 4561-0
Fax: +49 (0) 89 46010-10
E-Mail: infocenter@msd.de
Internet: www.msd.de



Contact:
Dr. Eva Wolf

Karlsplatz 8
D-80335 München
Phone: +49 (0) 89 5998 933
Fax: +49 (0) 89 5998 9353
E-Mail: info@mucresearch.de
Internet: www.drevawolf.de



Contact:
Anca Todea

Maxhüttenstraße 11
D-93055 Regensburg
Phone: +49 (0) 941 3782498
Fax: +49 (0) 941 6308648
E-Mail: info@multi-service-monitoring.de
Internet: www.multi-service-monitoring.de



Contact:
Prof. Dr. Gabriele Multhoff

Kirchenstrasse 82
D-81675 München

E-Mail: pieken@multimmune.de
Internet: www.multimmune.de

MUC Research GmbH

CRO

Keywords: Medical Writing, Clinical Trial Management and Monitoring, Data Management and Biostatistics, Logistics, Regulatory Affairs, Hepatology, Infectious Diseases

MUC Research is specialized in clinical research, i.e. the planning, conduct and analyses of clinical and diagnostic studies. MUC Research has extensive research experience in the field of infectious diseases such as HIV/AIDS or hepatitis B and C as well as in various other therapeutic areas. The services of MUC Research include the statistical planning of interventional and observational cohort studies, the establishment of electronic study platforms involving medical data bases and electronic case report forms (eCRFs), data management, clinical monitoring, statistical analyses and medical writing.

multi service monitoring

CRO

Keywords: Oncology, Clinical Trial Management and Monitoring, Autoimmune Diseases, Devices, Regulatory Affairs, Drug Development,

multi-service-monitoring (in the BioPark, founded in 2003, 5 employees) is a clinical research organisation (CRO) that is specialised in monitoring of non-commercial clinical trials and medical clinical trials with devices. All tasks are carried out in accordance with the appropriate national regulations and the international guidelines ICH/GCP and "DIN ISO 14155".

multimmune GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Antibody, Cell Therapy, Vaccines, Oncology

multimmune is a biopharmaceutical company dedicated to the discovery and development of new products for the treatment of cancer. The company focuses on the development of drug candidates to treat heat shock protein 70 (Hsp70) positive tumors, as surface-bound Hsp70 is a tumor-specific marker expressed on about 50-75% of various cancer entities, e.g. lung, breast, colon, pancreas. Currently, four approaches are being explored to destroy cancer cells: (1) by extracorporeal activation of Natural Killer (NK) cells with a synthetic peptide (ready to go into phase II), (2) by using an antibody against Hsp70 (preclinical), (3) by inducing tumor specific apoptosis with a recombinant human serine protease(preclinical), (4) by direct infusion of an Hsp70 peptide (preclinical).

MWM Biomodels GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Pharmacokinetics, Transgenic Animals, Cardiovascular Diseases, Diabetics, Respiratory Diseases

MWM Biomodels GmbH is a spin-off company of the LMU Munich and Minitube, specialized in the development and characterization of transgenic large animal models for biomedical research. Current projects are focused on genetically modified pigs for xenotransplantation as well as transgenic pig models of diabetes mellitus, muscular dystrophy and immunodeficiency. MWM Biomodels offers support starting from the design of a project, the development of expression and targeting vectors, the generation of genetically modified large animals, their phenotypic characterization and the performance of preclinical studies.

Myriad GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Molecular Diagnostics, Biomarker Discovery & Development, Genomics, Personalized Medicine, Oncology

Myriad is a leading molecular diagnostic company based in Salt Lake City, Utah. Myriad's key focus is to personalize cancer therapy by the discovery and commercialization of targeted tests to assess a person's risk of developing disease, guiding treatment decisions and assessing risk of disease progression and recurrence. Originally founded in 1991, Myriad has spent more than twenty years to help patients and care givers to better understand the role genes play in hereditary cancers, such as breast, colon, endometrial, ovarian, pancreatic, and skin cancers. Since 2011/2012 Myriad is building onto its strong tradition and extending the geographic footprint in Europe. The central European laboratory of Myriad GmbH has opened in Martinsried/Munich in March 2012. The Company provides caregivers access to the technology of its BRACAnalysis[®] test for genetic predisposition to hereditary breast and ovarian cancer, Prolaris[®] - a test to assess prostate cancer aggressiveness to predict disease outcome, Colaris[®] - a test for genetic predisposition to colon and endometrial cancer, and Colaris AP[®] - a test for genetic predisposition to polyposis colon cancer. In addition to the laboratory in Munich, Myriad operates its European headquarters in Zurich, Switzerland and regional offices in Paris, France, Madrid, Spain, and Milan, Italy.



Contact:
Dr. Christian Simmet

Hauptstr. 41
D-84184 Tiefenbach
Phone: +49 (0) 8709 9229-0
Fax: +49 (0) 8709 9229-39
E-Mail: csimmet@minitube.de
Internet: www.mwm-biomodels.com



Contact:
Dr. Heinz-Jörg Oehl

Bunsenstr.7
D-82152 Martinsried
Phone: +49 (0) 89 414 1424-00
Fax: +49 (0) 89 8757 8170
E-Mail: info@myriadgenetics.de
Internet: www.myriad.com



Contact:
Dr. Niels Fertig

Gabrielenstr. 9
D-80636 München
Phone: +49 (0) 89 2189 979-72
Fax: +49 (0) 89 2189 979-60
E-Mail: info@nanion.de
Internet: www.nanion.de



Contact:
Dr. Michael Steiner

Würmstraße 4
D-82319 Starnberg
Phone: +49 (0) 8151 959022-0
Fax: +49 (0) 8151 959022-9
E-Mail: info@nanosaar.com
Internet: www.nanosaar.com

Nanion Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: [Devices](#), [Nanobiotechnology](#)

Nanion Technologies is a spin-off from the Center for Nanoscience (CeNS) of the Ludwig-Maximilians-University of Munich (LMU). Nanion combines bio- and microtechnology in a company serving the life sciences industry by offering products and services which will dramatically increase the speed and efficiency of the drug discovery process in an important segment of the pharmaceutical market. Nanion bases its business on a proprietary chip technology and will design and develop High Throughput Screening (HTS) systems for ion channel active drugs (ICADs). Ion channels are prime targets for innovative medicines aimed at many important diseases.

nanoSaar AG

NANOTECHNOLOGY

Keywords: [Nanobiotechnology](#)

nanoSaar AG, based in Starnberg, is the exclusive license owner of the patented MJR nanotechnology. Our business approach is to commercialize our proprietary economic MJR production capabilities in the following industries: pharma OTC, food & beverage, cosmetics, consumer products, medical, fragrance, (petro)chemical additives, biocides, catalyzers, paints/coatings, construction, batteries and electronics. The MJR technology can produce nano/micro-particles, emulsions and encapsulations with a highly defined size. Our MJR technology creates superior results compared to spray drying, milling, high pressure homogenization and other technologies. The continuous low cost production setup allows for an unlimited industrial scale-up. We offer product development services and buildup of MJR production capacity at the customer site. We also offer in-house production services with our proprietary products and common new business development for nano applications in licensing and joint venture models. The nanoSaar team has a long term experience and a worldwide contact network. Additional keywords: MJR nanotechnology, nanoparticle, nanoemulsion, nanoencapsulation

NanoScape AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, New Materials

NanoScape is a developer and producer of porous nanoscale materials, functional surfaces, and technological solutions for downstream-processing. It offers different separation and extraction techniques based on liquid membranes or microemulsions, which increase the quantity or quality of a range of products using only a single purification step. The NanoZeolite materials are cage-like structures with very high loading capacity and good thermal and mechanical resistance which, through modification of the particle size or pore diameter, and functionalisation of the surface chemistry, can be adapted to meet the requirements of the individual customer. Using such materials intelligent separation techniques can be realized, as well as bind-and-elute-applications and drug-delivery systems for functional molecules. These can be encapsulated and stabilised within NanoScapes nCAP material, allowing release profiles to be tailored to provide constant dosage levels over a tunable time period.

NanoTemper Technologies GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Bioanalytics, Devices

NanoTemper Technologies is a high-tech company providing solutions for biomolecular analytics. The company develops, produces and markets innovative technologies and instrumentation used by thousands of scientists across four continents. NanoTemper Technologies stands for strong commitment to quality and high precision instrumentation made in Germany. The deeply experienced and globally operating team of experts strongly focuses on the users benefits by ensuring maximum efficiency for research in Pharmaceutical or Biotech industries as well as in an academic basic research setting. With headquarters in Munich, Germany, and subsidiaries in the UK, Poland, US, Brazil and India, the company is rapidly expanding worldwide.



Contact:
Dr. Andreas Kohl

Rupert Mayer Str. 44
D-81379 München
Phone: +49 (0) 89 4613 3443-10
Fax: +49 (0) 89 4613 3443-30
E-Mail: info@nanoscape.de
Internet: www.nanoscape.de



Contact:
Dr. Philipp Baaske

Flößergasse 4
D-81369 München
Phone: +49 (0) 89 4522 895-0
Fax: +49 (0) 89 4522 895-60
E-Mail: info@nanotemper.de
Internet: www.nanotemper.de



Contact:

Dr. Rainer Paffenholz

Neumarkter Straße 18

D-81673 München

Phone: +49 (0) 89 3585-4000

Fax: +49 (0) 89 3585-4010

E-Mail: munich@ndareg.com

Internet: www.ndareg.com



Contact:

Dr. Stefan Schiefer

Bunsenstr. 5

D-82152 Martinsried

Phone: +49 (0) 89 787939-78

Fax: +49 (0) 89 787939-79

E-Mail: info@neaspec.com

Internet: www.neaspec.com

NDA Regulatory Service GmbH

CRO

Keywords: Regulatory Affairs, Pharmacovigilance, Drug Development

NDA Group is one of the leading Regulatory Affairs consultancies in Europe. With ~100 employees and offices in Sweden, UK and Germany, NDA has successfully provided Regulatory Support throughout Europe for over 15 years. NDA Regulatory Service GmbH in Munich was founded by a core group of regulatory experts from the European headquarter of an international pharmaceutical company. Our consultants are experienced professionals who offer expert knowledge and understanding of European regulations, guidelines and procedures. They are proficient in all regulatory activities associated with small molecules, biologicals and advanced therapies. We are dedicated to guide our clients smoothly through product development and registration in Europe.

Neaspec GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Analytical Chemistry, Microscopy, Nanobiotechnology, Molecular Diagnostics

Trusted to deliver cutting-edge solutions for nanoscale optical imaging & spectroscopy for research laboratories in industry and academic institutions is central to Neaspecs philosophy. Neaspec developed the neaSNOM microscope that combines the best of two worlds the nanoscale resolution of atomic force microscopy (AFM) with the analytical power of FT-IR infrared imaging & spectroscopy. neaSNOM thus allow to study chemical, structural and electronic properties of a sample at a spatial resolution up to 1000-times higher when compared to conventional technology like micro FT-IR. The non-destructive measurement method is equally suited for organic and inorganic samples and requires only standard AFM sample preparation.

NEOVII Biotech

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Gene Therapy, Cell Therapy, Antibody, Immune Therapy, Hematology, Drug Development

Neovii Biotech GmbH (formerly Fresenius Biotech GmbH) is a globally operating company dedicated to deliver targeted biopharmaceutical treatment options in transplantation medicine and hematological oncology. The focus of the activities is the development and commercialization of immunologically active biopharmaceutical therapeutics based on innovative antibody technologies. Clinical and development activities as well as manufacturing are located in Germany with an additional development unit in the USA. Neovii Biotech is manufacturing and commercializing the medicinal product 1. Grafalon® and holds the EU marketing authorization for the trifunctional antibody Removab® (INN: Catumaxomab). Neovii Biotech GmbH is a company of the Neopharm Group.

NeuroProfile GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

NeuroProfile is committed to the discovery and development of novel therapeutics for the treatment of Central Nervous System (CNS) diseases. The main objective is the identification and commercialization of novel neuronal drug targets (disease-related genes or proteins) for the most important neurodegenerative diseases Alzheimer and Parkinson and for psychiatric disorders such as schizophrenia and depression. Our targets will be the basics for forthcoming drug generations with new mechanisms of action that not only ameliorate the disease symptoms, but potentially prevent or block progression of the disease. Several patent pending target candidates are run in preclinical validation projects.

New Diagnostics GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Toxicology, Bioanalytics, R&D Service, Endocrinology, In-Vitro-Diagnostics

The new_diagnostics GmbH is a biotechnology company based in Freising with a subsidiary in Dresden. We are your partner for biosensor technology and effect-directed analysis in the areas of environment, food and beverages as well as medical diagnostics. With our validated yeast-based bioassays (A-YES®, A-YAS® and A-YPS), we focus on effect-related analyses of hormonally active substances in water samples and extracts. Our A-YES® is currently participating in the standardization process within the framework of the ISO working group ISO 19040-2 Water quality Determination of the estrogenic potential of water and waste water. Besides onsite trainings on how to use our assays, we also offer order analyses. With our bioanalytical expertise we offer customized solutions for your needs.

neovii

Contact:

Am Haag 6+7
D-82166 Gräfelfing
Phone: +49 (0) 89 898888-0
Fax: +49 (0) 89 898888-619
E-Mail: info@neovii.com
Internet: www.neovii.com



Contact:

Dr. Thomas Rohrmeier

Keilsteiner Breiten 6
D-93055 Regensburg
Phone: +49 (0) 941 785 369-0
Fax: +49 (0) 941 785 369-9
E-Mail: info@neuroprofile.com
Internet: www.neuroprofile.com



bioanalytical solutions for food, the environment & medical applications

Contact:

Moosstr. 92 c
D-85356 Freising
Phone: +49 (0) 8161 8870979
Fax: +49 (0) 8161 8878332
E-Mail: mena.eidens@new-diagnostics.com
Internet: www.new-diagnostics.com

NIGU

AlzChem Group

Contact:

Dr. Frank Fleischer

Beuthener Str. 2

D-84478 Waldkraiburg

Phone: +49 (0) 8621 86-3633

Fax: +49 (0) 8621 86-3598

E-Mail: frank.fleischer@alzchem.com

Internet: www.nigu.de



Contact:

Dr. Christian Fritsch

Roonstr. 25

D-90429 Nürnberg

Phone: +49 (0) 911 273-0

Fax: +49 (0) 911 273-12653

E-Mail:

novartis.kommunikation@novartis.com

Internet: www.novartis.de



Contact:

Am BioPark 9

D-93053 Regensburg

Phone: +49 (0) 941 698 091-00

Fax: +49 (0) 941 698 091-01

E-Mail: info@numares.com

Internet: www.numares.com

NIGU Chemie GmbH

PHARMA & CHEMICAL INDUSTRY

Nigu offers a full range of high-purity guanidine salts for biotechnological applications, which meet the supreme quality standards set by the biopharmaceutical industry. The product group includes several grades of guanidine hydrochloride for separation and purification of recombinant proteins and antibodies. Guanidine thiocyanate for nucleic acid based diagnostics is another integral part of the portfolio. A typical example is to provide guanidine-salts and recycling of used solutions as a complete package to the biopharmaceutical industry.

Novartis Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 136,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit <http://www.novartis.com>.

numares AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Metabolomics, Biomarker Discovery & Development, Drug Development, Clinical Diagnostics, Nephrology, Metabolic Diseases

numares HEALTH develops and markets integrated test systems for human diagnostics. These create a detailed image of the human metabolism from bodily fluids on the basis of nuclear magnetic resonance (NMR). Diagnostic tests interpret the individual metabolic images of the patient with the help of innovative software solutions and provide valuable information about the formation, extent and severity of diseases. The ability to perform different tests on the same platform in fully automated and high throughput operations shows the efficiency and cost-effectiveness of numares systems.

Nuvisan GmbH

CRO

Keywords: Oncology, Small Molecules, Peptide/Protein, Pharmacokinetics, PCR, ELISA/EIA

Nuvisan Pharma Services is a global provider of product development and support services to the pharmaceutical, biotechnology and medical device industries. We deliver services ranging from a single test to fully integrated drug development programs. Together with Focus we are pleased to offer our sponsors the complete spectrum of drug development services and assist the sponsor in bringing safe and effective pharmaceutical products to market.

Omegamatrix GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Prof. W.S. Harris, Sanford University - USA, and Prof. C. von Schacky, University of Munich, invented and defined the HS-Omega-3 Index in 2004. Then, in 2006 Schacky founded Omegamatrix GmbH, as a Laboratory, to deal with the ever growing number of research projects, applications and samples. Initially proposed as a risk factor for sudden cardiac death, it now indicates cardiovascular risk as well. First studies have shown its association to life expectancy in general. Other applications, still in development, range from psychiatric diseases to pregnancy and lactation.

OmicScouts GmbH

BIOTECH BIOINFORMATICS

Keywords: Proteomics, Bioinformatics, Drug Development, Biomarker Discovery, Oncology, Inflammation, Infectious Diseases

OmicScouts is a proteomics company providing innovative proteomics and integrated bioinformatics solutions for key issues in drug and biomarker discovery. Founded in 2014 as spin-off of the TU München, the company supports drug discovery, disease and systems biology and (pre-)clinical research with a broad portfolio of advanced mass-spectrometry-based technologies. OmicScouts' chemical proteomics technologies alongside the licensed Cellular Thermal Shift Assay (CETSA™) technology reveal cellular drug targets and selectivity profiles in an unbiased and comprehensive manner. Other technologies enable the proteome-wide profiling of posttranslational modifications and protein expression for drug mode-of-action analyses or biomarker discovery studies. OmicScouts maintains several collaborations with pharmaceutical, biotechnology, diagnostics and IT companies.



Contact:

Wegenerstr. 13
D-89231 Neu-Ulm
Phone: +49 (0) 731 9840-0
Fax: +49 (0) 731 9840-280
E-Mail: bdinfo@nuvisan.com
Internet: www.nuvisan.com



Omegamatrix GmbH

Contact:

Adrian Passow

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 5506 300-7
Fax: +49 (0) 89 5506 300-8
E-Mail: info@omegamatrix.eu
Internet: www.omegamatrix.eu

Contact:

Dr. Hannes Hahne

St.-Valentin-Straße 5
D-85356 Freising
Phone: +49 (0) 8161-71 42 65
E-Mail: info@omicscouts.com
Internet: www.omicscouts.com



Contact:
Claudia Stibi

Zugspitzstr. 5
D-85757 München-Karlsfeld
Phone: +49 (0) 151 2062 1612
Fax: +49 (0) 89 380122159
E-Mail: request4more@oncolead.com
Internet: www.oncolead.com

origenis

Contact:
Michael Almstetter

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 7801676-0
Fax: +49 (0) 89 7801676-777
E-Mail: info@origenis.de
Internet: www.origenis.de

OncoLead GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Oncology

Oncolead, is a privately owned service provider company. We offer a unique cellular screening of anticancer agents in a panel of 80-200 cancer cell lines. Routine operation and highly standardized processes guarantee our customers the results within 2-4 weeks with outstanding reproducibility for cellular screening. Customers will further benefit from a comprehensive data analysis including correlation of activity profile with mutation status and with activity profile of thousands of known anticancer agents. We provide complementary tests using a complete 80+ cell line panel: an in vitro combination of more than 500 combination pairs, development of drug tolerance or test of different drug schedules using a longer (3-4 weeks) drug treatment. All these data are requested in translational research and clinical development and help our customers to increase confidence in making drug development decisions.

origenis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Combinatorial Chemistry, Medicinal Chemistry, Automation, Combinatorics, Molecular Modelling, Small Molecules

Origenis is a leader in small molecule drug discovery with over 14 years of experience in the field. Origenis is a privately owned company based in Martinsried, Germany. Origenis runs its own patented Drug Discovery platform MOREsystem[®]. The unique platform combines state-of-the-art drug design, patent analysis, chemical synthesis and biological characterization performed in an integrated manner on 20.000 square feet of integrated lab space. Origenis runs research alliances as well as active in-house programs. Origenis is currently focusing on anti-inflammatory and CNS drugs. Origenis is offering a variety of out-licensing opportunities. Origenis offers access to its proprietary patent database Cippix[®] - www.cippix.com.

Oryx GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

ORYX is a privately held Munich based biotech company. The company develops three highly innovative drug candidates for the treatment of a whole range of cancers, originating from leading research institutions like the German Cancer Research Center (DKFZ) and the University of Heidelberg. The ORYX clinical development portfolio consists of an oncolytic virus and two therapeutic cancer vaccines. In 2015, these candidates successfully completed clinical Phase I/IIa trials. Currently, the oncolytic virus ParvOryx is being further developed in a Phase I/IIa pilot study in patients with metastatic pancreatic cancer and VicOryx, one of the therapeutic vaccines, is being tested in an additional clinical Phase I trial in combination with standard cisplatin-based chemotherapy. ORYX holds exclusive, world-wide patents and utilization licenses for all its development projects.



Contact:

Marktplatz 1

D-85598 Baldham

Phone: +49 (0) 8106 21 311-0

Fax: +49 (0) 8106 21 311-66

E-Mail: info@oryx-medicine.com

Internet: www.oryx-medicine.com

Weitnauer

Rechtsanwälte

München
Berlin
Hamburg
Düsseldorf
Mannheim

Rechtssicher entwickeln, herstellen, verwerten

Das Weitnauer Life Science Team bietet branchenspezifische Vertragsgestaltung für Unternehmen der Biotechnologie und Pharmaindustrie

- CTAs, MSAs, CRO-, CMO- und andere Verträge
- Kooperationen, Lizenzdeals, M&A-Transaktionen
- Individuelle Beratungspakete für start-ups
- Übernahme ausgelagerter Aufgaben der Rechtsabteilung
- Ein Netzwerk hochqualifizierter Branchenexperten

weitnauer.net



Veranstalter des LawLab –
Recht für Biotech im IZB





Otsuka Novel Products GmbH

Contact:

Erika-Mann-Str. 21
D-80636 München
Phone: +49 (0) 89 2060205 30
Fax: +49 (0) 89 2060 205-55
Internet: <http://otsuka-onpg.com>



Contact:

Am BioPark 13
D-93053 Regensburg
Phone: +44 (0) 1865 58 2004
Fax: +44 (0) 1865 41 2355
E-Mail: contact@oxbiolabs.com
Internet: www.oxbiolabs.com



Contact:

Dachauer Str. 44a
D-80335 München
Phone: +49 (0) 89 551553-50
Fax: +49 (0) 89 551553-51
E-Mail: info@paediacro.de
Internet: www.paediacro.eu

Otsuka Novel Products GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Clinical Diagnostics, Antibiotics, Infectious Diseases

Otsuka Novel Products GmbH (ONPG) was founded in 2011 in Munich, as an Otsuka group company. With an international network of 145 subsidiaries and 39,000 employees in 23 countries, and regions across Europe, Asia-pacific, America and the Middle East, Otsuka researches, develops, manufactures and markets innovative and original products with a focus on pharmaceutical products for the treatment of diseases. ONPG will initially focus on infectious diseases, working in collaboration with other group companies to develop improved diagnostic tools and novel products for the treatment of tuberculosis.

Oxford BioLabs Ltd.

BIOTECH DEVICES & REAGENTS

Oxford BioLabs Ltd. is a science-based company tackling Androgenetic Alopecia (AGA). A small group is located in Regensburg, BioPark. Our goal is to create a new standard of care for the treatment of AGA. Oxford BioLabs is developing novel therapies for the treatment of androgenetic alopecia (AGA), which is commonly known as male and female pattern baldness. Available therapies include drugs or hair transplant surgery, which treat acute symptoms but lead to side effects, hospitalization and unsatisfactory patient outcome. Currently there is no cure against AGA and new treatment options are urgently needed

PaediaCRO GmbH

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Medical Writing

PaediaCRO – your specialised CRO for your product development in paediatric use. Founded in 2007 by Prof. Dr. med., Dr. rer. nat., Dr. h. c. mult. Dieter Adam, Dr. rer. nat. Josef Hofer and Dipl.-Math. Jürgen Wyen, PaediaCRO will support you in the development of solutions for your products in paediatric use. A smile of a healthy child is our vision. To achieve this, PaediaCRO develops with its partners medicinal products to save children's life and improve their quality.

PAN Biotech GmbH

BIOTECH DEVICES & REAGENTS

PAN-Biotech GmbH is a modern and innovative company with its headquarters in Aidenbach/Germany. PAN-Biotech was founded in 1988 and is today a major producer of biotechnological products which are worldwide distributed and used in research and industry. The product range includes new serum- and proteinfree media, sera (FCS) from different countries of origin including important special variants and a broad variety of media for cell culture. Important new product areas are our automated cell culture systems for research and industry as well as new services all around the cell culture and cell processing. As a specialist for cell culture we can offer you nearly the complete range of products and services that you need for your successful cell culture. additional competencies: quality control of biotechnological products, practical solutions for cell culture, nutrients for cells.

Panacea Biotec GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Panacea Biotec is the third largest biotechnology company (as per ABLE Survey, 2011), as well as among the top 50 pharmaceutical companies (as per ORG IMS March 2010) of India. Panacea Biotec Germany GmbH is located in Munich and delivers and markets products in transplantation, immun-suppression and anti-infection.

PARI Pharma GmbH

MEDTECH

Keywords: Drug Development, Drug Delivery, Analytical Chemistry, Liposomes, Antibiotics, Infectious Diseases, Respiratory Diseases

PARI Pharma focuses on the development of aerosol delivery devices and comprehensive inhalation drug development to advance aerosol therapies where drug and device can be optimized together. Based on PARI's 100-year history working with aerosols, PARI Pharma develops treatments for pulmonary and nasal administration customized with advanced delivery platforms, such as eFlow (lower respiratory) and Vibrent (upper respiratory) Technologies. PARI Pharma partners with pharmaceutical companies to develop new or improved therapies. PARI Pharma has several clinical development programs ongoing, either partnered or on its own, for cystic fibrosis, asthma, COPD, respiratory syncytial virus (RSV) infection, and treatments for lung transplant patients among other indications. PARI Pharma, a PARI Medical Holding company, is located near Munich, Germany with a major presence in the United States.



Contact:
Jens Hartmann

Gewerbepark 13
D-94501 Aidenbach
Phone: +49 (0) 8543 6016-30
Fax: +49 (0) 8543 6016-49
E-Mail: info@pan-biotech.de
Internet: www.pan-biotech.de



Contact:
Gerd-Peter Heberling

Landshuter Allee 8-10
D-80637 München
Phone: +49 (0) 89 5455 83-50
Fax: +49 (0) 89 5455 83-33
E-Mail: info-de@panaceabiotec.com
Internet: www.panaceabiotec.de



Contact:
Michael Hahn

Lochhamer Schlag 21
D-82166 Gräfelfing
Phone: +49 (0) 89 742846-0
Fax: +49 (0) 89 743846-30
E-Mail: m.hahn@pari.de
Internet: www.paripharma.com



Contact:

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 51728659-0
Fax: +49 (0) 89 51728659-88
E-Mail: info@pelobiotech.com
Internet: www.pelobiotech.com



Contact:

Dr. Peter Remiger

Heinrich-Mack-Str. 35
D-89257 Illertissen
Phone: +49 (0) 7303 12-0
Fax: +49 (0) 7303 12-387
E-Mail: peter.remiger@pfizer.com
Internet: www.pfizer.com

Pelo Biotech GmbH

BIOTECH DEVICES & REAGENTS

PELOBIOTECH is competent for cells and offers the broadest portfolio of animal & human cells and media. We bring your research from bench to bedside. You get the whole variety of solutions from tissue dissociation to cryopreservation for research and clinical applications.

- Tissue Dissociation Enzymes
- Defined & Xeno-free Media
- Human & Animal Primar & Stem Cells
- Diseased Human Primary & Stem Cells
- Cancer Stem Cells
- Tagged & KO Cells
- ES/iPS Cells, Media & Tools - Reprogramming Tools & Small Molecules
- Cryo-Preservation Media w/ & w/o DMSO
- Cytokines, Growth Factors & Chemokines
- 2D/3D Cell Culture Systems
- 2D/3D Microfluidic Systems
- Cell based Assays
- TR-FRET Reagents
- Premium Grade & GMP Products
- High-Performance Microsphere Products for Sample Preparation

Pfizer Manufacturing Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, Infectious Diseases, CNS, Cardiovascular Diseases, Automation

Pfizer is a leading pharmaceutical company with headquarters in the US which develops, produces and distributes medicines and vaccines in different therapeutic fields. The product portfolio of the Pfizer Illertissen manufacturing site is specialized in solid dosage forms sold globally. We stand for a high degree of automation, system integration and innovation with an excellent supply performance. We provide innovative concepts and services in Containment Manufacturing and Wallet Packaging with a proven high quality and high service level at competitive costs. The unique expertise is proven by renowned awards achieved: Overall „Facility of the Year Award“ from „International Society for Pharmaceutical Engineering“ (ISPE) in 2008 for the fully automated containment manufacturing facility and „Healthcare Compliance Packaging Council“ (HCPC)-Columbus Award 2011“ for innovative compliance packaging solutions realized with wallet cards.

Pharma Stulln GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Ophtalmology, Respiratory Diseases

Experience in manufacturing eye drops in bottles and single-dose-units for more than 30 years. Pharma Stulln fulfills international standards in modern production of sterile preparations. Pharma Stulln has approximately fifty well established pharmaceutical customers in Germany, Europe and international countries such as Australia, China, Canada etc. Pharma Stulln is specialist in manufacturing: Eye drops, Nasal sprays, Respiratory solutions, Lens care products. In our production building in seven separate rooms high-performance bottelpack®-filling machines are placed for manufacturing individual products. A modern zone concept fulfills European and international standards for the production of sterile fluid pharmaceuticals. Advanced water treatment and ventilation technology combined with continuous monitoring ensure a continuous high level of quality production.

Pharmalog – Institut für klinische Forschung GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Pharmalog Institut für klinische Forschung GmbH acts as an European full service CRO with an excellent reputation in clinical trials phase I–IV since 1983. Our staff of 42 colleagues in our office plus further central field based monitors conducts clinical and non-interventional trials. We operate in Germany and all EU/EEU-countries, using our large pool of motivated investigators in clinics/ practices. Our local monitors are native speakers.

We work

- transparent for our clients
- accurate in planning, realization and evaluation of clinical trials
- flexible focusing the needs of our customer
- friendly to assure a long lasting and strong collaboration with our clients

We have performed more than 400 clinical trials in all medical indications for medical products/-devices/biotechnology products according to ICH-GCP and FDA-standards for more than 50 nat./internat. pharmaceutical companies.

We offer full service or modular approach (e.g. monitoring, data management/ statistics), reasonable pricing due to short contact ways and low overhead costs. Pharmalog is TÜV – certified and member of the BVMA.

pharma **STULLN**

Contact:
Dr. Karl Luschmann

Werksstraße 3
D-92551 Stulln
Phone: +49 (0) 9435 3008-0
Fax: +49 (0) 9435 3008-99
E-Mail: info@pharmastulln.de
Internet: www.pharmastulln.de



Contact:
Dipl. Stat. Holger Stammer

Neumarkter Str. 18
D-81673 München
Phone: +49 (0) 89 544637-0
Fax: +49 (0) 89 544637-50
E-Mail: pharmalog@pharmalog.com
Internet: www.pharmalog.com



Contact:

Rosenheimer Str. 43
D-83064 Raubling
Phone: +49 (0) 8035 88-0
Fax: +49 (0) 8035 88-143
E-Mail: info@pharmazell.com
Internet: www.pharmazell.com



Contact:

Dr. Peter Sonner

Ingolstädter Str. 20
D-80807 München
Phone: +49 (0) 89 375 0899-0
Fax: +49 (0) 89 375 0899-20
E-Mail: GermanOffice@pharm-olam.com
Internet: www.pharm-olam.com



Contact:

Dr. Thomas W. Becker

Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 444 899-41
Fax: +49 (0) 89 444 899-43
E-Mail: info@phatocon.com
Internet: www.phatocon.com

PharmaZell GmbH

PHARMA & CHEMICAL INDUSTRY; CMO

The in-house development and production of various multi-customer active pharmaceutical ingredients is one pillar of PharmaZell API business model. A product list of currently offered generic APIs is available and information about new products under development and/or evaluation can be provided upon request. The development and production of different single-customer (exclusive) active pharmaceutical ingredients is the other pillar of our API business model. PharmaZell draws upon a long history of successful custom synthesis projects, performed on a proprietary basis for innovation driven pharmaceutical companies worldwide. The company is also diversified into finished dosage form development. Formulation and analytical development labs as well as pilot/pivotal facilities are available at its Indian site in Vizag. The site develops entire dossiers and modular services to customers.

Pharm-Olam International Deutschland GmbH

CRO

Pharm-Olam International is a global, full service, Phase I-IV CRO with offices across Europe, North America, Latin America, South Africa, and India. In Germany, we have conducted trials since 1999 and have a local office in Munich along with regional staff. Our staff are highly experienced and can provide a range of services including Marketing Surveillance (AMG § 67.6) - from protocol writing to delivery of final report, auditing, monitoring and regulatory. Our Munich office also supports neighboring Austria and Switzerland. Let us evaluate your protocol at several of the largest centers in Germany and worldwide to determine projected enrollment by contacting german.office@pharm-olam.com

PhaToCon (Pharm/Tox Concept)

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Pharmacology, Antibody, Tissue Engineering/Cell Culture, Drug Delivery, Drug Development, Regulatory Affairs

You think about Quality-Management (QM) to improve efficiency, data reliability and comparability? However, you work at full capacity and additional resources are not available? We offer individually tailored QM-Concepts in Research and Development as well as preclinical Study-Management with regard to regulatory requirements in Pharmacology / Toxicology (in vitro / in vivo). Our support is customized based on international standards like GLP/GMP, ISO, We operate from a scientific point of view and with our "hands-on" mentality we have strong execution skills. With our network of competence and capabilities we guide your project to success. Benefit from our know-how and our network of experienced partners: selected experts, toxicologists and more than 40 accredited testing laboratories.

Phytochem Referenzsubstanzen GbRmbH

BIOTECH DNA/PROTEIN ANALYTICS

Phytochem develops, produces and markets high purified substances for the pharmaceutical industry, research, analytics and authorities (main focus over 3,000 Natural Compounds). Phytochem synthesizes or isolates also Degradation products and Impurities in remedies or other rare drugs especially for customers needs with best equipment and experience. Lot specific testing is guaranteed. Phytochem products were used as Reference Standards for research and development: (Identity standard Data File: IDF) also for quality control as Primary Standards (Reference Substance Masterfile: RMF) and full documented Method Validation. Additional products and consulting services in the fields of Funcional Foods, Dietary Supplements, Food Additionals and Cosmetics are new focuses from Phytochem.

Pieris Pharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Drug Development

Pieris Pharmaceuticals, Inc. is an international Nasdaq-listed (PIRS) clinical-stage biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that are safer and more effective than conventional approaches. Exclusive to Pieris, Anticalins promise to address high-unmet medical needs and expand the potential of targeted therapeutics.

PIKA Weihenstephan GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, New Materials, Analytical Chemistry, PCR

PIKA Weihenstephan was founded in 2000 as a spin-off from the Technical University of Munich-Weihenstephan. Our focus is the fast detection and identification of microorganisms which may occur as spoilers during the production process of beer and beverages, but also in a diversity of other applications. Besides offering analyses for customers, PIKA Weihenstephan is producing and selling enrichment media and kits to be used for fast and specific process control. We are specialists in microbiology, both in conventional and in DNA analyses, especially PCR based methods. All processes at PIKA Weihenstephan are certified according to DIN EN ISO 9001:2008.



Contact:
Hans Rausch

Krumbacherstr. 9
D-89335 Ichenhausen
Phone: +49 (0) 731 97205-45
Fax: +49 (0) 731 97205-46
E-Mail: phytochem@t-online.de
Internet: www.phytochem-standards.de



Contact:

Lise-Meitner-Str. 30
D-85354 Freising-Weihenstephan
Phone: +49 (0) 8161 1411 400
Fax: +49 (0) 8161 1411 444
E-Mail: info@pieris.com
Internet: www.pieris.com



Contact:
Dr. Gudrun Vogeser

Raiffeisenstr. 31a
D-85276 Pfaffenhofen
Phone: +49 (0) 8441 87948-30
Fax: +49 (0) 8441 87948-31
E-Mail: info@pika-weihenstephan.de
Internet: www.pika-weihenstephan.de



Contact:
Dr. Werner Deininger

Industriestraße 1
D-93077 Bad Abbach
Phone: +49 (0) 9405 96 999-10
Fax: +49 (0) 9405 96 999-28
E-Mail: info@polyquant.com
Internet: www.polyquant.com



Contact:
Dr. Thorsten Klein

Max-Planck-Str. 14
D-86899 Landsberg a. L.
Phone: +49 (0) 8191 985 688-0
Fax: +49 (0) 8191 985 688-99
E-Mail: info@postnova.com
Internet: www.postnova.com



Contact:
Dr. Peter Oberosler

Hansastr. 32
D-80686 München
Phone: +49 (0) 89 57877-0
Fax: +49 (0) 89 57877-400
E-Mail: genl.info@ppdi.com
Internet: www.ppdi.com

PolyQuant GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Proteomics, In-Vitro-Diagnostics, Laboratory, Biomarker Discovery & Development, Peptide/Protein, Clinical Diagnostics

PolyQuant is a service provider commercializing the technology of multiplex protein quantification via QconCAT. Technology: QconCAT allows absolute quantification of multiple (5-100) proteins simultaneously. The method is based on gene synthesis and mass spectrometry; it is a highly sensitive and cost-efficient assay applicable to samples of any nature. Applications: Protein biomarker research and validation; compound screening and toxicology evaluation; elucidation of the stoichiometry of protein complexes; quality control of expressed proteins; research and analysis of biological pathways. Products and services: Full service protein quantification based on particular project requirements as well as individual QconCATs and calibration standards for MS and HPLC standardization.

Postnova Analytics GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices

Postnova Analytics is manufacturer of Field Flow Fractionation (FFF) for nanoparticle, protein and bio/polymer separation, fractionation and characterization. Postnova offers a complete FFF product range for applications in Biopharmaceutical, Nanotechnology, Environmental, Food, Cosmetics and Polymers. Field-Flow Fractionation coupled to Multi-Angle Light scattering (MALS), Dynamic Light Scattering (DLS) and ICP-MS detection offers access to high resolution size and molar mass separation, characterization and element speciation. Products are CentrifugalFFF for Nanoparticles, FlowFFF for Biopharmaceuticals and ThermalFFF for Polymers.

PPD Germany GmbH & Co. KG

CRO

Keywords: Medical Writing, Logistics, Devices, Drug Development

PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.

PreciPoint GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Automation, Devices

PreciPoint, located in Freising, is a manufacturer of digital microscopes and complex lab automation devices. PreciPoints core competency is combining optics, mechanics, electronics, firmware and software to modern micro imaging applications. Currently, the company is focused on Whole Slide Imaging, Digital Pathology and Virtual Microscopy. Our well-rounded engineering staff develops practical, economical and precisely manufacturable solutions for a wide array of complex problems.

PreSens Precision Sensing GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Drug Development, Tissue Engineering/Cell Culture, Analytical Chemistry

PreSens is a world leader in the field of chemical-optical sensors. It develops, manufactures and distributes sensor systems for Biotech & Pharma, Food & Beverage, Scientific Applications and Medical Devices. PreSens offers out-of-box products and engineering of customized sensors, focusing on parameters which are essential for life: oxygen, pH, carbon dioxide and biomass - and other parameters on request. Over the last 17 years, we have delivered our special microsensors and our non-invasive systems for various applications such as respirometry, biology, or medical research. We also offer imaging solutions: 2D-sensing of oxygen-, pH- and CO₂-distributions. PreSens is certified EN ISO 13485:2003 + AC:2007 and ISO 9001:2008. Together with its partners it offers service all over the world.

Prevtec microbia GmbH

PHARMA ANIMAL HEALTH

Prevtec microbia is an agri-food biotechnology company specialized in developing technologies and marketing products for improving the health of food animals in order to increase production performance and food safety. Prevtec microbia's mission is to be a world leader in the development and commercialization of products providing an alternative to antibiotics for the prevention of bacterial infections and the improvement of food animal performance. The company has offices in Montreal and Saint-Hyacinthe, Quebec (Canada). Its German based subsidiary is run in conjunction with Klifovet AG.



Contact:

Alois-Steinecker-Str. 22
D-85354 Freising
Phone: +49 (0) 8161 976979-0
E-Mail: vertrieb@precipoint.de
Internet: www.precipoint.de



Contact:

Am BioPark 11
D-93053 Regensburg
Phone: +49 (0) 941 94272-100
Fax: +49 (0) 941 94272-111
E-Mail: info@presens.de
Internet: www.presens.de



Contact:

Geyerspergerstr. 27
80689 München
Phone: +49 (0) 89 58 00 82-0
Fax: +49 (0) 89 58 00 82-7777
E-Mail: info@cinfabiotech.com
Internet: www.prevtecmicrobia.com/en/



Contact:

Am Klopferspitz 19
D-82152 Planegg/Martinsried
Phone: +49 (0) 89 23 14 163-0
Fax: +49 (0) 89 23 14 163-99
E-Mail: info@preomics.com
Internet: www.preomics.com



Contact:

Dr. Andreas Schütz

Fraunhoferstr. 22
D-82152 Martinsried
Phone: +49 (0) 89 452289-700
Fax: +49 (0) 89 452289-717
E-Mail: info@project-pharmaceutics.com
Internet: www.project-pharmaceutics.com



Contact:

Dr. Torsten Neufeind

Bunsenstr. 7a
D-82152 Martinsried
Phone: +49 (0) 89 700761-0
Fax: +49 (0) 89 700761-15
E-Mail: business@proteros.com
Internet: www.proteros.com

PreOmics GmbH

BIOTECH DEVICES & REAGENTS

The PreOmics GmbH develops and commercializes tools for mass spectrometry-based proteomics. The main focus are easy and optimized sample preparation methods enabling fast, efficient and sensitive measurements at high throughput. PreOmics further develops instruments for automated fractionation and enrichment to achieve complete proteomics and to facilitate the analysis of signal-transduction pathways. PreOmics addresses customers in research, drug development and diagnostics.

ProJect Pharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Small Molecules, Peptide/Protein, Antibody, Liposomes, Drug Delivery, Drug Development

ProJect Pharmaceuticals, based in Martinsried/Munich, Germany, transforms proteins, peptides and cytotoxic molecules into pioneering drugs. ProJect Pharmaceuticals adds value to clients bio-pharmaceutical products by applying innovative concepts of pharmaceutical development.

We offer:

- predictive formulation analytics
- formulation development including in-depth protein analytics
- lyophilization process development and optimization
- processing of Arte's Lyo Dual Chamber Prefillable™ syringe
- development of liposomal formulations and manufacturing processes
- manufacturing of preclinical study material
- technology-transfer including scale-up to GMP-manufacturing

Proteros biostructures GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Oncology, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, Small Molecules, Fine Chemicals/Reagents, 3D-Structural Analysis

Proteros is Europe's largest and most experienced biotechnology company in the field of X-ray protein structure analysis and a leading partner for fully integrated lead discovery. Successful in business since 1998, Proteros collaborates with more than 80 international pharma, biotech and agricultural companies. Proteros services delivers protein crystallography, profiling and screening and tailor-made proteins. Lead discovery combines these unique technologies and medicinal chemistry to generate novel lead compounds for a variety of therapeutically relevant target proteins. Flexible business models, makes Proteros an ideal partner to the Pharmaceutical and Biotech Industry.

quattro research GmbH

BIOTECH BIOINFORMATICS

quattro research addresses the needs of life science and chemical industry by providing state-of-the-art solutions to manage all scientific data produced in research projects. Our applications help scientists to optimise the value of their research data, e.g. the electronic lab notebook quattro/LJ or the compound management solution quattro/CM. quattro research offers software and consulting services to build and integrate heterogeneous data sources and applications, such as compound registration, HTS, LIMS or SAP, into efficient and user friendly data management platforms.

QUINTILES GmbH

CRO

Keywords: Clinical Trial Management and Monitoring

Quintiles is the largest provider of biopharmaceutical development and commercial outsourcing services. With more than 32,000 employees working in about 100 countries, we have helped develop or commercialize all of the top-100, best-selling drugs on the market. With extensive therapeutic, scientific and analytics expertise, we help biopharmaceutical and health sciences customers navigate the increasingly complex landscape with more predictability to enable better outcomes. For more information visit the company's Website at <http://www.quintiles.com>

RAPID Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Oncology, CNS, Cardiovascular Diseases, Bone/Joint Diseases, Devices

RAPID Biomedical GmbH is specialised in RF coils for MRI and NMR spectroscopy. The company collaborates with research institutes, hospitals and MR system manufacturers worldwide. Our products include 1H MR resonators for clinical studies at all magnetic field strengths and for all organs. We also supply multi-nuclear (e.g. 1H / 31P) MR-coils for combined MRI and MRS in clinical and basic science investigations. We offer custom made MR probeheads for routine animal research and various accessory devices. Our recent work concentrates on dual tuned coils and multi array coils for parallel MRI both for human as well as for animal studies. Our sister company RAPID MR International, LLC (www.rapidmri.com), situated in Columbus, Ohio, is contact partner for customers from the United States, Canada and South America.



Contact:
Dr. Bernhard Schirm

Fraunhoferstraße 18a
D-82152 Martinsried
Phone: +49 (0) 89 990 1629-0
Fax: +49 (0) 89 990 1629-99
E-Mail: info@quattro-research.com
Internet: www.quattro-research.com



Contact:

Mühlweg 2
D-82054 Sauerlach
Phone: +49 (0) 8104 8980
Fax: +49 (0) 8104 8980-99
Internet: www.quintiles.de



Contact:
Dr. Florian Odoj

Kettelerstr. 3-11
D-97222 Rimpfing
Phone: +49 (0) 9365 8826-43
Fax: +49 (0) 9365 8826-99
E-Mail: info@rapidbiomed.de
Internet: www.rapidbiomed.de



Contact:
Dr. Albrecht Pfahler

Münchner Freiheit 18
D-80802 München
Phone: +49 (0) 89 33039921-0
Fax: +49 (0) 89 33039221-30
E-Mail: info@remark-pharma.de
Internet: www.remark-pharma.de



Contact:

Am Klopferspitz 19
D-82152 Planegg/Martinsried
E-Mail: info@rigontec.com
Internet: www.rigontec.de

REMARK GmbH Pharmaservices & Consulting

CRO

Keywords: Drug Development, Medical Writing

REMARK is a privately owned pharma services and consulting company founded in 1999. Quality and speed are the decisive factors in the success of a company involved in the healthcare market. To reach your goals our business unit Clinical Research offers the following services:

- Strategic Consulting
- Project Management
- Quality Assurance
- Pharmacovigilance Services
- Training / Coaching
- Medical Writing
- Due Diligence

Together with our unit Pharma Marketing, REMARK bridges the gap between development and marketing. For more information visit our web site at www.remark-pharma.com

Rigontec GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Immune Therapy, Drug Development

Rigontec is the leader in Retinoic Acid Inducible Gene I (RIG-I) targeting RNA therapeutics. The Company has first mover position in accessing the RIG-I innate immune pathway to pioneer a novel immuno-oncology approach that is designed to achieve immediate and long-term immune system activation specifically against cancer cells. Funded by premier healthcare-focused venture capital and led by an experienced leadership team and Board, Rigontec is focused on actively advancing its innovative pipeline. The first program RGT100 is expected to reach the clinic in early 2017 targeting cancer. The RIG-I pathway represents an essential part of the innate immune system that is usually activated to attack a viral pathogen. Rigontec uses a proprietary advanced RNA-based technology to direct this immune response against a patient's distinct cancer cells, thereby harnessing the body's immune reaction mechanism to efficiently destroy the cancer cells as well as enable long-term immunity against the cancer. In addition to malignant diseases, Rigontec's innovative RNA platform technology has also shown utility for the treatment of infectious diseases further broadening the applicability of this groundbreaking new class of drugs. Founded in 2014, the Company has raised EUR 14.25 million in a Series A financing round including experienced life science investors Wellington Partners, Boehringer Ingelheim Venture Fund, NRW.BANK, High-Tech Gründerfonds (HTGF), Forbion Capital Partners, Sunstone Capital and MP Healthcare Venture Management.

Ritter GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Pharmacogenetics, PCR, Genomics, ELISA/EIA, Automation, Devices

As a very productive brand-supplier, Ritter provides over 40 years of know-how in developing and producing fine high-precision plastic parts. Ritter produces in accordance to the local quality standards only in own production plants. The company is DIN ISO 9001:2000 certified and works according to the DIN EN ISO 13485:2003. The 200 employees are engaged to provide packaging solution for construction chemicals (cartridges), laboratory and medical products (liquid handling systems, products for dialysis and robotic systems).

Roche Diagnostics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Antibody, PCR, ELISA/EIA, Automation, Clinical Diagnostics, Drug Development

Roche Diagnostics GmbH is part of Roche, Switzerland, a leader in research focused healthcare with combined strength in pharmaceuticals and diagnostics. Roche is also the world's largest biotech company with medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience and is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. At Penzberg, Roche operates one of the largest biotechnology facilities in Europe for research, development and production of biotechnology based diagnostics and active pharmaceutical ingredients. The portfolio comprises test systems for the life science market, diagnosis, patient stratification and therapy monitoring. Pharma specializes in therapeutic human Proteins with focus on monoclonal antibodies and biomarkers for oncology.



Contact:
Diplom Wirtschaftsingenieur Michael Fuchs

Kaufbeurer Str. 55
D-86830 Schwabmünchen
Phone: +49 (0) 8232 5003-0
Fax: +49 (0) 8232 5003-70
E-Mail: info@ritter-online.de
Internet: www.ritter-medical.de



Contact:

Nonnenwald 2
D-82377 Penzberg
Phone: +49 (0) 8856 60-0
Fax: +49 (0) 8856 60-3896
E-Mail: penzberg.allgemein@roche.com
Internet: www.roche.de



Eine gesunde Entscheidung

Contact:

Ameet Mallik

Industriestr. 25

D-83607 Holzkirchen

Phone: +49 (0) 8024 476-0

Fax: +49 (0) 8024 476-2599

E-Mail: info.sandoz@sandoz.com

Internet: www.sandoz-biosimilars.com



Contact:

Am Klopferspitz 19

D-82152 Planegg/Martinsried

Phone: +49 (0) 89 21546375

E-Mail: info@secarna.com

Internet: www.secarna.com

Sandoz International GmbH

PHARMA & CHEMICAL INDUSTRY

Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees across more than 160 countries, offering a broad range of high-quality, affordable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 position globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics. In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has benefitted from strong growth of its acquisitions, which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriol Therapeutics (US), and Fougera Pharmaceuticals (US).

Secarna Pharmaceuticals GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Secarna Pharmaceuticals GmbH & Co. KG ("Secarna") is a biopharmaceutical company based in Munich, Germany. The company has developed a state-of-the-art drug discovery platform, encompassing proprietary bioinformatic systems, screening platforms, as well as advanced in vitro compound characterization assays, focusing on next generation antisense molecules. Currently, Secarna has active pre-clinical programs in a range of indications including immuno-oncology, immunology, and anti-virals. Our strategy is to leverage our drug discovery platform to develop disruptive and highly differentiated therapeutics, also with industry partners.

Securetec Detektions-Systeme AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Analytical Chemistry, Antibody, Toxicology, Small Molecules

Established in 1995, Securetec Detektions-Systeme AG provides leading edge technologies to facilitate detection of drugs, explosives, and other hazardous substances. By close cooperation with its customers Securetec understands the specific demands of traffic safety, customs, and drug enforcement authorities across the globe. Securetec's competencies cover tailor-made development and production of immunological test solutions reflecting in highly reliable products for day-to-day use. The specific technologies are successfully employed across a multitude of rapid identification applications of drugs and hazardous substances. We detect to protect - Securetec is proud to play a part in making today's world a safer one.

Sension GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA/EIA, Autoimmune Diseases, Antibody

Sension develops immunoassays and rapid test systems for on-site analysis. The tests find broad applications in the fields of food analysis, environmental analysis, medical diagnostics, reproductive management in agriculture, and in the monitoring of samples for mold. Also technologies for label production to prevent products from counterfeiting are realized. Sension is realizing own product developments, but also performs R&D developments for partners and customers and specifically focus on the specific needs required.

SequiServe GmbH

BIOTECH DNA/PROTEIN ANALYTICS

SequiServe offers the following custom services in molecular biology: DNA-sequencing (plasmids, PCR-products, BACs, PACs, primer-walking). Purification of PCR products.



Contact: Dr. Torsten Stadthagen

Lilienthalstr. 7
D-85579 Neubiberg
Phone: +49 (0) 89 2030 8016-51
Fax: +49 (0) 89 2030 8016-52
E-Mail: info@securetec.net
Internet: www.securetec.net



Biologische Detektions- und Schnelltestsysteme

Contact:
Dr. Marcus Meyr

Provinostr. 52, Gebäude B14
D-86153 Augsburg
Phone: +49 (0) 821 455799-0
Fax: +49 (0) 821 455799-22
E-Mail: info@sension.eu
Internet: www.sension.eu



Contact:
Eva Metzger

Joh.-Seb.-Bach-Str. 7
D-85591 Vaterstetten
Phone: +49 (0) 8106 8887
Fax: +49 (0) 8106 301565
E-Mail: service@sequiserve.de
Internet: www.sequiserve.de



Contact:
Arnd Prilipp

Elsenheimerstr. 53
D-80687 München
Phone: +49 (0) 89 57095-01
Fax: +49 (0) 89 57095-126
E-Mail: info@de.netgrs.com
Internet: www.servier.de

SIGMA-ALDRICH®

Contact:
Dr. Udo Sticher

Eschenstr. 5
D-82024 Taufkirchen
Phone: +49 (0) 89 6513-0
Fax: +49 (0) 89 6513-1169
E-Mail: deorders@sial.com
Internet: www.sigma-aldrich.com



Contact:
Dr. Franz Kerek

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
Fax: +49 (0) 89 856625-56
E-Mail: info@sinatur.net
Internet: www.sinatur.net

SERVIER Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Diabetics, CNS, Cardiovascular Diseases, Bone/Joint Diseases, Drug Development

Following its international success, SERVIER Deutschland GmbH has established an independent branch in Munich since 1996. SERVIER is one of the very dynamic pharmaceutical companies in Germany, experiencing a growth-rate in double figures on average. The reason for this is not only the approved and merchandised drugs but also new, innovative products. The success of the new drugs is supported by the SERVIER Forschung und Pharma-Entwicklung GmbH (also in Munich), which manages many different projects throughout the German-speaking region.

Sigma-Aldrich Chemie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Antibody, Genomics, CNS, Small Molecules, Knock Out, PCR

Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Sigma-Aldrich operates in 36 countries and has over 7,600 employees providing excellent service worldwide.

SiNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Diabetics

SiNatur owns the patent rights for the structure, preparation and medicinal applications Sub-Nano-Silicic Acid (SNSA). This recently discovered SNSA is the first biologically active form of silicic acid and of silicon generally. The substance is a potent inhibitor of P-type ATPases and of certain Protein-Phosphatases with IC50 in the nanomolar range. Due to the ubiquitous presence of Si in living organisms the discovery of the first biological active form of this element will have a broad scientific and practical impact. SiNatur is developing medicinal applications of SNSA first of all in the therapy of diabetes and of gastric hyperacidity.

SIRION BIOTECH GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Gene Transfer, Drug Development, Drug Delivery, Knock Out, RNAi & Antisense

SIRION Biotech was founded in 2006 in Munich and maintains offices in Tokyo and New Hampshire. It stands for sophisticated cell modeling and viral vector platforms. These enable much improved target identification and compound screening in the drug, the food & cosmetic industries. Its technology has over the years been validated in more than 250 commercial projects with more than 70 academic and industrial organizations worldwide. As a result, primary cell immortalizations are being technically advanced, so are the recombinant construction of adenovirus serotype vectors serving for gene therapy applications and novel vaccines. Specifically, SIRION Biotech is offering a satisfaction guarantee on gene knockdowns of nearly 100 % (RNAiONE), cell lines with built-in reporter genes (SenCELL), next generation cell models with high on-target knockdowns. VariCHECK represents an inducible expression system for the functional analysis of protein variants. Ready-to-use-kits offer up to 50 fold transduction enhancement (AdenoBOOST) or convenient and reliable vector cloning & purification within just 4 weeks (AdenoONE). Commercial arrangements range from fee-for-service over exclusive rights on single clones all the way to milestone & licensing arrangements. The latter are suited for longer term complex product developments in the areas of gene therapy and vaccines. Molecular biologists experienced in the field stand ready for project discussions in Europe, Japan and USA.

siTOOLS Biotech GmbH

BIOTECH DEVICES & REAGENTS

siTools Biotech is a young, innovative Biotech start-up dedicated to provide innovative and superior RNAi reagents to the scientific community. siTools Biotech is located at Munich's biotech cluster in Planegg/Martinsried. "siPools" are highly complex but accurately defined pools of siRNAs. They enable highly efficient and reliable target gene silencing without detectable off-target effects.



Contact:
Dr. Christian Thirion

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700961-999
Fax: +49 (0) 89 700961-998
E-Mail: info@sirion-biotech.de
Internet: www.sirion-biotech.com



Contact:
Lochhamer Straße 29 a
D-82152 Planegg
Phone: +49 (0) 89 4431 2584
E-Mail: info@sitoolsbiotech.com
Internet: www.sitoolsbiotech.com



Contact:
Dipl. Ing. Ulrich Schubert

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 854 665-13
Fax: +49 (0) 89 854 665-15
E-Mail: ulrichschubert@smartecbio.de
Internet: www.smartecbio.de

Sourcia.

Contact:

Lochhamer Strasse 31
D-82152 Martinsried
Phone: +49 (0) 151 74403195

Internet: www.sourcia.eu



Contact:

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 540 4134-0
Fax: +49 (0) 89 540 4134-20
E-Mail: info@spherotec.com
Internet: www.spherotec.com

SMARTEC IngenieurBüro

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation, Chip/Array Technology, PCR, Tissue Engineering/Cell Culture

Smartec IngenieurBüro is your competent partner for individual system approaches and instrument development in the biological laboratory. Smartec IngenieurBüro convinces with know-how within the ranges biotechnology, analytics, genetic engineering, micro technology as well as micro fluidic. Smartec IngenieurBüro solves tasks of instrumentation for molecular and immunological process engineering. Smartec IngenieurBüro supports you from the idea to all stages of the product. Smartec IngenieurBüro offers complete solutions, consisting of mechanics, optics, electronics, as well as firm- and software of a hand. Smartec IngenieurBüro consists of engineers and physicists which are predominantly settled in the ranges Research and Development (R&D) of bioanalytic systems.

Sourcia

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Clinical Trial Management and Monitoring, R&D Service, Devices

Sourcia is your high-experienced, flexible and independent partner in clinical development. While you are focusing on sciences, we are your partner in project management, operational set-up and execution of your Clinical Development Plan.

SpheroTec GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Oncology, Tissue Engineering/Cell Culture

Spherotec is a biotech company using 3D cell-culture systems that have similar properties to microtumors in cancer patients. On this basis, Spherotec offers pharmaceutical and biotech companies the opportunity to conduct functional tests of drug candidates for oncology in close to real conditions. This permits the early identification of promising substances and gives a broad profile of the effects of substances. The process also allows the definition of the kinds of tumors for which a substance or a combination of substances has the best clinical efficacy.

SSS International Clinical Research GmbH

CRO

Keywords: Medical Writing, Respiratory Diseases, Oncology, Cardiovascular Diseases, Hematology

SSS International Clinical Research is a Functional Service Provider for the pharmaceutical, biotechnological and medical device industry since 1993, with headquarter in Germany and subsidiaries in Romania, Poland and UK. We provide cost-effective, high quality, comprehensive and internationally integrated Clinical Operations Services throughout Europe. Our services have been proven for nearly 20 years and through many successful projects. The services include feasibility surveys in European countries, regulatory document preparation and submissions, site identification and initiation, investigator contract negotiations, clinical trials management, monitoring, and quality assurance. Our indication focus in the past years has lied on Oncology, Neurology, Nephrology, and Pulmonology. Due to our long standing partnerships we have deep insights into the potentials of many possible study sites in these areas.

Staburo GmbH – Statistical Consulting

CRO

Keywords: Data Management, Informatics, Cardiovascular Diseases, Oncology, Dermatology, Infectious Diseases, Data Management and Biostatistics

We are a biostatistics company based in Munich and are specialized in statistical consulting for clinical trials. We process your projects on a flexible basis according to your demands. Thereby your company benefits from our expertise in complex statistical questions (e.g. crossover studies in oncology). Our firm has profound knowledge in SAS programming for clinical studies - of course in compliance with ICH-GCP standards. Furthermore, we can organize statistics workshops to train your staff in statistical analysis tools (SAS, R).

SÜD-LABORBEDARF GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Devices

SLG is a German whole seller for molecular biology research consumables, located in Gauting near Munich since 1980. Our main business is high quality consumables such as gloves, liquid handling products, DNA/RNA kits and plastic ware like racks and cryo boxes. We sell by direct mail to Germany, Austria and Switzerland and through distributors in various European Union countries under our own brands SLG, SafeGrip, SL-Tip, SL-Pette and Hi Yield.



INTERNATIONAL CLINICAL RESEARCH

Contact:
Dr. Michael Sigmund

Landsberger Str. 23/25
D-82110 Germering
Phone: +49 (0) 89 800 650-0
Fax: +49 (0) 89 800 650-555
E-Mail: info@cro-sss.de
Internet: www.cro-sss.eu




Contact:
Hannes Buchner

Aschauer Str. 30a
D-81549 München
Phone: +49 (0) 89 5527 1520
E-Mail: info@staburo.de
Internet: www.staburo.de



Contact:
Fabian Schuler

Starnberger Str. 22
D-82131 Gauting
Phone: +49 (0) 89 850 6527
Fax: +49 (0) 89 850 7646
E-Mail: info@suedlabor.de
Internet: www.suedlabor.de



Contact:
Janine Braun

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 30905068-0
Fax: +49 (0) 89 30905068-68
E-Mail: info@shire.com
Internet: www.suppremol.com



Contact:
Dr. Hermann Schulz

Bayerstr. 53, SPI-Munich, 6. Stock
80335 Munich, Germany
Phone: +49 (0) 89 741 393 0
Fax: +49 (0) 89 741 393 39
E-mail: SPI-Munich@synlab.com
Internet: www.synlab.com/

SuppreMol GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Autoimmune Diseases, Rheumatoid Arthritis, Antibody, Drug Development, Peptide/Protein

SuppreMol is a privately held biotech company developing novel proteins to treat autoimmune diseases. The Company is pioneering the development of Fc gamma receptor (FcGamma-R) based therapeutics, a novel therapeutic concept, which relies on the immune regulatory effect of FcGamma-Rs. The most advanced clinical product, SM101, completed Phase II clinical trials to treat Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE). The SM101 dual mode of action has the potential to specifically rebalance the impaired functions of the immune system rather than just treating disease symptoms. This approach strongly suggests that SM101 has the capability to treat a variety of autoimmune diseases, including such conditions as Rheumatoid Arthritis (RA). SuppreMols monoclonal antibody platform technology has produced two preclinical candidates, SM2x1 and SM301, for the treatment of autoimmune diseases and allergies. On March 4th, 2015, SuppreMol was acquired by Baxter Biopharma, for a purchase price of about 200 Mio Euro.

synlab pharma institute (formerly INTERLAB GmbH) a division of synlab Umweltinstitut GmbH

CRO

Keywords: Biomarker Discovery & Development, Laboratory, Clinical Diagnostics, Logistics, R&D Service, Bioanalytics, Analytical Chemistry

Since 2014, SYNLAB pharma institute, Munich, Germany, has been supporting clinical trials for the Pharma and Biotech industries. The SYNLAB group is the leading provider of laboratory and diagnostic services in Europe. SYNLAB caters to the entire spectrum of laboratory analyses for human and veterinary medicine as well as environmental analyses. The synlab group has branches in 35 countries in Europe, South America, Africa and Near/Middle East. Around 13,000 employees, 4500 in Germany, contribute to the success of the corporate group. Our dedicated division SYNLAB pharma institute offers a unique range of laboratory services for Pharma, Biotech, Medical Devices and Cosmetics covering analytical needs in the preclinical development, during Phase 1-4 studies and in the manufacturing.

Syntacoll GmbH

PHARMA & CHEMICAL INDUSTRY

Syntacoll is the manufacturing division of Innocoll, Inc. and produces clinical supply or commercial product to its marketing partners and to Innocoll's two other divisions, Innocoll Technologies and Innocoll Pharmaceuticals. Using proprietary manufacturing processes, Syntacoll converts raw collagen material and incorporates medicinal compounds yielding finished pharmaceutical product in the form of a sponge or membrane. This system forms the basis of Innocoll's lead collagen-based technology, CollaRx. The sponge or membrane product format is a unique way to locally deliver a wide variety of medicinal compounds and is fully biodegradable and resorbable. The sponge and the membrane formats can be implanted at the time of surgery or applied topically to a chronic, acute or traumatic wound. Delivering drug locally to the site of action has a number of benefits, including the safe delivery of higher doses than could be achieved through systemic routes and avoidance of systemic side effects.

SynteractHCR Deutschland GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Metabolic Diseases, Nephrology, Oncology, Pain

Harrison Clinical Research has been an independent ISO 9001 certified CRO founded in 1987 in Munich with offices in UK, Belgium, Israel, Spain, Italy, France, Austria, Poland, Ukraine, Russia, USA and partners in Asia and Australia.

Apart from conduct of standard Phase I studies, our Phase I/IIa clinic is specialised on proof-of-concept studies in special patient populations and efficacy studies in various indications.

SynteractHCR is a multinational clinical research organization, formed from the merger of Synteract with Harrison Clinical Research in 2013, which provides global, full-service clinical trial services. We have more than two decades of experience supporting biopharma companies in all phases of clinical development across multiple therapeutic areas. We customize programs that will deliver timely, high quality data to help you get to decision points faster, taking time and cost out of drug development.

We deliver trials internationally. SynteractHCR has run trials in more than 60 countries across the globe, offering our clients strong international and regional clinical trial support throughout the world. Our geographic footprint extends from North America to Europe, and has an emerging presence in South America. We have a diverse, talented team of clinical development professionals.

Syntacoll

Contact:
Dr. Alexandra Dietrich

Donaustr. 24
D-93342 Saal/Donau
Phone: +49 (0) 9441 6860-0
Fax: +49 (0) 9441 6860-30
E-Mail: info@syntacoll.de
Internet: www.innocoll.de

SynteractHCR

Contact:

Albrechtstr. 14
D-80636 München
Phone: +49 (0) 89 126680-0
Fax: +49 (0) 89 126680-2444
Internet: www.synteracthcr.com



Contact:

Adams-Lehmann-Str. 56
D-80797 München
Phone: + 49 (0) 89 2155 3085
Fax: + 49 (0) 89 44005 5853
E-Mail: info@systasy.de
Internet: www.systasy.de

Therawis *Pharma | Diagnostics*

Contact:

Grillparzerstrasse 18
D-81675 München

Internet: www.therawis.com

Systasy Bioscience GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: R&D Service, Biomarker Discovery & Development, CNS, Personalized Medicine, Small Molecules, Drug Development

Systasy Bioscience GmbH, a growing start-up company founded 2012 in Munich, provides cost-effective and highly innovative solutions for the pharmaceutical industry to address critical and unmet medical needs. Systasys products and services are ranging from the analysis of cellular target activities and specificities up to the simultaneous analysis of multiple signaling pathways in living cells. Products and services are based on Systasys proprietary splitSENSOR and EXTassay technologies. Systasy takes advantage of their EXTassay technology to deliver profile analyses for a multitude of simultaneously occurring cellular events to customers. Thus, Systasys services and products are designed to match customers needs in the early phases of drug discovery and personalized medicine.

Therawis Pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Therawis is a privately held oncology-focused company with offices located in Munich, Germany, and was founded together with clinicians and scientists of the Technical University of Munich in September 2015.

Therawis develops and aims at to commercialize a comprehensive portfolio of predictive diagnostics to guide the optimal therapy for breast cancer patients.

These predictive assays will help to address unmet medical needs and major challenges in breast cancer therapy:

- to predict whether a patient will respond to standard-of-care systemic cancer therapy and if not
- to switch to an alternative cancer treatment option

Thermo Fisher Scientific GENEART GmbH

BIOTECH

Keywords: Genomics, Combinatorics

Since entering the Gene Synthesis market in 2000 GeneArt has established as the global market leader. GeneArt provides key technologies for Synthetic Biology projects for example for the construction of bacteria which produce complex biopolymers such as biofuels or organisms which degrade environmental toxins. Furthermore the company contributes key technologies necessary to develop and produce new therapeutics and vaccines. Customers also rely on GeneArt services to improve enzymes, such as the ones used as additives in detergents. GeneArt was awarded the worldwide largest gene synthesis contract for the completion of the „Mammalian Gene Collection (MGC) Program“ by the U.S. National Institutes of Health (NIH). In addition, GeneArt produced subgenomic elements for the construction of the first synthetic bacterial genome by the J. Craig Venter Institute. GENEART provides the key technologies for the development and production of new medicines, services for the improvement of proteins (e.g. industrial enzymes, antibodies) or to construct cells for complex biological processes (e.g. bio-factories for the production or degradation of (bio-)polymers). The Regensburg location is now part of Thermo Fisher Scientific Inc, the world leader in serving science, with revenues of \$17 billion and 50,000 employees in 50 countries.

Thermosome GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Liposomes, Small Molecules, Drug Development, Drug Delivery

Thermosome® is leveraging its proprietary drug delivery technology platform to create products with improved therapeutic index that exploit a novel MoA called intravascular drug release. Through its TSL technology, drug-loaded nanocarriers (Thermosomes) are created which after i.v. infusion release their content locally upon the influence of mild heat of 40-42°C achieved by various clinically established targeted heating techniques such as microwave or ultrasound. Thus, up to 15 fold higher local drug concentrations can be reached while simultaneously markedly reducing systemic exposure and potentially associated side effects. Our lead candidate is a formulation of a potent, but highly toxic chemotherapeutic agent and is envisioned to enter a FiH study in locally-advanced solid tumors.

ThermoFisher
SCIENTIFIC

Contact:
Dr. Marcus Graf

Im Gewerbepark B35
D-93059 Regensburg
Phone: +49 (0) 941 94276-0
Fax: +49 (0) 941 94276-711
E-Mail: geneart.info@lifetech.com
Internet: www.thermofisher.com



Contact:
Dr. Pascal Schweizer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7167 760-31
Fax: +49 (0) 89 7167 760-49
E-Mail: info@thermosome.com
Internet: www.thermosome.com



Contact:
Jean-Philippe Sobczak

Lichtenbergstraße 8
D-85748 Garching
E-Mail: info@tilibit.com
Internet: www.tilibit.com



TILL I.D. GmbH

Contact: Dr. Carolina Glas

Am Klopferspitz 19
D-82152 Planegg/Martinsried
Phone: +49 (0) 89 2032 4142 20
Fax: +49 (0) 89 2032 4142 90
E-Mail: info@till-id.com
Internet: www.till-id.com

tilibit nanosystems GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, New Materials, R&D Service

tilibit nanosystems specializes in the development and fabrication of nanostructures using the DNA origami method. This technology allows building discrete objects with user-defined shapes and mechanical properties on the scale of 10 to 1000 nanometers molecule by molecule from the bottom-up. User-defined chemical and mechanical features can be positioned with near-atomic control, and nanostructures can be assembled into macroscopic materials with novel mechanical or optical properties. Because of these capabilities, DNA origami is an enabling technology that creates novel and unparalleled opportunities toward the construction of „bionano“ products that promise tremendous technological progress. Tilibit nanosystems can design, assemble, purify, and characterize a fully customized nanostructure according to your specifications.

TILL I.D. GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Automation, Microscopy, Imaging, 3D-Structural Analysis

TILL I.D. GmbH is a small company at the interface of research and industry. We develop innovative concepts for light microscopy. Our aim is to take the microscope from the 19th into the 21st century by applying a scalable embedded approach rather than a modular one. Our inspiration is the smartphone, which can be differentiated into a variety of application-specific tools (apps). Our microscopes are platforms with a common design but the flexibility to combine different imaging techniques and light sources. The idea to build an intelligent, user-friendly microscope persists not only in the microscopes hardware, but also in our newly developed software. The prototypes are validated through our partners in the field of life science and medicine, and innovative solutions are licensed to our industrial partners.

TopLab GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Proteomics

TOPLAB GmbH is a leading ISO 9001 certified service provider with high end research facilities for proteomics, protein analytics, target and biomarker discovery and validation. The company has outstanding expertise in proteome analysis, protein identification and characterisation with more than 15 years experience. A portfolio of proprietary technologies has been developed and/or licensed that is able to significantly enhance the rate of discovery of potential biomarkers and novel therapeutic targets. The vision of TOPLAB is to support our clients from pharma, biotech and academia with highest quality standards, modern technologies and an experienced and highly motivated team, to achieve confident results in compliance with the timelines of our customers with calculable costs.

Transcatheter Technologies GmbH

MEDTECH

Keywords: Devices, Cardiovascular Diseases

TRANSCATHETER TECHNOLOGIES develops medical devices aimed at reducing the trauma of open-heart valve surgeries. Its re-positionable transcatheter aortic valve system TRINITY is at the forefront of next generation valve implantation technology. The new technology makes it possible to implant aortic valve prostheses without the need for traumatic open-heart surgery. Key features of TRINITY allow the physician to reposition the valve during implantation. ZERO PRESSURE CRIMPING technology protects the fragile biological leaflets when the stent is folded and expanded. This will increase the safety and durability of the valve prosthesis and will allow for implantation in younger patients.



Contact:
Dr. Elfriede Müller

Fraunhoferstr. 18 a
D-82152 Martinsried
Phone: +49 (0) 89 2441 45412-81
Fax: +49 (0) 89 2441 45412-86
E-Mail: info@toplab.de
Internet: www.toplab.de



Contact:
Dr. Wolfgang Goetz

Am BioPark 13
D-93053 Regensburg
Phone: +49 (0) 941 630998-95
Fax: +49 (0) 941 63099-897
E-Mail: info@transcathetertechnologies.com
Internet: www.transcatheter-technologies.com



Contact:
Dr. Yannick Böge

Steinberg 10
D-82392 Habach
Phone: +49 (0) 8847 695 78 0
Fax: +49 (0) 8847 695 78 29

E-Mail: info@triga-s.de
Internet: www.triga-s.de



Contact:
Dr. Horst Lindhofer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700 766-0
Fax: +49 (0) 89 700 766-11
E-Mail: mail@trionresearch.de
Internet: www.trionresearch.com



Contact:
Christian Wandersee

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 359099-0
Fax: +49 (0) 931 359099-12
E-Mail: office@vasopharm.com
Internet: www.vasopharm.com

TRIGA-S e.K. Scientific Support

CRO

Keywords: Other Diagnostics, Logistics, Molecular Diagnostics, Clinical Trial Management and Monitoring, In-Vitro-Diagnostics

TRIGA-S Scientific Support is a Clinical Research Organization for planning and conducting clinical and technical studies phase I-IV in the In-Vitro-Diagnostics (IVD) and medical device industry. During the past 20 years, TRIGA-S supported more than 50 clinical and technical studies worldwide, including >300 sites and >60.000 patients, in accordance to ICH-GCP, international and local guidelines. TRIGA-S provides service as contract laboratory and testing site for serum and body fluids based clinical chemistry, immunology or further IVD applications, including organization and preparation of samples for technical reviews. Our services: study management/ monitoring, data management, contract laboratory, testing site, sample management/ storage/ preparation, logistics.

TRION Research GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Immune Therapy, Antibody Production Service

TRION Research GmbH, founded in 1998, is a Biotech research company and a strategic partner of TRION Pharma GmbH focusing on the generation of novel Triomab® antibody candidates and the support of non-clinical and clinical development of Triomab® antibodies. The company offers Immunomonitoring Service, special antibody conjugation support, additional analytical service in tumor biology and further analytical support for reagent control to investigators, study sponsors and CROs. TRION Research is ISO 9001:2008 certified. The core competences of the company are:

- Immunomonitoring and logistical support for clinical and non-clinical studies
- Supply of purified antibodies (labeled and unlabeled)
- Development of immunological assays

vasopharm GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. The company is focused on the development of therapeutics which permits steering the bioavailability of biological NO, covering the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm's drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure after a traumatic brain injury.

Vectura GmbH

MEDTECH

Keywords: Inflammation, Respiratory Diseases, Infectious Diseases, Small Molecules, Peptide/Protein, Devices, Drug Delivery

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. In June 2016 Vectura completed a merger with Skyepharma PLC. Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.




Contact:
Bernhard Müllinger

Robert-Koch-Allee 29
D-82131 Gauting
Phone: +49 (0) 89 897969-0
Fax: +49 (0) 89 897969-22
E-Mail: info@vectura.com
Internet: www.vectura.com

TRIGA-S Scientific Support

TRIGA-S e.K. | Steinberg 10 | 82392 Habach
Tel. +49 (0) 88 47 - 695 78 0
info@triga-s.de | www.triga-s.de

Your partner for successful performance
of **clinical** and **technical studies**





Contact:
Barbara Brandlhuber

Emmy-Noether-Str. 2
D-80992 München
Phone: +49 (0) 89 15882-0
Fax: +49 (0) 89 15882-100
E-Mail: info@vermicon.com
Internet: www.vermicon.com



Contact:
PD Dr. Fritz Thümmeler

Lise-Meitner-Str. 30
D-85354 Freising-Weihenstephan
Phone: +49 (0) 8161 18516-11
Fax: +49 (0) 8161 18516-12
E-Mail: info@vertis-biotech.com
Internet: www.vertis-biotech.com



Contact:
Christian Sacher

Sembdnerstr. 5
D-82110 Germering
Phone: +49 (0) 89 800777-60
Fax: +49 (0) 89 800777-88
E-Mail: verum@verum.de
Internet: www.verum.de

vermicon AG

BIOTECH AGRO, FOOD, ENVIRONMENT

vermicon is an innovative and international solutions provider for microbiology. With its roots at the base of FISH development the company now has nearly 20 years of expertise. The development of the VIT® gene probe technology by vermicon made FISH accessible not only for academic research but also for every industrial microbiologist or actually anyone who has to rely on microbiology in their decisions. vermicon's highly qualified team of experts and its powerful technology portfolio enables the company to meet even complex microbiological challenges. Their philosophy is based on the fact that only cultivation-independent methods allow real insights into microbiology. The products, services and consulting services deliver not only rapid results, but focus additionally on highest specificity and reliability. With satisfied customers worldwide, vermicon creates impressive solutions and is actively participating in the evolution of modern microbiology.

vertis Biotechnologie AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: PCR, NGS, Informatics, Genomics

VERTIS was established in 2000 as a spin off from Technical University Munich-Weihenstephan, Germany. The company offers molecular biology services in the field of functional genomics with focus on Next Generation Sequencing (NGS) especially on transcriptome sequencing (RNA-seq). The company offers a complete product line, ranging from project consulting, nucleic acid isolation, sample preparation and DNA sequencing to bioinformatic sequence analysis and data mining. The strength of the VERTIS is customer-oriented flexibility, which is based on an innovative technology platform, the company has developed in its 13-year history. VERTIS is a pioneer in the analysis of small non coding RNAs (sncRNA) and of bacterial transcriptomes.

verum.de GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Dermatology, Diabetics, Oncology, Respiratory Diseases

Verum has been the first Western-Standard CRO specializing in CEE countries, operations starting in 1992. Our core business and key competence is Full Clinical Service for Phase II-IV in CEE countries. Our team consists of about 100 experts that share our experience of more than 120 trials with some 35.000 patients in indications like cardiovascular, neurology, psychiatry, pain, CNS-diseases and oncology. With offices from Eastern Europe to the US we are pooled for the success of our trials.

Viramed Biotech AG

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, ELISA/EIA, Infectious Diseases

Based on 20 successful years on the German IVD-Market, Viramed Biotech AG produces and markets IVD-Products, based on its proprietary research and development. The company focuses on Westernblot-, Stripe- and Elisa-test kits for serological screening and confirmation of infectious and autoimmune diseases. The major products are Westernblot tests for *Borrelia* sp., *Yersinia*, *Helicobacter p.*, Epstein-Barr-Virus, *Bordetella pertussis*, ENA and autoimmune liver diseases. New analytics based on purified and recombinant antigens are under development. The development of antigens and test kits for specific analytics are offered as service. The company aims to intensify export of existing products worldwide and appreciates further distribution contacts.

vivoPharm Europe Ltd

CRO

Keywords: Toxicology, Pharmacology, Drug Development, Oncology, Metabolic Diseases, Bone/Joint Diseases, Pharmacokinetics

vivoPharm is a contract research organization that offers integrated preclinical services in various disease areas, Safety Studies as well as analytical services to the biotechnology and pharmaceutical industries. We specialize in planning and conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug Applications (IND) filing. vivoPharm operates in AAALAC accredited and GLP compliant audited facilities located in Melbourne, Australia and Hershey, PA, USA. Its European office is based in Munich, Germany. vivoPharm operations follow strict quality control methods and meet the highest industrial standards, acknowledged by our customers worldwide. .



Contact:
Dr. Ludwig Furtmayr

Behringstr. 11
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 899336
Fax: +49 (0) 89 8599949
E-Mail: viramed@viramed.de
Internet: www.viramed.de



Contact:
Dr. Melanie Keller

Grillparzerstr. 25
D-81675 München
Phone: + 49 (0) 89 122 287 6-90
Fax: + 49 (0) 89 122 287 6-99
E-Mail: info@vivopharm.eu
Internet: www.vivoPharm.com



Contact:
Dr. Samson Fung

Ludwigstr. 8
D-80539 München
Phone: +49 (0) 89 206021-255
Fax: +49 (0) 89 206021-610
E-Mail: info@volvox-tx.com
Internet: www.volvox-tx.com



Contact:
Rachela Mohr

Hanns-Seidel-Platz 4
D-81737 München
Phone: +49 (0) 89 6279-0
Fax: +49 (0) 89 6279-1770
E-Mail: info@wacker.com
Internet: www.wacker.com



Contact:
Sylvia Wimmer

Grillparzerstr. 18
D-81675 München
Phone: +49 (0) 89 413138-0
Fax: +49 (0) 89 413138-99
E-Mail: info@wilex.com
Internet: www.wilex.com

Volvox Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody, Peptide/Protein, Small Molecules, Hematology, Oncology, Clinical Trial Management and Monitoring

Volvox Therapeutics is a private virtual biotechnology development company focusing on generating, creating and re-creating value from fallen angel and hidden treasure compounds that have fallen off development or lost their priority status due to issues occurring during early development stages. The company is focused on salvaging these compounds and carry them into the next development step thus creating value for patients and investors. Volvox was founded by an experienced management team with significant expertise in all phases of development and broad network of high caliber individuals and top advisors. Volvox key expertise is in oncology and immunology.

Wacker Chemie AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Antibody Production Service, Peptide/Protein, CRO/CMO, Nutraceuticals

WACKER is a globally active chemical company headquartered in Munich, Germany. With a wide range of state-of-the-art specialty products, WACKER is a leader in numerous industrial sectors. Its products are required in countless high-growth end-user sectors such as photovoltaics, electronics, pharmaceuticals and household/personal care products. Within its bio division, WACKER uses advanced biotech processes to offer innovative and tailored solutions and biotech products for the pharma and the food & nutrition industry. Its products include pharmaceutical proteins, cyclodextrins and fermentation-grade cysteine. The division focuses on developing customized solutions for growth sectors such as food additives and pharmaceutical actives.

Wilex AG

BIOTECH THERAPEUTICS & DIAGNOSTICS


Keywords: Drug Development, Antibody, Oncology, R&D Service

WILEX AG is a biopharmaceutical company acting as a holding company and Group parent. Research and development focus on the operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances the development of the innovative platform technology for antibody-drug conjugates based on the use of Amanitin as a payload (ATAC technology) and provides preclinical drug discovery and development services. WILEX has a couple of diagnostic and therapeutic Phase III drug candidates which are available for out-licensing for external partners. WILEX is listed at the Frankfurt Stock Exchange.

Winicker Norimed GmbH Medizinische Forschung

CRO

Winicker Norimed GmbH, located in Nuremberg, is an independent, owner-operated contract research organization. Our experienced, interdisciplinary team of approximately 132 employees manages your projects from the planning through the field phase to the analysis and the clinical study report or publication. We deliver quality services according to applicable laws and international guidelines based on either our own or our clients standard operating procedures. In cooperation with hospitals and primary care physicians, we manage phase II-IV clinical trials with pharmaceuticals, studies with medical devices as well as non-interventional and epidemiological studies.



Contact:
Jens Winicker

Deutschherrnstr. 15-19
D-90429 Nürnberg
Phone: +49 (0) 911 92680-0
Fax: +49 (0) 911 92680-8839
E-Mail: wn@winicker-norimed.com
Internet: www.winicker-norimed.com



**WANDER
IMMOBILIEN**

**Tel.: +49 (89) 85 89 63 - 0
kontakt@wander-immobilien.de**



You are looking for suitable laboratories?

We are your specialist!

www.wander-immobilien.de

Office, laboratories and production space

from 250 sqm – 10.000 sqm

**We are looking forward to send you
an attractive offer.**





Contact:
Prof. Dr. Arne Skerra

Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161 53730-90
Fax: +49 (0) 8161 53730-99
E-Mail: info@xl-protein.com
Internet: www.xl-protein.com



Contact:
Dr. Per Sonne Holm

Nymphenburger Str. 1
D-80335 München
Phone: +49 (0) 89 9931 7446
Fax: +49 (0) 89 5155 6413
E-Mail: info@xvir.com
Internet: www.xvir.com



Contact:

Staffelseestraße 4
D-81477 München
Phone: +49 (0) 89 7105020
E-Mail: HR@Zentiva.de
Internet: www.zentiva.de

XL-protein GmbH

BIOTECH

Keywords: Drug Development, Pharmacokinetics, Peptide/Protein

XL-protein is a biopharmaceutical company utilizing its proprietary 'PASylation' technology to develop second generation biopharmaceuticals with prolonged plasma half-life. PASylation of therapeutic proteins allows less frequent and lower dosing combined with better tolerability, also opening perspectives for follow-on products of approved biopharmaceuticals. PASylation - the genetic fusion with conformationally disordered polypeptide sequences composed of the amino acids Pro, Ala, and/or Ser - provides a superior way to attach a solvated random chain with large hydrodynamic volume to a biologically active protein. Thus, its typically rapid clearance via kidney filtration can be retarded by one to two orders of magnitude while the PAS moiety is biochemically inert and easily degradable.

XVir® Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Xvir Therapeutics GmbH was founded in 2004 and is focusing on the clinical development of novel cancer therapies for the treatment of various solid tumors, and in particular of drug-resistant or radiation-resistant tumors. Such cancer therapies are based on the use of oncolytic adenoviruses restoring drug sensitivity and radiation-sensitivity, respectively, of the tumors. Experimental evidence for the efficacy of Xvir's therapeutic approach has been provided in several animal studies. Xvir's therapeutic approach is covered by proprietary patents and patent applications, respectively.

Zentiva Inhalationsprodukte GmbH

PHARMA & CHEMICAL INDUSTRY

Zentiva, the generics business for the Sanofi group, is the third largest and fast growing generics company in Europe. With origins dating back to the 15th century, Zentiva is a valued generics partner. Today, we are at the forefront of developing modern, high-quality and affordable medicines. We currently operate in 50 markets, targeting a population of more than 1 billion people. Zentiva holds leading positions in several pharmaceutical markets, such as the Czech Republic, Romania and Turkey and is successfully expanding its business in other international markets. In Bavaria, Zentiva Inhalationsprodukte GmbH is located in Munich and runs a production plant in Höchstädt/Donau.

Zentrum für Humangenetik und Laboratoriumsdiagnostik (MVZ) Martinsried Dr. Klein, Dr. Rost und Kollegen

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Pharmacogenetics, PCR, Genomics, Chip/Array Technology, ELISA/
EIA, NGS, Clinical Diagnostics

The Center for Human Genetics and Laboratory Diagnostics in Martinsried is specialized in advanced laboratory testing in genetics, clinical chemistry and immunology (in particular: HLA testing). The laboratory is accredited according to DIN EN ISO/IEC 17025 and ISO 15189. The institution's clinical consultation focuses on pediatric genetics, infertility and inherited diseases. Among the applied technologies are: PID, NIPT (Prenatalis®), Next Generation and Sanger Sequencing as well as Array technologies, Blotting, FACS, FISH, HPLC, pyrosequencing, real-time PCR and tandem mass spectrometry. One of its newly established tests is the molecular genetic analysis of the human microbiome (enteralis).

CENTER FOR HUMAN GENETICS AND LABORATORY DIAGNOSTICS
Dr. Klein, Dr. Rost and Colleagues



Contact:
Dr. med. Hanns-Georg Klein

Lochhamer Str. 29
D-82152 Martinsried
Phone: +49 (0) 89 895578-0
Fax: +49 (0) 89 895578-780
E-Mail: info@medizinische-genetik.de
Internet: www.medicinische-genetik.de

CENTER FOR HUMAN GENETICS AND LABORATORY DIAGNOSTICS Dr. Klein, Dr. Rost and Colleagues



The Center for Human Genetics and Laboratory Diagnostics in Martinsried is specialized in advanced laboratory testing in **genetics, clinical chemistry, immunology, HLA typing, infectious diseases** and **molecular pathology**. The laboratory is accredited according to DIN EN ISO/IEC 17025 and ISO 15189. The Center's clinical consultation key competences are in **pediatric genetics, infertility** and **inherited diseases**.

Applied technologies include **NIPT (Prenatalis®), PGD, PBD, Next Generation** and **Sanger sequencing, array** and **blotting technologies, FACS, FISH, Immunofluorescence, real-time** and **digital PCR, HPLC, protein electrophoresis, tandem mass spectrometry, cobas®6000 technology**. One of our latest established tests is the molecular genetic analysis of the **human microbiome (enteralis)**.

MEDICAL SPECIALITIES



Human Genetics

Laboratory Medicine

Microbiology / Virology

Transfusion Medicine

Pathology

- gene panel analysis in rare diseases and molecular oncology
- whole exome sequencing in intellectual disability
- NGS-based ultrahigh-resolution HLA typing and blood group antigens
- array-based molecular karyotyping in pre-/postnatal diagnostics and oncology
- digital droplet PCR in liquid biopsies
- non-invasive prenatal testing (NIPT)  Prenatalis®
- preimplantation genetic diagnostics (PGD) - polar body diagnosis (PBD)
- NGS-based analysis of the human microbiome  enteralis
- tandem mass spectrometry in endocrinology and metabolic diseases
- latest cobas® technology in clinical chemistry and infectious diseases
- bioinformatic solutions for integrated diagnostics (MIDAS)



Experts in Integrated Diagnostics 

MVZ Martinsried
Lochhamer Str. 29
82152 Martinsried

Tel.: +49.89.895578-0
Fax: +49.89.895578-780

www.medical-genetics.de
info@medical-genetics.de



Contact:

Moosburger Str. 7
D-84072 Au i.d. Hallertau
Phone: +49 (0) 8752 8656-71
Fax: +49 (0) 8752 8656-72
E-Mail: manfred.seifert@zeta.com
Internet: www.zeta.com

Zeta Biopharma GmbH

BIOTECH & PHARMA PRODUCTION

The Zeta group of companies specialises in the development and supply of tailored process and procedure solutions for sterile and aseptic applications. Zeta Biopharma: Early cooperation in all technical disciplines within the framework of projects enables us to provide customers with: reliable, high-quality and integrated process solutions and technologies a user-oriented, productivity- and maintenance-optimised layout optimum economic, functional and technical safety for the operator without interfaces, for the purpose of a simultaneous engineering concept based on our specific knowledge and our project experience from the pharmaceutical industry and biotechnology. We have made it one of our central objectives to offer our customers added value in the shortest possible time via activated technology investment in order to have a sustainable positive impact on their return (ROI). Short project accomplishment times in accordance with the schedule, predominantly through efficient project management and targeted project accomplishment at the highest technical level, and the heavy involvement of our customers and partners in the project development and accomplishment process are our strategies for fulfilling this requirement.



CLUSTER
BIOTECHNOLOGY
BAVARIA



FORUM

Science & Health

5.- 6. Juli 2017

Veranstaltungsforum Fürstenfeld
Fürstenfeldbruck bei München

- Fokus Medizin der Zukunft
- anwendungsorientierte Gesundheitsforschung
- Fachdisziplinen überbrücken
- diskutieren, interagieren und netzwerken

← 1
WORKSHOP
2,3 →

managed by



BioEntrepreneurship Summit 2017

create the future of medicine

Munich, October 10 - 11, 2017

Program highlights

- inspiring key notes
- captivating panel discussions
- interactive workshops and insightful lectures
- exciting pre-seed showcases
- m⁴ award ceremony & party



learn from successful founders, get to know the ecosystem and your supporters, meet and understand investors, learn about key drivers of the industry and the essentials of bioentrepreneurship, spark your start-up project, be inspired

Bavarian Ministry of Economic Affairs and Media, Energy and Technology




www.bio-m.org

main sponsors:



in cooperation with:





„The unique worldwide reputation
of the IZB as a hotspot for life sciences
has been confirmed for us.“

*Johan Skog, PhD; John Boyce; Mikkel Noerholm, PhD (l to r)
Exosome Diagnostics GmbH
IZB firm*

**YOU HAVE THE IDEA.
WE HAVE THE LOCATION.**

Start your Lifescience-firm where the
world is newly discovered.



**Innovations- und
Gründerzentrum
Biotechnologie**

Fördergesellschaft IZB mbH
Am Klopferspitz 19
82152 Planegg/Martinsried

Phone + 49 (0)89.55 279 48-0
Fax + 49 (0)89.55 279 48-29
info@izb-online.de
www.izb-online.de



- 26,000 sq m of the most up-to-date office and laboratory space (S1 & S2) in Martinsried near Munich
- Find the Max Planck Institutes of Neurobiology and Biochemistry, the two top-ranking universities LMU & TU, the Clinical Centre Großhadern and more at the heart of the Campus Martinsried
- Home for more than 60 Biotech firms
- Faculty Club, Restaurants, Hotel and two Day-Care Centres directly at the IZB

WHERE THE FUTURE BECOMES REALITY

Catalyzing Global Life Science Innovation



TVM Capital Life Science Practice

TVM Life Science Management Inc., Montréal

TVM Life Science Management GmbH, TVM Capital GmbH, Munich

TVM Capital China Ltd., Hong Kong